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A B S T R A C T
Background
Visual field defects are estimated to affect 20% to 57% of people who have had a stroke. Visual field defects can affect functional ability
in activities of daily living (commonly affecting mobility, reading and driving), quality of life, ability to participate in rehabilitation, and
depression and anxiety following stroke. There are many interventions for visual field defects, which are proposed to work by restoring
the visual field (restitution); compensating for the visual field defect by changing behaviour or activity (compensation); substituting
for the visual field defect by using a device or extraneous modification (substitution); or ensuring appropriate diagnosis, referral and
treatment prescription through standardised assessment or screening, or both.
Objectives
To determine the effects of interventions for people with visual field defects after stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register, the Cochrane Eyes and Vision Group Trials Register, CENTRAL, MEDLINE,
Embase, CINAHL, AMED, PsycINFO, and PDQT Databse, and clinical trials databases, including ClinicalTrials.gov and WHO
Clinical Trials Registry, to May 2018. We also searched reference lists and trials registers, handsearched journals and conference
proceedings, and contacted experts.
Selection criteria
Randomised trials in adults after stroke, where the intervention was specifically targeted at improving the visual field defect or improving
the ability of the participant to cope with the visual field loss. The primary outcome was functional ability in activities of daily living
and secondary outcomes included functional ability in extended activities of daily living, reading ability, visual field measures, balance,
falls, depression and anxiety, discharge destination or residence after stroke, quality of life and social isolation, visual scanning, adverse
events, and death.
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Data collection and analysis
Two review authors independently screened abstracts, extracted data and appraised trials.We undertook an assessment ofmethodological
quality for allocation concealment, blinding of outcome assessors, method of dealing with missing data, and other potential sources of
bias. We assessed the quality of evidence for each outcome using the GRADE approach.
Main results
Twenty studies (732 randomised participants, with data for 547 participants with stroke) met the inclusion criteria for this review.
However, only 10 of these studies compared the effect of an intervention with a placebo, control, or no treatment group, and eight
had data which could be included in meta-analyses. Only two of these eight studies presented data relating to our primary outcome of
functional abilities in activities of daily living. One study reported evidence relating to adverse events.
Three studies (88 participants) compared a restitutive intervention with a control, but data were only available for one study (19
participants). There was very low-quality evidence that visual restitution therapy had no effect on visual field outcomes, and a statistically
significant effect on quality of life, but limitations with these data mean that there is insufficient evidence to draw any conclusions
about the effectiveness of restitutive interventions as compared to control.
Four studies (193 participants) compared the effect of scanning (compensatory) training with a control or placebo intervention. There
was low-quality evidence that scanning training was more beneficial than control or placebo on quality of life, measured using the
Visual Function Questionnaire (VFQ-25) (two studies, 96 participants, mean difference (MD) 9.36, 95% confidence interval (CI)
3.10 to 15.62). However, there was low or very-low quality evidence of no effect on measures of visual field, extended activities of
daily living, reading, and scanning ability. There was low-quality evidence of no significant increase in adverse events in people doing
scanning training, as compared to no treatment.
Three studies (166 participants) compared a substitutive intervention (a type of prism) with a control. There was low or very-low
quality evidence that prisms did not have an effect on measures of activities of daily living, extended activities of daily living, reading,
falls, or quality of life, and very low-quality evidence that they may have an effect on scanning ability (one study, 39 participants, MD
9.80, 95% CI 1.91 to 17.69). There was low-quality evidence of an increased odds of an adverse event (primarily headache) in people
wearing prisms, as compared to no treatment.
One study (39 participants) compared the effect of assessment by an orthoptist to standard care (no assessment) and found very low-
quality evidence that there was no effect on measures of activities of daily living.
Due to the quality and quantity of evidence, we remain uncertain about the benefits of assessment interventions.
Authors’ conclusions
There is a lack of evidence relating to the effect of interventions on our primary outcome of functional ability in activities of daily
living. There is limited low-quality evidence that compensatory scanning training may be more beneficial than placebo or control at
improving quality of life, but not other outcomes. There is insufficient evidence to reach any generalised conclusions about the effect
of restitutive interventions or substitutive interventions (prisms) as compared to placebo, control, or no treatment. There is low-quality
evidence that prisms may cause minor adverse events.
P L A I N L A N G U A G E S U M M A R Y
Interventions for visual field defects in people with stroke
Review question
Are there effective treatments for people who have visual field defects after stroke?
Background
Stroke can cause some people (20% to 57% of people with stroke) to lose the ability to see the entire space in front of them - often
one complete half of the normal field of vision is lost. These problems with seeing are called visual field defects. Visual field defects can
make it difficult for people to function normally - especially moving about freely, avoiding obstacles, reading, driving, and taking part
in rehabilitation for other stroke-related problems.
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We wanted to see whether treatments for visual field defects could improve stroke survivors’ abilities in activities of daily living (our
primary outcome of interest), or other (secondary) outcomes. Secondary outcomes that we were interested in included the size of the
visual field defect, independence (in functional abilities), quality of life, ability to scan/search for objects, reading ability, balance and
falls, depression and anxiety, and adverse events.
Study characteristics
We included 20 studies (involving 547 stroke participants) that investigated the effect of treatments for visual field defects. However,
only 10 of these studies compared the effect of a particular treatment with no treatment. Three of these studies investigated a type of
eye movement training designed to improve the lost visual field (a ’restitutive’ intervention). Four of the included studies investigated
the effect of scanning training, which involves training people to ’scan’ across the space in front of them and into the ’lost’ visual field,
in order to better cope with their lost vision (a ’compensatory’ intervention). Three of the included studies investigated the effect
of wearing a special prism on a pair of glasses, which increases the amount a person can see on their affected side (a ’substitutive’
intervention). One of the studies investigated the effect of specialised assessment by an orthoptist (a hospital-based vision specialist),
compared to standard care.
Search date
We searched for studies up to May 2018.
Key results
Only two studies presented data relating to how treatment can improve stroke survivors’ abilities in activities of daily living, and there
was a lack of consistency across studies that limited our ability to draw clear conclusions. There was insufficient evidence to draw any
conclusions about the effectiveness of restitutive interventions as compared to control. There was low or very low-quality evidence that
scanning training may help improve quality of life, but may have no effect on other outcomes (including adverse events). There was
low or very-low quality evidence that prisms may have an effect on ability to scan (look) for objects, but may cause a range of minor
adverse events (particularly headache) and may have no effect on other outcomes. Limitations with the evidence meant that we could
not draw any conclusions about the benefits of assessment interventions.
Quality of the evidence
The quality of the evidence was low to very low, and in general was insufficient to reach conclusions about the effects of interventions
for people with visual field defects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Restitutive interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual f ield defects
Settings: any rehabilitat ion sett ing
Intervention: rest itut ive intervent ions
Comparison: control, placebo, or no intervent ion
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Functional ability in activities of
daily living
(no data) No studies Insuf f icient evidence
Visual field
(TAP border posit ion in degrees
of visual angle f rom zero vert ical
meridian)
Af ter intervent ion
MD 1.02 (-1.37 to 3.41) 19
(1 study, Kasten 2007)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study had high ROB
for ’other bias’ (relat ing to potent ial
f inancial interest in the intervent ion),
study had uncertain ROB for allocat ion
concealment and incomplete outcome
data
• Indirectness - included
part icipants with diagnoses other than
stroke
• Imprecision - very small study
populat ion (n = 19)
Extended activities of daily living (no data) No studies Insuf f icient evidence
Reading ability (no data) No studies Insuf f icient evidence
Falls (no data) No studies Insuf f icient evidence
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Quality of life
(improved or not improved - de-
rived f rom percentage of those
who reported subject ive improve-
ments of vision)
OR 13.00 (2.07 to 81.48) 30*
(1 study, Kasten 2007)
* The data used in this analysis were
derived f rom 30 of the original 38
part icipants, which included data
f rom an addit ional 19 part icipants
with opt ic nerve injury who had also
received the same intervent ions in a
separate (but parallel) t rial. Part ici-
pants with opt ic nerve injury do not
meet the inclusion criteria for this
review
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study had high ROB
for ’other bias’ (relat ing to potent ial
f inancial interest in the intervent ion),
study had uncertain ROB for allocat ion
concealment and incomplete outcome
data
• Indirectness - analysis contained
data f rom a subset of part icipants
f rom a separate trial, who were not
relevant to this review
• Indirectness - included
part icipants with diagnoses other than
stroke
• Imprecision - very small study
populat ion (n = 19)
Scanning - cancellation (no data) No studies Insuf f icient evidence
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI :conf idenceinterval
MD: mean dif ference
n: number
OR: odds rat io
ROB: risk of bias
TAP: Tuebingen Automated Perimeter
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B A C K G R O U N D
Description of the condition
Following stroke, a common visual problem is loss of one-half of
the visual field in both eyes; this is called hemianopia or hemi-
anopsia. As it affects the same side in both eyes, it is termed a
homonymous hemianopia. For example, left hemisphere stroke
causes the loss of the nasal field of the left eye and temporal (outer
field) of the right eye, resulting in an inability to see to the right of
the centre of the field of view. Visual field defects are common fol-
lowing stroke; the prevalence has been reported as being between
20% and 57% of people (Ali 2013; Rowe 2007; Rowe 2009). The
extent of the loss within the visual field may vary, from the loss
of the entire half of the visual field to the loss of only a portion
of the affected half. It has been reported that 70% of those with
visual field loss will maintain a small area of central vision (macular
sparing) (Kerkhoff 1999).
The association between visual impairment and disability in ac-
tivities of daily living has been well-established (Wolter 2006).
Visual field defects can affect functional ability and quality of
life following stroke (Dombovy 1986; Jongbloed 1986). Studies
have demonstrated that people with visual field defects have an in-
creased risk of falling (Ramrattan 2001), and that visual field loss is
a predictor of poor functional status at discharge from a stroke unit
(Kaplan 1982). People report walking into objects, tripping and
falling, feeling unsafe, getting lost, and experiencing panic when
in crowded or unfamiliar areas (Windsor 2008). Stroke survivors
may struggle with reading, and with accomplishing everyday tasks
such as shopping and handling their finances (Warren 2009), and
they report severe difficulty returning to work, and marked loss of
self-confidence (Rowe 2017).
Visual field loss may also impact on a person’s ability to partici-
pate in rehabilitation, to live in their own home, and on depres-
sion, anxiety, social isolation, and quality of life following stroke
(Hepworth 2016; Jones 2006). Visual field defects often co-ex-
ist with visual neglect or other perceptual problems. Differentia-
tion between visual field defects and visual neglect can be difficult
(Jones 2006).
Description of the intervention
There are many different treatment and management approaches
available for peoplewith visual field defects. This review considered
any intervention that is specifically targeted at improving the visual
field defect or improving the ability of the person to cope with the
visual field loss.
Treatments for visual field defects can be described as restitu-
tion, compensation or substitution (Hämäläinen 2004; Kerkhoff
2000). In addition to these types of treatments, this review also
considered assessment and screening interventions that are specif-
ically targeted at people with visual field defects.
These interventions may include, but are not limited to, the fol-
lowing.
• Restitutive interventions: visual field training, contrast
sensitivity training, fusional (binocular vision) training.
• Compensatory interventions: saccadic (fast, simultaneous)
eye movement training , training in visual search strategies,
training eye movements for reading, use of eye blinks or colour
cues, training in activities of daily living.
• Substitutive interventions: prisms (Peli 2000; Rossi 1990),
eye patches, adapted lighting, magnification, environmental
modification.
• Assessment and screening interventions: standardised visual
assessment, screening and referral for visual assessment and
intervention.
These are all complex interventions and, therefore, there can be
substantial variations, even within interventions of the same type.
For example, there can be differences between interventions in
relation to the mode of delivery (e.g. therapist-delivered, self-di-
rected, or computer-based), personnel involved in delivery (e.g. vi-
sion specialists, such as orthoptists; stroke-care rehabilitation pro-
fessionals, such as occupational therapists), and in the dose of the
intervention (amount of training per day, or per week, and length
of intervention period).
How the intervention might work
Interventions for visual field defects are proposed to work by ei-
ther restoring the visual field (restitution); compensating (adapt-
ing) for the visual field defect by changing behaviour or activity
(compensation); substituting for the visual field defect by using a
device or extraneous modification (substitution); or ensuring ap-
propriate diagnosis, referral and treatment prescription through
standardised assessment or screening, or both.
Restitution
This includes the biochemical events that help restore functional
neural (nervous system) tissue, for example, the reduction of
oedema, absorptionof blood, restorationof normal neuronal phys-
iology and restorationof axon (part of a nerve cell) transport. In the
past, researchers thought that restitutive approaches would have
limited effect in visual rehabilitation (Kerkhoff 2000). However,
in the last decade, reports have suggested that expansion of the
visual field can be achieved with specific interventions after brain
or optic nerve injury (Romano 2008; Sabel 2000; Sahraie 2006).
Restitutive interventions include those where there is direct train-
ing of the impaired function or repetitive stimulation of the visual
field. Commercially available treatments, including NovaVision®
Visual Restorative Therapy, give people repeated exposure to stim-
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uli targeting a vision deficit in a direct attempt to help activate the
brain to restore vision (NovaVision 2009).
Compensation
Compensation aims to improve the mismatch between the skills
of those affected and the demands placed on them by their envi-
ronment by teaching them to compensate using a spared or intact
function (Kerkhoff 1999; Kerkhoff 2000; Peli 2000). Interven-
tions include teaching people compensatory visual search or scan-
ning techniques, varying from simple training strategies to inter-
ventions using computerised scanning schedules and specially-de-
veloped commercially available tools (such as NVT 2009). When
describing interventions for visual field defects, the term compen-
sation may be used synonymously with the term adaptation, but
we use the term compensation throughout this review.
Substitution
Substitution involves adaptation of visual components that have
been lost or disrupted through the use of optical devices or en-
vironmental modifications (Kerkhoff 1999; Kerkhoff 2000; Peli
2000). Optical devices can include prisms, which shift the image
received into an area that can be perceived, and typoscopes, which
provide a guide for eye movements when reading.
Assessment and screening interventions
These may work by ensuring that the visual field defect is appro-
priately diagnosed, enabling other interventions to be prescribed.
In those who have co-existing visual field defects and visual ne-
glect; determining the action of an effective intervention can be
difficult. The co-existence of visual neglect could prevent inter-
ventions aimed at the visual field defect from working effectively.
For example, teaching scanning techniques to people with visual
field defects may help them learn to compensate by scanning to
the affected field but may not be as effective in people with co-
existing visual neglect.
Why it is important to do this review
The services available to people with visual problems following
stroke are presently inconsistent. There are various treatment and
management approaches that are available for people with visual
field defects. However, these are used to varying degrees in clinical
practice (Rowe 2014), and clinicians lack research-based guidance
on the choice of treatment (Hanna 2017). There is a recognised
need to identify the evidence base for treatments for visual prob-
lems following stroke.There is considerable controversy and de-
bate about the effectiveness of restitutive interventions (Horton
2005a; Horton 2005b; Reinhard 2005; Sabel 2006). There are
a number of published reviews of the literature relating to inter-
ventions for visual problems following stroke. Barrett 2009 and
Riggs 2007 provided reviews of visual problems, which included
a small section relating to visual field problems after stroke; both
of these reviews were limited in their scope and methodological
quality. Bouwmeester 2007 completed a systematic review of the
effect of one intervention (visual training) on visual field defects in
people with brain damage, including stroke. Lane 2008 provided
a narrative review of evidence for interventions for visual field
loss. Das 2010 provided a narrative review with an emphasis on
restitutive interventions, and primarily discussed a range of cohort
studies that used localised, repetitive perceptual training aimed
at reversing visual field loss induced by cortical damage. Hanna
2017 provided a narrative review of evidence for visual impair-
ments, including visual field defect, summarising evidence from
earlier versions of this review and evidence from non-randomised
studies. There is agreement amongst these reviews that there is a
need for high-quality studies of the effectiveness of interventions
for visual field defects. In order to determine the current evidence
for the effectiveness of any treatment or management approaches
for stroke patients with visual field defects, and to enable appro-
priate planning and prioritisation of future primary research, it is
essential that there is an up-to-date high-quality systematic review
of the existing evidence base.
O B J E C T I V E S
The key objective of this review was to determine the effects of
interventions for people with visual field defects after stroke.
Research questions
• Do interventions for visual field defects improve functional
ability following stroke?
• Are interventions for visual field defects more effective at
improving functional ability in people with a visual field defect
only than in those both with a co-existing visual field defect and
visual perceptual problems?
Specific objectives
• To determine if in 1) all participants with visual field
defects following stroke (with or without visual perceptual
problems), 2) those with visual field defects and no visual
perceptual problems, and 3) those with co-existing visual field
defects and visual perceptual problems:
◦ restitutive interventions are more effective than
control, placebo, or no intervention at improving functional
ability in activities of daily living;
◦ compensative interventions are more effective than
control, placebo, or no intervention at improving functional
ability in activities of daily living;
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◦ substitutive interventions are more effective than
control, placebo, or no intervention at improving functional
ability in activities of daily living;
◦ assessment and screening interventions are more
effective than control, placebo, or no intervention at improving
functional ability in activities of daily living;
◦ any one active intervention is more effective than any
other active intervention at improving functional ability in
activities of daily living.
• To determine if in 1) all participants with visual field
defects following stroke (with or without visual perceptual
problems), 2) those with visual field defects and no visual
perceptual problems, and 3) those with co-existing visual field
defects and visual perceptual problems:
◦ restitutive interventions are more effective than
control, placebo, or no intervention at improving secondary
outcomes;
◦ compensatory interventions are more effective than
control, placebo, or no intervention at improving secondary
outcomes;
◦ substitutive interventions are more effective than
control, placebo, or no intervention at improving secondary
outcomes;
◦ assessment and screening interventions are more
effective than control, placebo, or no intervention at improving
secondary outcomes;
◦ any one active intervention is more effective than any
other active intervention at improving secondary outcomes.
• To explore the relationship between participant
characteristics and the effect of interventions aimed at improving
functional abilities in activities of daily living using subgroup
analysis.
• To make specific recommendations for future research into
the effectiveness of interventions for visual field defects based on
a knowledge of the existing evidence base.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and randomised controlled
cross-over trials (the first phase analysed as a parallel-group trial).
Types of participants
Adult participants (over 18 years of age) after stroke (using the
WorldHealthOrganization (WHO) definition of stroke, or a clin-
ical definition if not specifically stated; that is, signs and symp-
toms persisting longer than 24 hours) who have been diagnosed
as having a visual field defect.
Where studies included participants with visual field defects due to
reasons other than stroke (e.g. traumatic brain injury), in addition
to participants with visual field defects due to stroke, we included
these studies. We documented the number of participants with
each clinical diagnosis, and planned to use this information when
exploring heterogeneity.
We defined a visual field defect as a homonymous loss of vision
contralateral to the side of the lesion. We accepted a clinical diag-
nosis of visual field defect. We documented the method of diag-
nosing a visual field defect.
We excluded participants with monocular visual field defects due
to retinal stroke.
Types of interventions
We included any intervention that was specifically targeted at im-
proving the visual field defect or improving the ability of the par-
ticipant to cope with the visual field loss. We classified interven-
tions as either restitution, compensation, substitution, or assess-
ment and screening (see Description of the intervention).
We compared interventions with no treatment, placebo, and con-
trol, within four specific preplanned comparisons:
• restitutive interventions versus no treatment, placebo, or
control;
• compensatory interventions versus no treatment, placebo,
or control;
• substitutive interventions versus no treatment, placebo, or
control;
• assessment and screening interventions versus standard care.
We considered studies which compared one active intervention
with another active intervention within a narrative synthesis. We
did not plan to conduct any meta-analyses comparing one active
intervention with another active intervention as we anticipated
that there would be substantial variation in the interventions, and
that it would not make sense to combine the results.
Two review authors (CH, AP) independently classified the types
of interventions in each included trial as either restitution, com-
pensation, substitution, or assessment and screening. We antici-
pated that we might experience some difficulties in the classifica-
tion of some interventions, in particular, the classification of inter-
ventions as either restitutory or compensatory, and had planned
to reach consensus through discussion, involving a third review
author when necessary. If there was uncertainty about the action
of a particular intervention, we planned to carry out sensitivity
analyses to explore the effect of removing and including the rele-
vant trial(s). However, the two independent review authors agreed
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on all classifications and did not require further discussion with a
third review author.
Types of outcome measures
Where possible, we assessed the outcome at the end of the inter-
vention period and at a follow-up point (ideally six months af-
ter the intervention had finished, but we accepted any follow-up
point after the intervention period had finished, documenting the
time point).
Primary outcomes
Functional ability in activities of daily living (ADL)
We included the following validated scales: Barthel Activities
of Daily Living Index (Mahoney 1965), Functional Indepen-
dence Measure (FIM) (Smith 1990), modified Rankin Scale
(mRS) (Wilson 2002), Katz Index of Activities of Daily Living
(Katz 1963), and Rehabilitation Activities Profile (Van Bennekom
1995). If more than one of these functional ability scales was re-
ported, we used the scale appearing earliest in our list.
Secondary outcomes
We included the following secondary outcomes.We prestated out-
comemeasurement tools/scaleswhichwe anticipated, andplanned
that if more than one of the scales or measures was reported, we
would use the scale appearing earliest in our list. If additional tools/
scales were reported, but none from our prestated list, we included
these.
• Functional ability in extended activities of daily living
(EADL): Nottingham Extended Activities of Daily Living scale
(Nouri 1987), Lawton Instrumental Activities of Daily Living
(Lawton 1969), Frenchay Activities Index (Holbrook 1983),
Rivermead Activities of Daily Living (ADL) score (Lincoln
1990).
• Reading - reading ability: reading speed (text reading time),
reading accuracy (Wide Range Achievement Test
(WRAT)(Wilkinson 2006), Gray Oral Reading test (Bryant
2011).
• Visual field: visual field outcomes subdivided into 1) gross
visual screening: confrontation tests, Harrington Flocks Visual
Screener; 2) kinetic perimetry: Goldmann perimetry, Tangent
Screen measures; 3) static perimetry: Humphrey Automated
Perimetry, Tubinger Automated Perimetry (TAP), High
resolution perimetry (HRP). For perimetry outcomes: when
more than one measure had been taken with the same
instrument we reported border position for the intact visual field
and used it for analysis in preference to hit or detection rate.
• Balance: Berg Balance Scale (Berg 1989), Functional Reach
(Duncan 1990), Get-Up and Go test (Mathias 1986), Standing
Balance test, Step Test, or other standardised balance measure.
We did not include measures of weight distribution or postural
sway during standing as the relationship between ability to
maintain balance and these outcomes is not established.
• Falls: number of reported falls, Falls Efficacy Scale (Tinetti
1990).
• Depression and anxiety: Hospital Anxiety and Depression
scale (Zigmond 1983), Beck Depressive Inventory (Beck 1987),
General Health Questionnaire (Goldberg 1979), Geriatric
Depression Scale (Cinnamon 2011).
• Discharge destination or residence after stroke:
dichotomous variable - discharged to previous place of residence
(i.e. place of residence prior to stroke) or discharged to
alternative destination.
• Quality of life and social isolation: EQ5D (Rabin 2001),
Health-related quality of life scale (Williams 1999), Quality of
Well Being scale (Kaplan 1993), SF36 (Garrett 1993).
• Visual scanning: cancellation techniques.
• Adverse events: any reported adverse events, excluding falls,
death.
• Death.
Search methods for identification of studies
See the methods for the Cochrane Stroke Group Specialised
register. We searched for trials in all languages and arranged for
the translation of trials where necessary.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (May
2018), the Cochrane Eyes and Vision Group Trials Register (May
2018) and the following electronic bibliographic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 1) in the Cochrane Library (accessed
May 2018) (Appendix 1);
• MEDLINE Ovid (1950 to 16 May 2018) (Appendix 2);
• Embase Ovid (1980 to 16 May 2018) (Appendix 3);
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; 1982 to 16 May 2018) (Appendix 4);
• AMED Ovid (Allied and Complementary Medicine; 1985
to 16 May 2018) (Appendix 5);
• PsycINFO (1967 to 16 May 2018) (Appendix 6);
• ProQuest Dissertations & Theses (PQDT) database (1861
to 22 March 2015) (Appendix 7).
Searching other resources
In an effort to identify further published, unpublished and ongo-
ing trials we:
• searched the following registers of ongoing trials:
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◦ US National Institutes of Health Ongoing Trials
Register ClinicalTrials.gov (www.clinicaltrials.gov; May 2018)
(Appendix 8);
◦ World Health Organization International Clinical
Trials Registry Platform (apps.who.int/trialsearch; May 2018)
(Appendix 8);
◦ ISRCTN Registry (www.isrctn.org) (formerly known
as the Current Controlled Trials; www.controlled-trials.com)
(March 2015);
◦ Health Service Research Projects in Progress (
wwwcf.nlm.nih.gov/hsr project/home proj.cfm) (March 2015);
◦ National Eye Institute Clinical Studies Database
(clinicalstudies.info.nih.gov/cgi/protinstitute.cgi?NEI.0.html)
(March 2015);
◦ Stroke Trials Registry ( www.strokecenter.org/trials/)
(March 2015);
• handsearched the following journals and conference
proceedings:
◦ Australian Orthoptic Journal (1959 to August 2018);
◦ British Orthoptic Journal (1939 to August 2003);
◦ British and Irish Orthoptic Journal (2004 to August
2018);
◦ International Orthoptic Association ( IOA) (
www.liverpool.ac.uk/orthoptics/research/search.htm) (1967 to
August 2018);
◦ International Strabismological Association (ISA)
(1966 to August 2018);
◦ Proceedings of the European Strabismological
Association (ESA) (1969 to August 2018).
We searched the reference lists of included trials and review articles
about vision after stroke and contacted experts in the field.
Data collection and analysis
One review author (CH or PC) ran all the electronic searches,
downloaded references into bibliographic software, and removed
duplicates. One review author excluded any titles which were ob-
viously not related to stroke and vision (one of CH, PC, or AP).
We obtained the abstracts for remaining references and two re-
view authors (two of CH, AP, PC, SJ, AK) independently consid-
ered each of these abstracts, excluded any studies that were clearly
not RCTs or cross-over trials, and excluded any studies where the
intervention was not specifically aimed at improving the visual
field defect or the participant’s ability to cope with the visual field
defect. The review authors resolved any disagreements through
discussion, involving a third review author where necessary. We
obtained the full papers for any studies included at this stage.
Selection of studies
Two review authors independently applied the selection criteria by
considering and documenting the type of studies, type of partic-
ipants, intervention, comparison intervention, and the outcome
measures (two of AP, CH, SJ, AK). Each review author classified
studies as ’include’ or ’exclude’. If there was disagreement between
these two review authors, they reached consensus through discus-
sions involving a third review author.
We listed any excluded studies that included participants with
visual field defects in the Characteristics of excluded studies table
and provided the reason for exclusion. We did not list studies
that were excluded because they included participants who did
not have visual field defects (i.e. visual neglect, eye-movement
disorders, age-related visual problems) in the Characteristics of
excluded studies table unless the two review authors agreed that
there was a clear reason to do so.
Data extraction and management
We used a pre-designed data extraction form to extract data from
the included studies. Two review authors (two of AP, CH, SJ)
independently documented the following.
• Methods: study design, method of randomisation.
• Participants: number of participants, inclusion criteria, time
since stroke, type, nature and location of lesion. We documented
the method of diagnosing the visual field defect and the type and
extent of the visual field loss; the presence or absence of visual
perceptual problems, and the method of diagnosis; and the
country of origin of participants. We documented whether the
included participants had visual field defects only (no visual
neglect), co-existing visual field defects and visual neglect, or
whether the participants were a mixed group (some with and
some without visual neglect). If there was a mixed group of
participants, we documented whether data were available for the
visual field defect-only group and the group with co-existent
visual field and visual neglect. Where information was available,
we documented the presence or absence of eye movement
disorders or low vision, accepting a clinical diagnosis of these.
• Interventions: description of interventions given to each
treatment group including, if relevant, the duration, intensity,
frequency and dose. We classified the type of intervention as
restitution, compensation, substitution, or assessment and
screening; and the type of control as no treatment, placebo,
control, or standard care. We documented the professional
background of the person providing the intervention (e.g.
occupational therapist, orthoptist).
• Outcomes: we documented the primary and secondary
outcomes relevant to this review. If a study used a number of
different methods of measuring the same outcome, we noted the
outcome to be used for any subsequent analysis.
• Notes: we noted any important confounding variables. If
more than two intervention groups were included in the study,
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we noted the method of including these groups in any
subsequent analysis.
In addition, the review authors independently documented, if data
allowed, the following demographics of the included participants:
age, gender, place of residence, type of stroke, side of stroke, time
since stroke, initial visual field defect, and initial functional abil-
ity. The review authors resolved any data extraction discrepancies
through discussion.
Assessment of risk of bias in included studies
Two independent authors (two of AP, CH, SJ) assessed risk of
bias by grading the following domains as ’low risk’, ’high risk’ or
’unclear risk’ of bias for each included study. We documented this
within the ’Risk of bias’ tables.
Allocation concealment
Studies with adequate concealment included those that used cen-
tral randomisation at a site remote from the study, computerised
allocation in which records were in a locked readable file that could
be assessed only after entering participant details, or the drawing of
opaque envelopes. Studies with inadequate concealment included
those using an open list or table of random numbers, open com-
puter systems, or drawing of non-opaque envelopes. Studies with
unclear concealment included those with no or inadequate infor-
mation in the report.
Blinding
Adequate concealment included studies which stated that a
masked outcome assessor was used, and that had masking of par-
ticipants and key study personnel and did not identify any ’un-
masking’. Inadequate concealment included studies that did not
use masking of the outcome assessor, personnel, or participants,
where there was incomplete masking, or where the report clearly
identified that ’unmasking’ occurred during the study. We docu-
mented concealment as unclear if a study did not state, or if there
was insufficient information to judge, whether or not personnel,
participants, and outcome assessors were masked. We acknowl-
edged that for some (but not all) interventions for visual field de-
fects, masking of personnel or participants, or both, is not possible,
and considered the potential for any lack of blinding of personnel
or participants, or both, to introduce bias.
Incomplete outcome data
Studies adequately addressing incomplete outcome data either
had: no missing outcome data; missing outcome data that were
unlikely to be related to true outcome; missing outcome data that
were balanced in numbers across intervention groups, with similar
reasons formissing data across groups; a reported effect size (differ-
ence in means or standardised difference in means) among miss-
ing outcomes that were not enough to have a clinically relevant
impact on observed effect size; or missing data that had been im-
puted using appropriate methods. Studies inadequately addressing
incomplete outcome data either had: missing outcome data that
were likely to be related to true outcome, with either imbalance in
numbers or reasons for missing data across intervention groups; a
reported effect size (difference in means or standardised difference
in means) among missing outcomes enough to induce clinically
relevant bias in the observed effect size; as-treated analysis done
with substantial departure of the intervention received from that
assigned at randomisation. We documented addressing of incom-
plete outcome data as unclear if there was insufficient reporting to
allow this to be assessed, or if this was not addressed in the report.
Other bias
We assessed a study not to be free of other bias if it was assessed to
have at least one important risk of bias, such as: a potential source
of bias related to the specific study design used, an extreme baseline
imbalance, a claim to have been fraudulent, financial association
with the intervention, or some other problem. If there was insuf-
ficient information, or the information provided was unclear, we
documented the risk of other bias as unclear.
We produced a ’Risk of bias’ summary figure to illustrate the po-
tential biases within each of the included studies.
Measures of treatment effect
We used the Review Manager software RevMan 5.3 (RevMan
2014) to carry out statistical analyses to determine the treatment
effect of:
• restitutive interventions (compared to no treatment,
control, placebo, or standard care);
• compensatory interventions (compared to no treatment,
control, placebo, or standard care);
• substitutive interventions (compared to no treatment,
control, placebo, or standard care);
• assessment and screening interventions (compared to
standard care).
We used a random-effects model for all statistical analyses. For di-
chotomous, variables we calculated and reported Peto odds ratios
(ORs) with 95% confidence intervals (CIs). For continuous data,
we calculated the treatment effect using standardised mean differ-
ences (SMDs) and 95% CIs where studies used different scales for
the assessment of the same outcome, and using mean differences
(MDs) and 95% CIs where all studies used the same method of
measuring an outcome.
The primary outcome of functional ability in activities of daily
living, and secondary outcomes of functional ability in extended
activities of daily living, visual field data, balance, depression and
anxiety, and quality of life and social isolation comprise either
ordinal data from measurement scales, or continuous data. We
analysed these as continuous variables.
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Where reported outcomes had a measurement scale where a lower
value is indicative of a better outcome (e.g. depression and anxiety
scales) wemultiplied the reported values by -1 so that in all analyses
a higher value was indicative of a better outcome.
If studies reported change values and the baseline value was avail-
able, we calculated the value at follow-up (change value - baseline
value). If studies reported change values and the baseline value
was not available, we used these data in meta-analyses but planned
sensitivity analyses to investigate the effect of including the data.
We planned to analyse falls, discharge destination, adverse events,
and deaths as dichotomous variables.
Unit of analysis issues
We anticipated that the majority of trials would have a parallel-
group design in which each individual participant was randomised
to one of two, or more, treatment groups. Where studies had two
or more active intervention groups eligible for inclusion within
the same comparison (against a control, placebo, or no treatment
group), we intended to ’share’ the control group data between the
multiple pair-wise comparisons in order to avoid double counting
of participants within an analysis.
If studies used a randomised controlled cross-over design, we
planned to analyse data from the first phase only. We did not an-
ticipate that any studies would use a cluster-randomised design.
Dealing with missing data
If an included study did not report a particular outcome, we did
not include that study in the analysis of that outcome.
If an included study had missing data (e.g. reported means but
not standard deviations for the follow-up data), we took logical
steps to enter an assumed value. Such steps included estimating a
standard deviation (SD) based on a reported standard error and es-
timating a follow-up SD based on a baseline value. We performed
calculations of SDs from standard errors and P values using meth-
ods described in section 7.7.3.3 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We planned to do
sensitivity analyses to investigate the effect of entering assumed
values. We also contacted authors in an attempt to obtain missing
data.
Assessment of heterogeneity
We visually assessed heterogeneity by looking at the extent of over-
lap of the CIs on the forest plots. We considered the P value, con-
sidering that with P < 0.1 there was likely to be heterogeneity. We
considered the I2 statistic. We considered I2 > 50% as substantial
heterogeneity. If I2 > 50%, we explored the individual trial char-
acteristics to identify potential sources of heterogeneity.
Assessment of reporting biases
We attempted to avoid reporting biases by using a comprehensive
search strategy that included searching for unpublished studies
and searching trials registers. We planned to carry out sensitivity
analyses to explore the effect of publication type.
Data synthesis
Two review authors (AP, CH, or SJ) independently extracted data
from the included trials. One review author (AP) entered the data
into RevMan 5.3 (RevMan 2014), and the other review author
checked the entries. They resolved any disagreements through dis-
cussion, with reference to the original report.
Subgroup analysis and investigation of heterogeneity
We intended to explore heterogeneity by subgroup analyses to
investigate the effect of:
• time after stroke (zero to three months, three to six months,
more than six months);
• type of visual field defect (homonymous hemianopia, other)
(We anticipated that the majority of the participants would have
homonymous hemianopia. However, we documented the type of
visual field defect and planned subgroup analyses to investigate
the effect of including participants with types other than
homonymous hemianopia);
• extent of visual field loss if homonymous (complete
hemianopia, partial hemianopia, quadrantanopia);
• presence or absence of visual neglect (no visual neglect, all
participants with co-existing visual field defects and visual
neglect, mixed group of participants some with and some
without visual neglect);
• macular sparing, macular splitting field loss;
• type of treatment (e.g. for compensatory interventions:
saccadic eye movement, activities of daily living training; for
substitutive interventions: prisms, patches, environmental
modifications; for assessment and screening: by orthoptist,
occupational therapist, doctor).
We planned to use an established method for subgroup analyses
(Deeks 2001). We planned to carry out these subgroup analyses
when there were six or more studies included in a single analysis,
all with sufficient information to determine the subgroups.
Sensitivity analysis
We planned to carry out sensitivity analysis to explore the effect
of the following methodological features.
• Allocation concealment: we planned to re-analyse data,
excluding trials with inadequate or unclear allocation
concealment.
• Masking of outcome assessor: we planned to re-analyse
data, excluding trials without or with unclear masking of
outcome assessor.
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• Missing outcome data: we planned to re-analyse the data,
excluding trials with inadequate or unclear methods of dealing
with missing outcome data.
• Other bias: we planned to re-analyse the data, excluding
trials assessed to have other bias, or unclear as to whether they
had other bias.
• Type of intervention: we planned to re-analyse data,
excluding trials where the classification of the type of
intervention was uncertain.
• Publication type (peer-reviewed journal, conference abstract
or proceedings, doctoral dissertation): we planned to re-analyse
data including only those trials from peer-reviewed journals.
We planned to carry out these planned sensitivity analyses when
there are six or more studies included in a single analysis.
GRADE assessment and ’Summary of findings’ tables
We presented the results of the main preplanned comparisons of
the review in ’Summary of findings’ tables;
• restitutive interventions (compared to no treatment,
control, placebo, or standard care): Summary of findings for the
main comparison;
• compensatory interventions (compared to no treatment,
control, placebo, or standard care): Summary of findings 2;
• substitutive interventions (compared to no treatment,
control, placebo, or standard care): Summary of findings 3;
• assessment and screening interventions (compared to
standard care): Summary of findings 4.
Within each ’Summary of findings’ table, we summarised data for
the primary outcome of interest (functional ability in activities
of daily living), the six secondary outcomes for which we had
identified the greatest volume of evidence in previous versions of
this review (visual field, extended activities of daily living, reading
ability, falls, quality of life, scanning - cancellation), and any data
related to adverse events.
For each of the preplanned comparisons, we assessed quality of the
evidence using theGRADEapproach (Guyatt 2011a), considering
each of the following criteria.
• Risk of bias due to flawed design or conduct of studies
(Guyatt 2011b).
• Imprecision (e.g. when confidence intervals for treatment
effect are wide) (Guyatt 2011d).
• Inconsistency (e.g. when point estimates vary widely, I² is
large) (Guyatt 2011e).
• Indirectness (e.g. variations in participants, interventions,
comparisons, and outcomes) (Guyatt 2011f).
• Publication bias (may be explored with the use of funnel
plots and classed as not suspected, suspected, strongly suspected
or very strongly suspected) (Guyatt 2011c).
We documented identified concerns relating to any of the above
criteria, and downgraded the level of evidence accordingly (one
downgrade for each concern, and a maximum of two downgrades
for each of the listed criteria). If there were no downgrades the level
of evidence was high quality, if there was one downgrade the level
of evidence was moderate quality, if there were two downgrades
the level of evidence was low quality, and if there were more than
two downgrades the level of evidence was very low quality. We
used the following definitions of evidence.
• High quality: when further research is very unlikely to
change our confidence in the estimate of effect.
• Moderate quality: when further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate.
• Low quality: when further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate.
• Very low quality: when we are very uncertain about the
estimate.
One review author (AP) assessed quality of evidence, reported
identified concerns, and applied downgrades. Other review au-
thors checked agreement with these judgements and resolved any
disagreements through discussion.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies, Characteristics of
studies awaiting classification.
Results of the search
Results of the search are shown in Figure 1. Our search strategy
identified 17,224 records from the main electronic databases, and
we identified a further eight studies through our wider search.
One review author (AP, CH or PC) eliminated 15,658 titles that
were clearly irrelevant, and two review authors (AP, CH) applied
the inclusion criteria to the remaining 1574 abstracts, identifying
178 to be considered at full text. Of these, we identified a total
of 20 studies for inclusion. In addition, we identified seven ongo-
ing studies (see Characteristics of ongoing studies), and two stud-
ies that require further assessment (see Characteristics of studies
awaiting classification).
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Figure 1. Study flow diagram.
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Included studies
We included 20 studies (732 randomised participants, with data
available for 638, of whom547 (85%) had a diagnosis of ischaemic
or haemorrhagic stroke) in this updated review (Aimola 2011;
Bainbridge 1994; Bowers 2014; De Haan 2015; Elshout 2016;
Gall 2013; Jarvis 2012; Jobke 2009; Kasten 1998; Kasten 2007;
Keller 2010;Modden 2012; Plow 2010; Poggel 2004; Rossi 1990;
Roth 2009; Rowe 2010; Schuett 2012; Spitzyna 2007; Szlyk
2005).
The previous version of this review included 13 studies (344 ran-
domised participants, 285 of whom were participants with stroke)
(Bainbridge 1994; Carter 1983; Jobke 2009; Kasten 1998; Kasten
2007; Plow 2010; Poggel 2004; Rossi 1990; Roth 2009; Spitzyna
2007; Szlyk 2005; Weinberg 1977; Weinberg 1979). However,
we have excluded three of these studies from this update (Carter
1983, Weinberg 1977; Weinberg 1979: see Excluded studies for
reason for these exclusions).
There were only abstracts available for Bainbridge 1994 and Gall
2013. In the previous version, Plow 2010 was based on data from a
conference abstract and ongoing trials register data only; however,
for this update a full paper was available.
We present a brief overview of the studies below. Full descriptions
of the included studies can be found in the Characteristics of
included studies table and in Table 1 (Demographics of included
studies: settings of included studies), Table 2 (Demographics of
included studies: demographics of included participants), Table 3
(Demographics of included studies: visual problems of included
participants), and Table 4 (Outcome measures within included
studies).
Study design
Fifteen of the included studies were parallel-group randomised
controlled trials (RCTs), and five were randomised cross-over stud-
ies (Bowers 2014; Elshout 2016; Jobke 2009; Schuett 2012; Szlyk
2005).
Sixteen of the included studies randomised participants to one of
two treatment groups; three had three treatment groups (Kasten
2007; Modden 2012; Rowe 2010); and one was a cross-over AB/
BA design, where A was an active treatment and B a placebo; how-
ever participants were also randomised to receive one of two dif-
ferent active treatments, each of which had a related sham treat-
ment meaning that there were effectively four different treatment
groups (active 1, active 2, sham 1 and sham 2) (Bowers 2014).
Comparison versus control
Ten of the 20 included studies had a control (no treatment, stan-
dard care, or placebo) group, comparing 10 active treatments with
control (Rowe 2010 had two active treatment groups):
• three compared a restitutive intervention with control (Gall
2013; Elshout 2016; Kasten 1998);
• four compared a compensatory intervention with control
(Aimola 2011; De Haan 2015; Rowe 2010; Spitzyna 2007);
• three compared a substitutive intervention with control
(Bowers 2014; Rossi 1990; Rowe 2010);
• one compared assessment/screening with control (Jarvis
2012).
In Rowe 2010, the two active treatment groups (compensatory
and substitutive interventions) were compared with each other.
Ten of the 20 included studies did not have a control group. Nine
compared two different active treatments, and one had three active
treatment groups (Modden 2012):
• four compared different restitutive interventions (Jobke
2009; Kasten 2007; Plow 2010; Poggel 2004);
• three compared different compensatory interventions
(Keller 2010; Modden 2012; Schuett 2012);
• two compared different substitutive interventions
(Bainbridge 1994; Szlyk 2005);
• two compared compensatory and restitutive interventions
(Modden 2012; Roth 2009).
Interventions studied
Restitutive interventions
Nine studies (239 randomised participants) investigated the effect
of restitutive interventions.
In eight of these studies, the restitutive intervention studied was a
form of computer-based vision restoration therapy:
• Kasten 1998 and Elshout 2016 compared visual restitution
therapy with a placebo intervention;
• Jobke 2009 and Kasten 2007 compared the effectiveness of
two (or more) types of visual restitution therapy;
• Plow 2010 explored the effect of adding transcranial direct
current stimulation (tDCS) to visual restitution therapy;
• Poggel 2004 explored the effect of adding attentional
cueing to visual restitution therapy;
• Modden 2012 compared computerised restitution therapy
with two different compensatory interventions;
• Roth 2009 compared ’flicker-stimulation training’, which
the authors described as a “potential” restitutive intervention,
with a compensatory intervention.
In one of these nine included studies, the restitutive intervention
studied was a form of non-invasive brain stimulation using alter-
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nating current stimulation. This was compared with a placebo in-
tervention (Gall 2013).
Compensatory interventions
Eight studies (347 randomised participants) investigated the effect
of compensatory interventions:
• Aimola 2011 compared computer-based compensatory
training with a control;
• Spitzyna 2007 compared computer-based reading training
(“optokinetic nystagmus inducing reading therapy”, involving
reading scrolling right to left text) with a control;
• De Haan 2015 compared a compensatory scanning training
programme with a control;
• Rowe 2010 compared paper-based visual scanning training
with a control (and with a substitutive intervention);
• Keller 2010 compared two types of compensatory training -
audiovisual exploratory training and visual exploration training;
• Schuett 2012 compared two types of compensatory
training - visual exploration training and reading training;
• Modden 2012 compared computerised scanning training,
an occupational therapy compensatory training program, and a
computerised restitutive therapy;
• Roth 2009 compared computer-based scanning training
with restitutive training.
Substitutive interventions
Five studies (227 randomised participants) investigated the effect
of substitutive interventions. In all five studies, the substitutive
intervention studied was a type of prism:
• Rossi 1990 compared 15 diopter Fresnel prisms with no
prisms;
• Rowe 2010 compared 40 diopter Fresnel prisms with no
treatment, and with a compensatory intervention;
• Bowers 2014 compared 57 diopter oblique prism glasses
and horizontal prism glasses with five diopter sham prism glasses;
• Bainbridge 1994 compared full-field 15 diopter Fresnel
prisms with hemi-field 15 diopter Fresnel prisms;
• Szlyk 2005 compared 20 diopter Fresnel prisms with 18.5
dioptre Gottlieb VFAS (Visual Field Awareness System) prisms.
Assessment and screening interventions
One study (64 randomised participants) investigated the effec-
tiveness of an assessment and screening intervention on relevant
outcomes:
• Jarvis 2012 compared the effect of providing therapy staff
with information from an orthoptic assessment with no
intervention.
Populations studied
The reported diagnoses of the participants within the 20 included
studies were as follows:
• 14 studies recruited participants with mixed diagnoses
including stroke, trauma, surgery, and infections;
• five studies included participants with stroke only; and
• one study - the cause of the lesion was unclear.
(See details in Characteristics of included studies and Table 2).
Despite the high number of studies including participants with
mixed diagnoses, the majority of participants in the studies in
this review did have stroke (across all studies, 85% (520/611) of
participants with data reported had a diagnosis of stroke).
Fourteen of the 20 included studies included participants with vi-
sual field defects only (no visual neglect); seven of 14 studies clearly
stated the method of diagnosis of visual neglect (Bowers 2014; De
Haan 2015; Elshout 2016; Keller 2010; Roth 2009; Rowe 2010;
Schuett 2012), four of the 14 studies stated that participants with
neglect were excluded but did not state the method of diagnosis of
visual neglect (Kasten 1998; Kasten 2007; Modden 2012; Poggel
2004), and in the three remaining studies it was assumed (but
not clearly stated) that participants with visual field defects only
were included (Jobke 2009; Spitzyna 2007; Szlyk 2005). Four of
the included studies included participants who had visual neglect
in addition to, or instead of, visual field defects (Aimola 2011;
Bainbridge 1994; Jarvis 2012; Rossi 1990). In two studies, it was
unclear whether the participants had visual neglect or not (Gall
2013; Plow 2010). See Table 3.
Visual field measurement
All 20 included studies reported a measurement of the visual field
in order to inform participant inclusion or provide baseline in-
formation relating to visual field defect, or both. Seven reported
one visual field measure (De Haan 2015; Gall 2013; Jarvis 2012;
Modden 2012; Plow 2010; Schuett 2012; Szlyk 2005), 11 re-
ported two visual field measures (Aimola 2011; Bainbridge 1994;
Bowers 2014; Elshout 2016; Jobke 2009; Kasten 1998; Keller
2010; Rossi 1990; Roth 2009; Rowe 2010; Spitzyna 2007), and
two reported three visual field measures (Kasten 2007; Poggel
2004). Spitzyna 2007 reported a second measure only where the
first perimetric results had poor reliability.
In three studies, the perimetry equipment was unclear (Aimola
2011; Gall 2013; Jobke 2009), and in Rowe 2010, either of two
types of perimetry was reported (Esterman static programme or
Goldmann kinetic).
Visual field measurements were categorised as:
• gross visual screening: five studies reported gross visual
screening; two using the Harrington Flocks visual screener
(Bainbridge 1994; Rossi 1990), two using a confrontation
method (Bainbridge 1994; Jarvis 2012), one reporting the visual
field assessment from the Test Battery of Attentional
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Performance (Modden 2012), and one a subjective topographic
measure of perceived visual field defect (Plow 2010);
• kinetic perimetry: 10 studies reported measures of kinetic
perimetry; seven used Goldmann perimetry (Bowers 2014; De
Haan 2015; Elshout 2016; Keller 2010; Rowe 2010; Spitzyna
2007; Szlyk 2005), one used Tubingen kinetic perimetry
(Schuett 2012), one used tangent screen measures (Rossi 1990),
and one used an unspecified kinetic perimeter (Aimola 2011);
• static threshold perimetry: eight studies reported static
perimetry measures; two used standard automated perimetry
(Gall 2013; Jobke 2009), four used Tubinger automated
perimetry (TAP) (Kasten 1998; Kasten 2007; Poggel 2004; Roth
2009), and two used Humphrey automated perimetry (Elshout
2016; Spitzyna 2007);
• static suprathreshold (inclusive of full field 120, Esterman,
campimetry, tangent screen): five studies reported static
suprathreshold measures; two reported Esterman measures
(Aimola 2011; Rowe 2010), one reported Humphrey full field
120 (Bowers 2014), one reported suprathreshold checks on a
Goldmann perimeter (Keller 2010), and one reported high
resolution campimetry (Poggel 2004);
• resolution perimetry: six studies reported resolution
perimetry measures; five used high resolution perimetry (HRP)
(Jobke 2009; Kasten 1998; Kasten 2007; Plow 2010; Poggel
2004), and one used scanning laser ophthalmoscopy (Roth
2009).
Sample size
On average, included studies randomised 36 participants (stan-
dard deviation, 22 participants) into the trial prior to attrition.
This ranged from just 10 participants (Szlyk 2005), to 87 partic-
ipants (Rowe 2010). Only five of 19 studies recruited more than
50 participants: Aimola 2011 (n = 70), Bowers 2014 (n = 73), De
Haan 2015 (n = 54), Jarvis 2012 (n = 64), and Rowe 2010 (n =
87). A total of 732 participants were recruited across the 20 in-
cluded studies, with data available for 638 participants, of whom
547 were stroke patients. See Table 2 for recruitment numbers
across all included studies.
Outcome measures
Table 4 summarises the outcome measures within the included
studies, and highlights which studies had data which was suitable
for inclusion in meta-analyses within this review.
Primary outcome
• Functional ability in activities of daily living. Three studies
included a measure of functional ability: Rossi 1990 reported the
Barthel Index, Jarvis 2012 reported the FIM, and Modden 2012
reported the extended Barthel Index (German version).
Secondary outcomes
• Visual field. As reported above, all 20 included studies used
at least one measure of visual field at inclusion/baseline.
However, two of the studies did not measure visual field as an
outcome (i.e. measured following treatment) (Bowers 2014;
Jarvis 2012); in one cross-over study, while it was measured as an
outcome, no measurement was taken immediately after the
cross-over (Schuett 2012); while in Aimola 2011 it was unclear
whether this was measured as an outcome or just at baseline. The
methods of assessing visual field as a study outcome are
summarised in Table 4. Visual field outcomes of potential
relevance to our meta-analyses included measures of: 1) gross
visual screening: four studies (Bainbridge 1994; Rossi 1990,
Modden 2012, Plow 2010); 2) kinetic perimetry: seven studies
(Aimola 2011; De Haan 2015; Elshout 2016; Keller 2010; Rowe
2010; Spitzyna 2007; Szlyk 2005); 3) static threshold perimetry:
eight studies (Jobke 2009; Kasten 1998; Kasten 2007; Elshout
2016; Gall 2013; Poggel 2004, Roth 2009, Spitzyna 2007); 4)
static superthreshold perimetry: four studies (Keller 2010; Poggel
2004; Rossi 1990; Rowe 2010); and 5) resolution perimetry; six
studies (Jobke 2009; Kasten 1998; Kasten 2007; Plow 2010;
Poggel 2004; Roth 2009).
• Extended activities of daily living. Three studies reported a
measure of extended activities of daily living (other than a
measure of reading ability). Two were measures of functional
mobility: Bowers 2014 quantified “Perceived difficulties with
mobility” using “a 5-point rating scale (no difficulty to extreme
difficulty) for seven situations (items) relevant to homonymous
hemianopia, including at home, in stores, outdoors, in
unfamiliar areas, in familiar areas, in crowded areas, and noticing
objects off to the side when walking”; and De Haan 2015 used
an independent mobility questionnaire. Rowe 2010 reported the
Nottingham Extended Activities of Daily Living index.
• Reading. Ten studies reported measures of reading ability
(Aimola 2011; De Haan 2015; Elshout 2016; Jobke 2009; Keller
2010; Modden 2012; Roth 2009; Rowe 2010; Schuett 2012;
Spitzyna 2007). The measures used were the Radner reading test
in three studies (De Haan 2015; Jobke 2009; Rowe 2010), tests
of reading speed in seven studies (Aimola 2011; De Haan 2015;
Elshout 2016; Keller 2010; Roth 2009; Schuett 2012; Spitzyna
2007), and measures linked to the correctness of reading in four
studies (De Haan 2015; Jobke 2009; Modden 2012; Schuett
2012). Text reading time data were displayed graphically by
Spitzyna 2007 but actual data were confirmed by
correspondence with the author.
• Falls. One trial reported the number of falls (Rossi 1990).
• Quality of life. Ten trials reported measures of quality of life
(Aimola 2011; De Haan 2015; Gall 2013; Jobke 2009; Kasten
1998; Kasten 2007; Keller 2010; Plow 2010; Roth 2009; Rowe
2010), with several reporting more than one type of measure.
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The National Eye Institute Visual Functioning Questionnaire
(NEI-VFQ) was used by five studies (Aimola 2011; De Haan
2015; Gall 2013; Jobke 2009; Rowe 2010), the Short-Form 12
(SF-12) by two studies (Gall 2013; Rowe 2010), the World
Health Organization Quality of Life Bref (WHOQOL-Bref ) by
one (Roth 2009), the Impact of Visual Impairment profile (IVI)
and Veterans Affairs Low Vision Visual Function Quaestion (LV-
LFQ) by one (Plow 2010), and the EQ-5D (standardised
EuroQol health-related quality of life instrument) by one (Rowe
2010). A number of different, often self-designed, questionnaires
of satisfaction, improvement and visual ability levels were also
used (see Table 4). The quality of life data from Kasten 1998
were included as a dichotomous variable as the data presented in
the published paper were a percentage of those who reported
subjective improvements of vision; the results were for both the
pre- and post-chiasmal group, with 30 of the 38 participants
responding.
• Visual scanning. Eight trials reported measures of visual
scanning as assessed by a range of scanning and cancellation
techniques (Aimola 2011; Bainbridge 1994; De Haan 2015;
Keller 2010; Modden 2012; Rossi 1990; Roth 2009; Schuett
2012). In addition, one reported the visual scan test from the
Test Battery of Attentional Performance (Modden 2012), and
one also used a video eye tracker (Roth 2009). Reported data
included scanning/search time and number of errors or
omissions (see Table 4). Where a study reported a range of
scanning outcomes, we prioritised measures of scanning time for
meta-analyses. De Haan 2015 used three different visual
scanning tests, and reported a range of different data; we used the
results of the “parallel search test” for all trials (target present and
target absent), but explored the impact of using alternative data.
Excluded studies
We excluded 158 papers after assessment of the full paper (see
Figure 1). Sixty-two of the 158 clearly did not meet the inclusion
criteria, and 30 of the 158 were duplicate publications of excluded
studies. Fifty-seven of the 158 papers required more in-depth ap-
praisal prior to exclusion; we have provided our reasons for ex-
clusion of these studies in the Characteristics of excluded studies
table. We excluded the majority of these because the intervention
was not specifically targeted at the ability of the participant to
cope with visual field loss (32/57), or because the study was not
randomised (22/57). We found one study did not include partic-
ipants with stroke, one was focused on central alexia, and one was
exploring agreement using a visual screening tool.
We included three studies in the previous (2011) version of this
review (Carter 1983, Weinberg 1977 and Weinberg 1979), but
they have been excluded in this update: in the 2011 version, we
included studies that investigated the effectiveness of visual scan-
ning training and techniques even if the population of partici-
pants had not been clearly defined as having visual field defects.
Carter 1983, Weinberg 1977 and Weinberg 1979 included pop-
ulations of participants with ’visual scanning’ problems, who may
have had either visual field defects or visual neglect, or both. For
this latest update, we reconsidered and reversed this decision: we
have excluded populations of participants with ’visual scanning
problems’, but no confirmed visual field defect, to ensure that all
included studies are focused on stroke survivors with confirmed
visual field defects.
Studies awaiting classification
Two studies are awaiting classification (Ghandehari 2011; Sand
2017). Ghandehari 2011 compared two different pharmacological
interventions (Neuroaid and Piracetam) without a control group.
The selection criteria, which were prestated for this review, did not
clearly state whether pharmacological interventions were relevant
for inclusion, but discussion amongst review authors supports the
conclusion that it would be appropriate to include any trials of
pharmacological interventions if they are specifically focused on
improving outcomes in participants with visual field defects.How-
ever, it remains unclear whether this study is a randomised con-
trolled trial or not, as there is inconsistent reporting of the study
design, and we await clarification from the study authors. Prior
to any future updates of this review, we will clarify the selection
criteria and methods to ensure that the inclusion (or exclusion)
of pharmacological interventions is addressed. Sand 2017 is an
ongoing study; however, it was not possible to determine from
available information whether this was a randomised controlled
trial or not.
Ongoing studies
Seven studies are listed as ongoing studies. Two ongoing studies
compare a form of visual restitutive training with control (Feldon
2017; NCT02886663); one is comparing a form of transcranial
electrical stimulation with control (Gall 2015); one is comparing
a pharmacological intervention focused on restitution of the vi-
sual field with a placebo (NCT02737930); and one is comparing
two different modes of delivery of computer-based compensatory
scanning interventions with a control (ISRCTN16023965). Two
of these studies, listed as ongoing in the previous version of this
review, are now complete (Hayes 2010; Komm 2009), but we
have been unable to obtain results from the authors. If results are
not available at the time of the next update, we will exclude these
studies.
Risk of bias in included studies
We have described the assessment of risk of bias for individual
studies in the ’Risk of bias’ tables in Characteristics of included
studies, summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Although all 20 included studies were described as randomised
controlled trials, only 10 of them reported sufficient information
on the method of randomisation to assess whether the randomi-
sation and allocation concealment methods were adequate, and,
in two of these studies, we judged them to be at high risk of bias:
in Keller 2010 some of the allocation appeared to have been alter-
nate, rather than random, and, in Modden 2012, randomisation
was through throwing of a dice, with no allocation concealment.
Blinding
In the majority of included studies, the nature of the intervention
meant that it was not possible to mask (blind) participants or
people involved in their care. We judged blinding as low risk of
bias if there was evidence that the outcome assessor was masked to
the treatment allocation of the participants - six of the 20 studies
clearly reported having a masked outcome assessor. In eight of the
20 studies this information was unclear, and in six of the 20 studies
we judged that there was a high risk of bias as the outcome assessor
was not masked.
Incomplete outcome data
Lack of information about the management of incomplete out-
come data, and whether or not there had been dropouts or par-
ticipants excluded from the studies, made it difficult to assess risk
of bias relating to incomplete outcome data for all the studies. In
four of the 20 studies, we considered that adequate reasons for
dropouts were provided, numbers of dropouts were even between
groups, or intention-to-treat analysis was carried out. However,
in five of the 20 studies where we felt that incomplete outcome
data were not adequately addressed, and that dropouts were either
unbalanced or might be related to the intervention studied (e.g.
because people dropped out or were excluded because of low com-
pliance), we judged risk of bias to be high. For the remaining 11
studies, we were unclear as to whether or not incomplete outcome
data were adequately addressed.
Other potential sources of bias
Lack of information and details of methodology within the in-
cluded studies generally made it difficult for us to assess the po-
tential risk due to other biases. However, four of the studies of
visual restitution therapy were carried out by researchers who have
acknowledged a financial interest in this intervention (as stated
in Poggel 2004) (Jobke 2009; Kasten 1998; Kasten 2007; Poggel
2004), and Bowers 2014 declared a financial conflict of interest
relating to the prisms that were being investigated. We assessed
this to potentially introduce a source of bias. We identified con-
cerns that the increased attention given to the treatment group,
as opposed to the control group, in De Haan 2015 may create a
high risk of bias. For two of the studies, only abstracts were avail-
able and there was insufficient information on which to assess bias
(Bainbridge 1994; Gall 2013). We judged the remaining 12 stud-
ies as unlikely to be at risk of other potential sources of bias, but
based this assessment on the absence of information suggesting
bias rather than the presence of information indicating that the
study was free from bias.
Studies included in meta-analyses within this review
From the 20 studies included in this review, there are only eight
studies included inmeta-analyseswithin this review (Aimola 2011;
Bowers 2014; De Haan 2015; Jarvis 2012; Kasten 1998; Rossi
1990;Rowe 2010; Spitzyna 2007). These eight studies randomised
428 participants. The studies relevant to our prestated compar-
isons (seeObjectives), and includedwithin the plannedmeta-anal-
yses are:
1. Restitutive interventions versus no treatment, placebo, or
control
• Kasten 1998 (visual restitution therapy versus placebo, n =
19). We have included data from this study in relevant analyses.
2. Compensatory interventions versus no treatment,
placebo, or control
• Aimola 2011 (n = 52), De Haan 2015 (n = 49), Rowe 2010
(n = 70), and Spitzyna 2007 (n = 22) are all relevant and have
data included in relevant analyses.
3. Substitutive interventions versus no treatment, placebo,
or control
• Rossi 1990 (prisms versus no treatment, n = 39) and Rowe
2010 (prisms versus control, n = 59). We have included data
from these studies in relevant analyses.
• Bowers 2014 (prisms versus placebo, n = 67). This is a
cross-over study and data were principally presented after the
cross-over; however, there were data for one outcome (extended
activities of daily living) presented before the cross-over, with
data suitable for inclusion in analysis.
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4. Assessment or screening versus no treatment, placebo, or
control
• Jarvis 2012 (assessment versus control, n = 39). We have
included data from this study in relevant analyses.
Studies not included in meta-analyses
Ten of the studies included in this review did not have a control
group and are therefore not included in meta-analyses.
These 10 studies each compared one active intervention with an-
other active intervention:
• Jobke 2009, Kasten 2007, Modden 2012, Plow 2010,
Poggel 2004, and Roth 2009 all investigated restitutive
interventions, and did not include a no-treatment, placebo, or
control group.
• Keller 2010, Modden 2012, Roth 2009, and Schuett 2012
all investigated compensatory interventions, and did not include
a no-treatment, placebo, or control group.
• Bainbridge 1994 and Szlyk 2005 both investigated
substitutive interventions, and did not include a no-treatment,
placebo, or control group.
The results from relevant outcomes from these studies are sum-
marised in Table 5 and Table 6 and in a narrative synthesis below.
One study did have a relevant control group (alternating current
stimulation versus placebo, n =39) butwas published as an abstract
only andwe have been unable to identify data suitable for inclusion
(Gall 2013).
One study did have a relevant control group (visual restitution
training versus placebo, n = 30) but was a randomised cross-over
trial and we have been unable to obtain data from the first phase
only, in order to include data in meta-analyses (Elshout 2016).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: Restitutive interventions versus control; Summary
of findings 2 Summary of findings: Compensative interventions
versus control; Summary of findings 3 Summary of findings:
Substitutive interventions versus control; Summary of findings 4
Summary of findings: Assessment/screening interventions versus
control
Restitutive interventions versus no treatment,
placebo, or control
There was one included study: Kasten 1998 (see Summary of
findings for the main comparison). Data were available for visual
field and quality of life outcomes, but not for any other outcomes
of interest to this review. Stroke survivors with visual neglect were
not included in Kasten 1998, therefore these analyses relate to
participants with visual field defects only (no co-existing visual
neglect).
Visual field
See Analysis 1.1. Data fromKasten 1998 (19 participants) showed
that there was no statistically significant effect of a restitutive in-
tervention as compared to control (MD 1.02, 95% CI -1.37 to
3.41) for the visual field outcome (confrontation). We judged this
evidence to be of very low quality.
Quality of life
See Analysis 1.2. Data from Kasten 1998 showed that there was a
statistically significant effect of a restitutive intervention as com-
pared to control (OR 13.00, 95% CI 2.07 to 81.48). The data
used in this analysis were derived from 30 randomised partici-
pants, and included data from participants with optic nerve in-
jury who had also received the same interventions in a separate
(but parallel) trial. A total of 38 participants were randomised, of
whom 19 had stroke and 19 had optic nerve injury; data were
only available for 30 of 38 of these participants for this outcome.
Separate data were not available for participants with stroke only.
We judged this evidence to be of very low quality.
Compensatory interventions versus no treatment,
placebo, or control
Included studies: Aimola 2011; De Haan 2015; Rowe 2010;
Spitzyna 2007 (see Summary of findings 2). Stroke survivors with
visual neglect were not included in De Haan 2015; Rowe 2010;
Spitzyna 2007, while participants in Aimola 2011 could have co-
existing neglect: data are presented in subgroups relating to the
inclusion of participants with neglect.
Visual field
See Analysis 2.1. Data from two studies (95 participants) showed
that there was no statistically significant effect of compensatory
interventions compared with control (SMD -0.11, 95% CI -0.92
to 0.70, heterogeneity: I² = 75%) (De Haan 2015; Rowe 2010).
We judged this evidence to be of very low quality. Several factors
could contribute to the substantial heterogeneity, including dif-
ferent inclusion criteria (e.g. participants had to be < 26 weeks
post stroke in Rowe 2010) and very different interventions (see
Characteristics of included studies). However a key factor to note,
which limits confidence in these findings, is that there was a sig-
nificant difference in baseline assessment between groups in De
Haan 2015).
Extended activities of daily living
See Analysis 2.2. Data from two studies (97 participants) showed
that there was no statistically significant benefit in favour of com-
pensatory interventions compared with control (SMD 0.49, 95%
CI -0.01 to 0.99, heterogeneity: I² = 25%) (De Haan 2015, Rowe
2010). We judged this evidence be of very low quality.
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Reading
See Analysis 2.3.Data from four studies (162 participants) showed
that there was no statistical significant effect of compensatory in-
terventions compared with control (SMD 0.26, 95% CI -0.05
to 0.58, heterogeneity: I² = 0%) (Aimola 2011; De Haan 2015;
Rowe 2010; Spitzyna 2007). We judged this evidence to be of low
quality. Although some of the participants in Aimola 2011 may
have had neglect, there was no downgrade for indirectness as the
test for subgroup differences demonstrated no significant differ-
ences between the studies including or not including participants
with neglect (P = 0.43).
Quality of life
See Analysis 2.4. Data from two studies (96 participants) showed
that there was a statistically significant effect of compensatory in-
terventions compared with control (MD 9.36, 95% CI 3.10 to
15.62), withminimal heterogeneity (I² = 0%), based on the results
for the total score for the VFQ-25 assessment (De Haan 2015;
Rowe 2010). We judged this evidence to be of low quality.
Scanning - cancellation
See Analysis 2.5. Data from two studies (97 participants) showed
that there was no statistically significant effect of compensatory
interventions compared with control (SMD -0.01, 95% CI -0.40
to 0.39), with minimal heterogeneity ( I² = 0%) (Aimola 2011;
De Haan 2015). We judged this evidence to be of low quality.
Although some of the participants in Aimola 2011 may have had
neglect, there was no downgrade for indirectness as the test for
subgroup differences demonstrated no significant differences be-
tween the studies including or not including participants with ne-
glect (P = 0.55). Substituting the De Haan 2015 ’parallel search
test’ data for ’all trials’ with other presented data, including the
’serial search test’ data and ’dot counting test’, or substituting the
’target present’ data for the ’all trials’ data, did not change the non-
significant result.
Adverse events
See Analysis 2.6. Rowe 2010 collected and reported data relating
to adverse events, stating that: “Two patients (6.7%) in the visual
search training arm experienced seven adverse events (six fatigue
and one headache). No adverse events were recorded for the stan-
dard care arm”. De Haan 2015 did not report adverse events as an
outcomemeasure, but stated that: “No important harms caused by
the training or the assessments were encountered, nor reported by
the participants”.Data fromRowe 2010 (see Analysis 2.6), showed
that there was no difference in the odds of a participant having an
adverse event with compensatory scanning training, when com-
pared to control (OR 15.18, 95% CI 0.24 to 112.57). We judged
this evidence to be of low quality.
Substitutive interventions versus no treatment,
placebo, or control
Included studies: Bowers 2014; Rossi 1990; Rowe 2010 (see
Summary of findings 3). Stroke survivors with visual neglect were
not included in Bowers 2014 and Rowe 2010, while partici-
pants in Rossi 1990 could have co-existing neglect. Substitutive
prisms were worn during the outcome assessment by participants
in Bowers 2014 and Rossi 1990, but were not worn during out-
come assessment by participants in Rowe 2010. As the wearing of
the substitutive intervention during outcome assessment should
theoretically expand the size of the visual field, the data arising
from these different approaches (wearing or not wearing prisms)
were presented as subgroups, and no pooled total was calculated.
Functional activities of daily living (primary outcome)
See Analysis 3.1. Data from one study (39 participants, wearing
prisms during assessment; participants may have co-existing ne-
glect) showed that there was no statistically significant effect of a
substitutive intervention compared with control for the primary
outcome of functional activities of daily living (MD -4.00, 95%
CI -17.86 to 9.86) (Rossi 1990). We judged this evidence to be
of very low quality.
Visual field
See Analysis 3.2. Data from one study (46 participants; no ne-
glect) showed that there was no statistically significant effect of a
substitutive intervention compared with control when the substi-
tutive intervention (prism) was not being worn (SMD 0.12, 95%
CI -0.46 to 0.70) (Rowe 2010). Data from one study (39 partic-
ipants; possibly co-existing neglect) showed that there was a sta-
tistically significant effect of a substitutive intervention compared
with control when the substitutive intervention (prism) was being
worn (SMD1.12, 95%CI 0.44 to 1.80) (Rossi 1990). There was a
statistically significant difference between the subgroups in which
participants did and did not wear prisms during assessment (P =
0.03). We judged this evidence to be of very low quality.
Extended activities of daily living.
See Analysis 3.3.Data fromone study (48 participants, no neglect)
showed that there was no statistically significant effect of a substi-
tutive intervention compared with control when the substitutive
intervention (prism) was not being worn (SMD 0.20, 95% CI -
0.44 to 0.85) (Rowe 2010). Data from one study (61 participants,
no neglect) showed that there was no statistically significant effect
of a substitutive intervention compared with control for measures
of extended activities of daily living, using a mobility score (SMD
0.24, 95% CI -0.26 to 0.75) (Bowers 2014). There was no statis-
tically significant difference between the subgroups that did and
did not wear prisms during assessment (P = 0.92). We judged this
evidence to be of very low quality.
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See Analysis 3.4. Data from one study (45 participants, no ne-
glect) showed that there was no statistically significant effect of a
substitutive intervention compared with control when the substi-
tutive intervention (prism) was not being worn (MD 2.80, 95%
CI -7.13 to 12.73) (Rowe 2010). We judged this evidence to be
of low quality.
Falls
SeeAnalysis 3.5.Data fromone study (39participants, possible co-
existing neglect) showed that there was no statistically significant
effect of a substitutive intervention compared with control for the
risk of falls (OR 1.21, 95% CI 0.26 to 5.76) (Rossi 1990). We
judged this evidence to be of very low quality.
Quality of Life
See Analysis 3.6. Data from one study (43 participants, assessed
not wearing prisms; no neglect) showed that there was no statis-
tically significant effect of a substitutive intervention compared
with control for a measure of quality of life (MD 8.40, 95% CI
-4.18 to 20.98) (Rowe 2010). We judged this evidence to be of
low quality.
Scanning (cancellation)
See Analysis 3.7. Data from one study (39 participants, assessed
wearing prisms; possibly co-existing neglect) showed that there
was a statistically significant effect of a substitutive intervention
compared with control for measures of scanning (MD 9.80, 95%
CI 1.91 to 17.69) (Rossi 1990). We judged this evidence to be of
very low quality.
Adverse events
Rowe 2010 collected and reported data relating to adverse events,
stating that “Eighteen patients (69.2%) in the Fresnel prisms arm
experienced a total of 42 adverse events of which 28 were classified
as headache. No adverse events were recorded in the standard care
arm”. The reported adverse events in the group wearing prisms
were: headache (28 events in six participants); diplopia (five events
in five participants); visual confusion (four events in three partici-
pants); difficulty with navigation (two events in two participants);
dizziness (two events in one participant); optical glare/aberrations
(one event in one participant). Analysis 3.8 shows that there was
an increased odds of a participant having an adverse event if they
were wearing prisms (OR 87.32, 95% CI 4.87 to 1564.66). We
judged this evidence to be of low quality.
Assessment or screening interventions versus no
treatment, placebo, or control
Included study - Jarvis 2012 (see Summary of findings 4).
Functional activities of daily living (primary outcome)
See Analysis 4.1. Data from Jarvis 2012 (37 participants) showed
that there was no statistically significant effect of an assessment
intervention compared with control for measures of functional
activities of daily living (MD -6.97, 95% CI -23.78 to 9.84). We
judged this evidence to be of very low quality.
Subgroup and sensitivity analyses
As there were no more than six trials in any single meta-analysis,
as prestated in our protocol, we did not carry out the planned
subgroup or sensitivity analyses. There were two exceptions to this:
• we carried out subgroup analysis to explore the effect of
including studies in which participants may have had neglect in
addition to visual field defects. This decision was made as there
was one study in which some of the participants may have had
neglect (Aimola 2011), and we considered the implications for
including this group of participants of key clinical importance.
Results of these analyses are reported above;
• we carried out subgroup analyses to explore different ways
of doing assessment in studies investigating the use of prisms (i.e.
assessment wearing or not wearing prisms). This was considered
central to the clinical relevance of the pooled result. Results of
these analyses are reported above.
One active intervention versus another active
intervention (narrative synthesis)
As planned, no meta-analyses have been carried out to pool data
from studies that compared one active intervention with another
active intervention. A summary of results for relevant outcomes
for these comparisons is provided in Table 5 and Table 6, and a
brief narrative summary below.
Studies comparing two similar active interventions
(See Table 5)
One restitutive intervention versus another restitutive
intervention
We found two studies that compared the effectiveness of two
(or more) types of visual restitution therapy (Jobke 2009; Kasten
2007). Jobke 2009 compared extrastriate visual restitution therapy
with conventional visual restitution therapy in a cross-over study
including 18 participants. After the first phase of the study, the
extrastriate visual restitution therapy group had improved in mea-
sures of visual field (detection performance in HRP) by 5.9% and
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the conventional visual restitution therapy group had improved
by 2.9%. No significant changes were found for either group for
Radner reading scores. Kasten 2007 compared three treatment
groups: 1) standard visual restitution therapy with single stimu-
lation, 2) visual restitution therapy with parallel co-stimulation,
and 3) visual restitution therapy with moving co-stimulation. We
found no statistically significant differences between groups for
measures of the visual field (perimetry).
We found two studies that investigated the addition of another in-
tervention to visual restitution therapy (Plow 2010; Poggel 2004).
Plow 2010 investigated the effect of adding transcranial direct cur-
rent stimulation (tDCS) to visual restitution therapy and reported
a greater increase in detection accuracy (perimetry) in the group
receiving tDCS (9.37% increase compared to 5.55% increase in
control group). Poggel 2004 compared standard visual restitution
therapy with visual restitution therapy plus attentional cueing in
19 participants; results were primarily presented graphically and
as whole-group data: the authors concluded that the visual field
border increased significantly more in the participants in the at-
tentional cueing group.
One compensative intervention versus another compensative
intervention
We found three studies that compared different compensative in-
terventions (Keller 2010; Modden 2012; Schuett 2012). Keller
2010 compared audiovisual training and visual exploration train-
ing in 10 participants, reporting that audiovisual training was bet-
ter than visual exploration training for outcomes of activities of
daily living, reading, and visual scanning. Schuett 2012 compared
reading training and visual exploration training in 36 participants
within a cross-over study. We used data reported from before the
cross-over period to calculate effect sizes for Schuett 2012 (see
Figure 3); this demonstrated that visual exploration training was
significantly more beneficial than reading training at improving
scanning outcomes, and there was a trend towards reading training
improving reading outcomes more significantly than visual explo-
ration training. Modden 2012 compared 45 participants within
three groups; one receiving computer-based restitution therapy,
one computer-based compensation therapy, and one standard oc-
cupational therapy.We judged the occupational therapy interven-
tion to be a compensatory intervention. We found no differences
between the groups receiving the computer-based compensatory
therapy and occupational therapy interventions for measures of
visual field enlargement, reading, or visual scanning.
Figure 3. One compensatory intervention versus another compensatory intervention. Effect sizes for
Schuett 2012 (see Table 5)
One substitutive intervention versus another substitutive
intervention
We found two studies that compared the effectiveness of two types
of prism (Bainbridge 1994; Szlyk 2005). Bainbridge 1994 com-
pared the effect of full-field and hemi-field prisms in 18 partici-
pants, and reported a significant effect in favour of full-field prisms
for the cancellation test and Harrington Flocks Visual Field score.
Szlyk 2005 compared Fresnel prisms and the Gottlieb Visual Field
Awareness System in 10 participants and found no statically sig-
nificant differences in outcomes between the two groups, although
this was a cross-over study with no data presented for the period
of time before the cross-over.
Studies comparing two different types of active intervention
(see Table 6)
Compensation intervention versus restitutive intervention
Two studies compared the effectiveness of a compensation inter-
vention and a restitutive intervention (Modden 2012; Roth 2009).
Roth 2009 compared explorative scanning training (a compensa-
tion intervention) with flicker stimulation training (a restitution
intervention) in 29 participants, finding no significant differences
between groups for key outcomes (although there were differences
between groups at baseline for some outcomes). Modden 2012
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compared 45 participants within three groups; one receiving com-
puter-based restitution therapy, one computer-based compensa-
tion therapy, and one standard occupational therapy. In Table 6,
we compared the results of the groups receiving computer-based
training. There were no significant differences reported for these
groups for measures of visual field enlargement, activities of daily
living, reading, or visual scanning.
Compensation intervention versus substitution intervention
One study compared the effectiveness of a compensative inter-
vention (paper-based visual search training) and a substitutive in-
tervention (Fresnel prisms) (Rowe 2010). This was a three-armed
study, with a control (standard care) treatment; data from the ac-
tive treatment arms compared to the control treatment have been
included in meta-analyses within this review. We found no signif-
icant differences between the compensative and substitutive inter-
vention for measures of visual field, extended activities of daily liv-
ing, and reading. We found a statistically significant difference in
favour of the compensative intervention for the measure of quality
of life (using the VFQ-25).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Compensative interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual f ield defects
Settings: any rehabilitat ion sett ing
Intervention: compensat ive intervent ions
Comparison: control, placebo, or no intervent ion
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Functional ability in activities of
daily living
(no data) No studies Insuf f icient evidence
Visual field
(Funct ional f ield score and rela-
t ive change in visual f ield score,
combined)
Af ter intervent ion
SMD -0.11 (-0.92 to 0.70
(no signif icant ef fect)
95
(2 studies, De Haan 2015; Rowe
2010)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - one study
judged as high risk of bias for at
least one domain
• Inconsistency - one study
had baseline dif ferences
• Inconsistency - I2 = 75%
• Indirectness - studies
explored very dif f erent
compensatory intervent ions
Extended activities of daily living
(Mobility quest ionnaire and
change in Nott ingham EADL, com-
bined)
Af ter intervent ion
SMD 0.49 (-0.01 to 0.99)
(no signif icant ef fect)
97
(2 studies, De Haan 2015; Rowe
2010)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - one study
judged as high risk of bias for at
least one domain
• Indirectness - outcome
measures were very dif f erent; for
one study outcome was a
mobility measure, rather than a
general measure of EADL
• Indirectness - studies
explored very dif f erent
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compensatory intervent ion
s
Reading ability
(Reading speed; various tests)
Af ter intervent ion
SMD 0.26 (-0.05 to 0.58)
(no signif icant ef fect)
162
(4 studies, Aimola 2011; De Haan
2015; Rowe 2010; Spitzyna 2007)
⊕⊕©©
low
Reasons for downgrades:
• Risk of bias - three studies
judged as high risk of bias for at
least one domain
• Indirectness - studies
explored very dif f erent
compensatory intervent ion
Falls (no data) No studies Insuf f icient evidence
Quality of life
(Nat ional Eye Inst itute Visual
Funct ion Quest ionnaire (NEI -
VFQ-25) total score)
Af ter intervent ion
MD 9.36 (3.10 to 15.62)
(favours compensatory)
96
(2 studies, De Haan 2015; Rowe
2010)
⊕⊕©©
low
Reasons for downgrades:
• Risk of bias - two studies
judged as high risk of bias for at
least one domain
• Indirectness - studies
explored very dif f erent
compensatory intervent ions
Scanning - cancellation
(cancellat ion tests - t ime to com-
plete)
Af ter intervent ion
SMD -0.01 (-0.40 to 0.39)
(no signif icant ef fect)
97
(2 studies, Aimola 2011; De Haan
2015)
⊕⊕©©
low
Reasons for downgrades:
• Risk of bias - two studies
judged as high risk of bias for at
least one domain
• Indirectness - studies
explored very dif f erent
compensatory intervent ions
Adverse events
(number of part icipants with re-
ported events during intervent ion
period)
OR 5.18 (0.24 to 112.57
(favours control)
108
(2 studies, De Haan 2015; Rowe
2010)
(NB. no events recorded in De
Haan 2015, which did not explic-
it ly report adverse events as an
outcome measure)
⊕⊕©©
low
Reason for downgrades:
• Inconsistency - no events
f rom one study, means pooled
result was not est imable for that
study; large conf idence intervals
• Indirectness - studies
explored very dif f erent
compensatory intervent ions
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI :conf idenceintervals
EADL: extended act ivit ies of daily living
MD: mean dif ference
NEI-VFQ-25: National Eye Inst itute Visual Funct ion Quest ionnaire
OR: odds rat io
SMD: standardised mean dif ference
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2
8
In
te
rv
e
n
tio
n
s
fo
r
v
isu
a
l
fi
e
ld
d
e
fe
c
ts
in
p
e
o
p
le
w
ith
stro
k
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Substitutive interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual f ield defects
Settings: any rehabilitat ion sett ing
Intervention: compensat ive intervent ions
Comparison: control, placebo, or no intervent ion
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Functional ability in activities of
daily living
(Barthel Index)
Af ter 4 weeks of treatment
Wearing prisms
MD -4.00 (-17.86 to 9.86)
(no signif icant ef fect)
39
(1 study, Rossi 1990)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study judged
as high risk of bias for at least
one domain
• Indirectness - included data
f rom part icipants with neglect
• Imprecision - small study
populat ion (n = 39)
Visual field
(change in visual f ield area &
change in error scores, f rom base-
line)
Af ter intervent ion
Not wearing prisms
SMD 0.12 (-0.46 to 0.70)
Wearing prisms
SMD 1.12 (0.44 to 1.80)
85
(2 studies, Rossi 1990; Rowe
2010)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - one study
judged as high risk of bias for at
least one domain
• Indirectness - included data
f rom part icipants with neglect
• Indirectness - studies
cannot be combined due to
dif ferences in test ing (wearing/
not wearing prisms)
Extended activities of daily living
(Change in EADL f rom baseline;
mobility improvement scores, in
Logits)
Af ter intervent ion
Not wearing prisms
SMD 0.20 (-0.44 to 0.85)
Wearing prisms
SMD 0.24 (-0.26 to 0.75)
99
(2 studies, Bowers 2014; Rowe
2010)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - one study
judged as high risk of bias for at
least one domain
• Indirectness - one study
outcome was a mobility
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measure, rather than a general
measure of EADL
• Indirectness - included
part icipants with diagnoses
other than stroke
• Indirectness - studies
cannot be combined due to
dif ferences in test ing (wearing/
not wearing prisms)
Reading ability Not wearing prisms
MD 2.80 (-7.13 to 12.73)
(no signif icant ef fect)
45
(1 study, Rowe 2010)
⊕⊕©©
Low
Reasons for downgrades:
• Imprecision - small study
populat ion (n = 45)
• Imprecision - wide
conf idence intervals
Falls
(number of falls)
Af ter intervent ion
Wearing prisms
OR 1.21, (0.26 to 5.76)
(no signif icant dif f erence)
39
(1 study, Rossi 1990)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study judged
as high risk of bias for at least
one domain
• Indirectness - included data
f rom part icipants with neglect
• Imprecision - small study
populat ion (n = 39)
Quality of life
(Visual Funct ion Quest ionnaire
(VFQ-25))
Af ter intervent ion
Not wearing prisms
MD 8.40 (-4.18 to 20.98)
(no signif icant ef fect)
43
(1 study, Rowe 2010)
⊕⊕©©
Low
Reasons for downgrades:
• Imprecision - small study
populat ion (n = 43)
• Imprecision - wide
conf idence intervals
Scanning - cancellation
(line cancellat ion errors)
Af ter intervent ion
Wearing prisms
MD 9.80 (1.91 to 17.69)
(favours subst itut ive)
39
(1 study, Rossi 1990)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study judged
as high risk of bias for at least
one domain
• Indirectness - included data
f rom part icipants with neglect
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• Imprecision - small study
populat ion (n = 39)
• Imprecision - wide
conf idence intervals
Adverse events
(number of part icipants with re-
ported events during intervent ion
period)
OR 87.32 (4.87 to 1564.66)
(favours control)
59
(1 study, Rowe 2010)
⊕⊕©©
Low
Reason for downgrades:
• Inconsistency - large
conf idence intervals
• Imprecision - data f rom only
one study
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
EADL:extendedactivitiesof dailyliving
MD: mean dif ference
OR: odds rat io
SMD: standardised mean dif ference
VFQ-25: Visual funct ion quest ionnaire
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Assessment/ screening interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual f ield defects
Settings: any rehabilitat ion sett ing
Intervention: assessment/ screening intervent ions
Comparison: control, placebo, or no intervent ion
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Functional ability in activities of
daily living
(FIM)
Af ter intervent ion
MD -6.97 (-23.78 to 9.84)
(no signif icant ef fect)
37
(1 study, Jarvis 2012)
⊕©©©
very low
Reasons for downgrades:
• Risk of bias - study judged as
high risk of bias for at least one
domain
• Imprecision - small study
populat ion (n = 37)
• Imprecision - wide conf idence
intervals
Visual field (no data) No studies Insuf f icient evidence
Extended activities of daily living (no data) No studies Insuf f icient evidence
Reading ability (no data) No studies Insuf f icient evidence
Falls (no data) No studies Insuf f icient evidence
Quality of life (no data) No studies Insuf f icient evidence
Scanning - cancellation (no data) No studies Insuf f icient evidence
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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FIM:FunctionalIndependenceMeasure
MD: mean dif ference
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D I S C U S S I O N
Summary of main results
We found 20 studies (732 randomised participants, with data for
638 participants, 547 of whom were participants with stroke) that
investigated interventions for visual field defects in people with
stroke. However, only 10 of these studies compared the effect of an
interventionwith a placebo, control, or no treatment group, which
were the comparisons of interest to the review question, and only
eight had data suitable for inclusion within meta-analyses. Only
two of these eight studies presented data relating to our primary
outcome of functional abilities in activities of daily living, and
there was a lack of consistency in outcome measures used across
studies, which limited our ability to draw generalised conclusions.
Effect of restitutive interventions
Three studies (88 participants) compared a restitutive interven-
tion with a control, but data were only available for one (19 par-
ticipants). There was very low-quality evidence that visual restitu-
tion therapy had no effect on visual field outcomes, and a statisti-
cally significant positive effect on quality of life. However, the data
relating to the quality of life outcome must be interpreted with
caution as the data used for analysis combined the population of
interest with an additional 19 participants with optic nerve injury
who had been included in a separate (but parallel) trial. These par-
ticipants had damage to the anterior visual pathway, a population
which was specifically excluded from this review, and in none of
the participants was the optic nerve damage due to stroke. We,
therefore, do not believe that the findings based on data from this
population are applicable to the population of patients with visual
field loss due to post-chiasmal stroke. There is, therefore, insuf-
ficient evidence to draw any conclusions about the effectiveness
of visual restitution therapy as compared to placebo, control, or
no treatment. There was also some very limited evidence from
two small studies which compared different types of restitutive
interventions that there may be some benefits to adding either
attentional cueing or tDCS to visual restitutive therapy, while a
further two small studies found no difference in different modes
of delivering visual restitution therapy.
Effect of compensatory interventions
Four studies (193 participants) compared a compensatory inter-
vention with a control. There was low-quality evidence of a ben-
eficial effect on measures of quality of life. However, there was
low- or very low-quality evidence of no effect on measures of vi-
sual field, extended activities of daily living, reading, and scan-
ning ability. Findings from a small study comparing two different
types of compensatory therapy conflicts with the evidence of no
effect on scanning outcome, demonstrating a beneficial effect of
visual exploration therapy on scanning outcomes when compared
to reading training. There is, therefore, some limited low-quality
evidence that compensatory scanning training may improve an
important outcome (quality of life) in people with visual field de-
fects following stroke, but further research is very likely to have
an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Studies comparing different
active interventions provide some very limited evidence that there
may be benefits associated with audiovisual training, rather than
visual exploration training alone, and suggest that compensatory
training, as delivered during standard clinical practice, may be as
effective as computer-based training interventions.
Effect of substitutive interventions
Three studies (166 participants) compared a substitutive interven-
tion (a type of prism) with a control. There was low- or very low-
quality evidence that prisms did not have an effect on measures
of activities of daily living, extended activities of daily living read-
ing, falls, or quality of life, but that they may have an effect on
scanning ability. Evidence from one study indicates that people
using prisms may have a higher odds of adverse events, particu-
larly headache. However, it is important to note a fundamental
difference between these studies in that, in two of the studies, par-
ticipants in the treatment group wore prisms during the outcome
assessments (Bowers 2014; Rossi 1990), while in one study none
of the participants wore prisms during outcome assessment by
participants (Rowe 2010). Evidence relating to measures of visual
field demonstrated a significant difference between studies that
measured outcome whilst wearing or not wearing the substitutive
device, with a beneficial effect when the prisms were worn during
testing but not without. However, due to the quality and quantity
of evidence, we remain uncertain about the benefits of prisms.
Effect of screening/assessment interventions
One study (39 participants) compared the effect of assessment by
an orthoptist to standard care (no assessment) and found very low-
quality evidence that there was no effect on measures of activi-
ties of daily living. However, due to the quality and quantity of
evidence, we remain uncertain about the benefits of assessment
interventions.
Ten studies compared the effect of two of more different active
interventions and did not include a control group.
In summary, this review has identified:
• a lack of evidence relating to the effect of interventions on
our primary outcome (functional ability in activities of daily
living);
• low-quality evidence that compensatory scanning training
is more beneficial than placebo or control at improving quality of
life, but not other outcomes;
• insufficient evidence to reach any generalised conclusions
about the effect of restitutive interventions, substitutive
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interventions (prisms), or screening/assessment interventions as
compared to placebo, control or no treatment;
• low-quality evidence that prisms may result in an increase
in the number of people experiencing adverse events (particularly
headache).
Overall completeness and applicability of
evidence
Studies with control, placebo, or no treatment group
Although we identified 20 studies that investigated the effect of
interventions for visual field defects after stroke, only 10 of these
studies (and only eight with data) compared the effect of an in-
tervention with a control, placebo, or no treatment group, which
was the question of interest to this review. The remaining 10 stud-
ies compared different types of interventions, with nine of these
studies comparing interventions of the same ’type’ (i.e. comparing
two substitutive interventions or two restitutive interventions);
arguably, comparisons of different active interventions have little
merit until such time as the benefits (and harms) of active inter-
ventions, as compared to control, placebo, or no treatment have
been established. Three studies did compare the relative effects
of two different types of intervention (i.e. compensatory versus
restitutive, or compensative versus substitutive). Thus, although
we made the decision to include all the studies which investigated
the effectiveness of interventions for visual field defects, in fact
only nine of these studies included comparisons that were directly
relevant to the review question, focusing on a comparison with a
control, placebo, or no treatment group. Five of the 20 included
studies, including two of the 10 studies with a control/placebo
comparison, were cross-over studies. The reporting of data from
after the cross-over in studies with this design limited our ability
to incorporate data within meta-analyses in this review, and there
is a risk that outcomes from after the cross-over are affected by the
treatments administered prior to the cross-over.
Restitutive interventions versus no treatment, placebo, or
control
Kasten 1998 was the one study comparing a restitutive interven-
tion with a control or placebo, with data suitable for inclusion
in our meta-analyses. This study included 19 participants, only
10 of whom had stroke. The study did not measure our primary
outcome of interest (functional ability in activities of daily living).
There was an uneven distribution of stroke patients between the
two groups (with two stroke patients out of the nine participants
in the treatment group and eight stroke patients out of 10 par-
ticipants in the control group). This uneven distribution means
that only two patients with stroke received an active intervention,
providing evidence from which it would be inappropriate to gen-
eralise. Furthermore, for quality of life outcome data, the 19 par-
ticipants in this study had been combined with the results of 19
participants in another similar study. However, the additional 19
participants all had optic nerve injury rather than post-chiasmal
injury. Due to the nature of the participants included in this study,
it would not be appropriate to make generalisations from this evi-
dence to the population of stroke patients with visual field defects
after stroke. Our confidence in the findings from this evidence is
very low.
Compensatory interventions versus no treatment, placebo,
or control
Wewere able to combine data from four studies (162 participants)
comparing compensatory (scanning) interventions with control
or placebo in meta-analysis. None of these studies measured our
primary outcome of interest (functional ability in activities of daily
living). Visual field defects in the participants included in these
studies were confirmed using perimetry (see Table 3). Three of the
studies included participants with visual field defects and no co-
existing visual neglect; two of these studies excluded participants
with neglect based on clinical testing (De Haan 2015;Rowe 2010),
while one only included participants with a left-sided cerebrovas-
cular accident where patients rarely experience persistent neglect
(Spitzyna 2007). One study included participants who had visual
field defects but possibly also co-existing visual neglect (Aimola
2011); clinical testing confirmed that only three of the 52 partic-
ipants had confirmed neglect. Participants included those from a
mixed population (i.e. stroke and other neurological conditions)
for three of the four studies; 41 of the 49 participants had stroke in
De Haan 2015, 39 of 52 had stroke in Aimola 2011, and 13 of 22
had stroke in Spitzyna 2007. All participants had stroke in Rowe
2010. The majority of participants in these studies, therefore, had
visual field defects following stroke and did not have co-existing
neglect (as confirmed by clinical testing); therefore, it would be
appropriate to generalise from these results to the population of
stroke survivors with visual field defects and no neglect.
The nature of the scanning training in the four studies com-
bined within the meta-analyses varied considerably; two investi-
gated computer-based scanning training, one focused on visual
exploration training (Aimola 2011), one on reading training us-
ing scrolling horizontal text (Spitzyna 2007), one was a training
programme, primarily delivered face-to-face by an occupational
therapist (De Haan 2015), and one was a self-delivered paper-
based scanning exercise (Rowe 2010). It is likely that the nature
of these interventions will result in varied scanning movements
of the eye. As well as differences in the mode of delivery of the
scanning training, there were also differences in the amount of
training. These differences in the compensatory interventions re-
duce confidence in any findings, and limit ability to generalise
from these findings. During the GRADE assessment of quality of
evidence, we applied a downgrade to each comparison combining
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results from these studies due to the variations in the interventions
studied. We, therefore, have low- to very-low confidence in the
findings from this evidence.
Substitutive interventions versus no treatment, placebo, or
control
Two studies compared a substitutive intervention (prisms) with a
no treatment control (Rossi 1990; Rowe 2010). Rossi 1990 mea-
sured our primary outcome of interest (functional ability in activ-
ities of daily living). Both studies only included participants with
stroke, but Rossi 1990 included participants with visual neglect
in additional to visual field defect. The studies both investigated
the effect of Fresnel prisms. There was a fundamental difference
between these studies relating to the assessment of outcome: Rossi
1990 measured outcomes whilst participants in the intervention
group wore the assigned prisms, whilst Rowe 2010 measured out-
comes while participants were not wearing any assigned prisms.
It has been argued that the rationale for prisms is that they pro-
vide visual field expansion when in use, and that consequently
outcomes from clinical trials exploring the effectiveness of prisms
should be measured with participants wearing the prisms (Bowers
2014). In contrast, Rowe 2010 measured outcomes without use
of assigned prisms in order to preserve blinding of outcome as-
sessor and enable direct comparison of study treatment groups. It
was, therefore, not appropriate to pool data from these different
studies of prisms, as the wearing of prisms during assessment in
one study but not the other makes the results incomparable. This
is an important issue which must be appropriately considered in
future trials. Due to the methodological limitations of these stud-
ies, and the inability to combine results, we have low to very low
confidence relating to this evidence.
Assessment/screening intervention versus control
One study explored the effect of implementing a full visual assess-
ment by an orthoptist and sharing the results with hospital staff
(Jarvis 2012). This study measured our primary outcome of in-
terest (functional ability in activities of daily living). The evidence
was judged to be very low quality, limiting our confidence in the
findings from this study.
Quality of the evidence
For this updated review,we judged the quality of evidence using the
GRADE approach. We judged all evidence included within meta-
analyses to be of lowor very lowquality. Key factors contributing to
downgrading of the evidence within these comparisons included:
Risk of bias
We identified concerns about the methodology for the majority of
included studies, and there were often insufficient details available
from incomplete reporting of methodological details. We judged
only eight of the 20 studies to be at low risk of bias for allocation
concealment, six of the 20 for blinding of outcome assessment,
and four of the 20 for incomplete outcome assessment. Further-
more, five of the studies were carried out by researchers who have
acknowledged a financial interest in intervention (Bowers 2014;
Jobke 2009; Kasten 1998; Kasten 2007; Poggel 2004); we assessed
this as potentially introducing a source of bias.
Imprecision
The number of participants within the included studies was small,
ranging from 10 to 87 participants, with only five of the 20 studies
including more than 50 participants. While there were a total of
732 randomised participants, variations in studies made it inap-
propriate for the majority of study data to be combined within
analyses, and themaximumnumber of participantswith data com-
bined in a single analysis was 162 (Analysis 2.3). The small num-
ber of participants within the included studies and suitable for
combination within meta-analyses limits the conclusions that can
be drawn from this evidence.
Indirectness
A number of factors contributed to indirectness of the data in-
cluded within meta-analyses. In particular:
• population: there was considerable heterogeneity between
the populations recruited to individual studies. In addition to
stroke-related differences, such as time post-stroke, initial
impairment, and the presence of other stroke-related
impairments (e.g. communication, mobility), this was
confounded by the inclusion of participants with conditions
other than stroke, and in opposing the decision to either include
or exclude participants with visual neglect. The variations in
populations contributed to decisions to downgrade the quality of
evidence, as this reduced our certainty in the reported findings;
• interventions: this review aimed to synthesise evidence
relating to a wide range of different interventions for visual field
defects following stroke and preplanned categories to support
appropriate combination of evidence. However, we found
substantial variations in the interventions within these different
categories in relation to the details of the delivered interventions.
In particular, the compensative interventions had considerable
variation in the mode of delivery, with interventions varying from
computer-based scanning training and reading training, paper-
based scanning training, to face-to-face scanning and mobility
training. What is being delivered in terms of the eye movements
being trained with these different interventions is likely to vary
considerably, and - while data from these ’scanning’ interventions
have been combined - the variations in interventions limit our
ability to be confident about the pooled result;
• outcomes: as is highlighted in Table 4, there was a lack of
consistency in the outcomes assessed by individual studies, and
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in the assessment tools used to do this. While there is an
argument that outcome measures should be carefully selected
according to the anticipated action of, or scientific rationale for,
the intervention (Bowers 2017), the variations in interventions
do not fully explain the lack of consistency between the outcome
measures. Within the studies of prisms, the difference in choice
of outcome measure was further confounded by opposing
decisions relating to whether outcomes were assessed wearing or
not wearing the prisms. The variations in outcome measures
limited the ability to pool data from individual studies in a
meaningful way, and where measures have been pooled, limited
our certainty in the result.
In summary, we judged the quality of the evidence synthesised
within this review to be low to very low, and this limits our con-
fidence in the results. Future research needs to address the factors
which contribute to this level of evidence, in order to produce
results which are useful and meaningful.
Potential biases in the review process
Publication bias
Through a thorough searching process we are quite confident that
we should have identified all relevant published studies. However,
at the peer review stage of this review update, we were alerted to
the fact that we had erroneously excluded a relevant study (Elshout
2016): while this was corrected prior to publication, it does high-
light the potential for human error in our process of screening
titles. A limitation of our search strategy for this update is that we
have not searched a number of trials databases beyondMarch 2015
(Current Controlled Trials, Health Service Research Projects in
Progress, National Eye Institute Clinical Studies Database, Stroke
Trials Registry); this may have limited our ability to identify on-
going trials, but ought not to have impacted on our identification
of completed trials. It must be acknowledged that there is a small
possibility that there are additional studies (published and unpub-
lished) that we did not identify. We had planned to explore the
effect of publication type using sensitivity analyses; however, all
data included in meta-analyses were from peer-reviewed journals.
Categorisation of interventions
Although we anticipated that we may experience difficulty in cat-
egorising the interventions studied into our predefined categories
of restitutive, compensative, and substitutive interventions, this
was not the case and the categorisation process was a clear and
unambiguous process. This was because the studies we identified
were primarily visual restitution therapy (restitutive), compen-
satory scanning training (compensative), or prisms (substitutive).
We are, therefore, confident that our categorisation of interven-
tions has not introduced bias into the review process. However, we
did find substantial differences between the interventions within
each category (see discussion above), and decisions to combine
data from varied interventionsmay reduce applicability of these re-
sults. Future updates of this review should, therefore, consider and
preplan which interventions it is clinically relevant to combine.
Involvement of key stakeholders to inform this decision making
for future updates would be an advantage.
Inclusion criteria: participants
In the previous version of this review, we reported that the inclu-
sion criterion that was judged as most difficult to assess by the in-
dependent review authors was the participants. The particular dif-
ficulty encountered was with studies that did not appear to include
the diagnosis of visual field defects as an inclusion criterion. In the
previous version, we identified and included several studies that
either used a clinical assessment of ’scanning’ as an inclusion cri-
terion without formally assessing or diagnosing either visual field
defects or visual neglect, or which included participants with a
right-sided cerebrovascular accident, making the assumption that
these participants would have visual neglect (and possibly also vi-
sual field defects). For this update of the review, we addressed this
difficulty by only including studies that reported a method for
diagnosing visual field defects at the recruitment stage. This led
to the exclusion of a number of studies that had previously been
included, but in which the participants did not have confirmed vi-
sual field defects (Carter 1983; Weinberg 1977; Weinberg 1979).
We made this change between the previous version and this up-
dated version of the review in order to reduce potential bias in the
review process; however, we acknowledge that this may have led
to the exclusion of studies in which some participants had visual
field defects that were not confirmed through clinical diagnosis
(e.g. instead manifesting as a scanning problem).
Outcomes
Categorisation of some reported outcome assessments into our
predefined outcomes of interest was difficult in some cases. For
this update of the review, we added a table to report our categori-
sation of outcomes to ensure transparency in this process (Table
4). We also reconsidered categorisation of all outcomes from tri-
als included in the previous version of the review, and made a
number of changes through a process of consensus. For example,
Plow 2010 reported the Veterans Affairs Low Vision-Visual Func-
tional Questionnaire (LV-VFQ) which “assesses an individual’s vi-
sual ability to perform ADLs across 4 domains, including read-
ing, mobility, visual motor function, and visual processing”. This
measure arguably relates to both extended activities of daily living
and quality of life. In the first version of this review, this was listed
as a measure of EADL: however, this was changed to being listed
as a measure of QoL outcome for subsequent updates, following
consensus discussion between review authors.
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The primary outcome for this review was functional ability in
activities of daily living, measured using standardised scales. It
has been argued that measurement of effectiveness in rehabil-
itation ought to take into account patients’ individual goals
(Turner-Stokes 2009). There is growing evidence that goal attain-
ment scaling (a standardisedmethod of scoring performance of pa-
tient-specific tasks) may provide a valid, reliable, sensitive method
of evaluating outcomes that are of greatest importance to individ-
ual patients (Krasny-Pacini 2016). This scale was not considered
for inclusion within this review, and could be considered for future
updates.
As has been discussed under Quality of the evidence, variations in
outcomes and outcomes assessment tools between included stud-
ies created challenges for the synthesis of evidence within this
review. The need to make judgements and decisions relating to
categorisation and pooling of outcomes created potential for the
introduction of bias into the review process. We have aimed for
transparency in our decision making and reporting in an attempt
to avoid the introduction of bias. However, to support the cre-
ation of meaningful evidence syntheses and meta-analyses, there
is a need for consensus between stroke survivors, their families
and carers, health professionals, and researchers in relation to core
outcomes for trials relating to interventions for visual field defects
after stroke as recommended by the COMET Initiative.
Agreements and disagreements with other
studies or reviews
Agreements and disagreements between this
updated version and previous version
In the previous 2011 version of this review, we stated the key
conclusions and implications for practice arising from the evidence
as follows.
• There is limited evidence which supports the use of
compensatory scanning training for patients with visual field
defects (and possibly co-existing visual neglect) to improve visual
field, scanning, and reading outcomes.
• There is insufficient evidence to reach a conclusion about
the impact of compensatory scanning training on functional
activities of daily living.
• There is also insufficient evidence to reach generalised
conclusions about the benefits of visual restitution therapy
(restitutive intervention) or prisms (substitutive intervention) for
patients with visual field defects after stroke.
Key changes in the methods between different versions of this
review include:
• updated searches in this updated version, increasing the
number of included studies;
• amended inclusion criteria, leading to the exclusion of
studies in which participants did not have confirmed visual field
defects;
• the use of the GRADE approach to systematically assess
quality of evidence in this updated version.
These changes have highlighted further uncertainty around pre-
vious limited evidence supporting the use of compensatory inter-
ventions and have introduced evidence relating to adverse events
associated with substitutive interventions, but have not resulted
in any changes in conclusions relating to restitutive or substitutive
interventions.
• There is limited low-quality evidence that compensatory
scanning training may improve an important outcome (quality
of life) in patients with visual field defects following stroke, but
further research is very likely to have an important impact on our
confidence in the estimate of effect and is likely to change the
estimate. There is insufficient evidence to reach a conclusion
about the impact of compensatory scanning training on other
outcomes.
• There remains insufficient evidence to reach generalised
conclusions about the benefits of visual restitution therapy
(restitutive intervention) or prisms (substitutive intervention),
and there is insufficient evidence to reach conclusions about the
effect of screening or assessment interventions for patients with
visual field defects after stroke.
• There is now some low-quality evidence from one study
that prisms may result in an increased number of adverse events,
particularly headache.
Agreements and disagreements with other published
reviews
The Royal College of Physicians updated the evidence included in
the earlier version of this review, concluding that there is “insuffi-
cient evidence regarding the effectiveness of interventions aimed
at improving function in people with visual field defects” (ISWP
2016). This updated review is in agreement with the conclusions
drawn from the evidence in the guideline.
The Scottish Intercollegiate Guideline Network (SIGN) guide-
lines for stroke rehabilitation state that there is “limited poor qual-
ity evidence suggesting that visual scanning compensatory training
techniques may be effective in improving functional outcomes af-
ter stroke” (SIGN 2011). This SIGN guideline (updated in 2010)
is based on a number of other reviews (Barrett 2009; Bouwmeester
2007; Jones 2006). While the previous version of our review was
in agreement with the recommendations made by the Royal Col-
lege of Physicians and SIGN guidelines, our updated review has
highlighted further uncertainty relating to the effect of compen-
satory interventions. The National Institute for Clinical Excel-
lence (NICE) stroke guidelines recommends that “eye movement
therapy” is provided to “people who have persisting hemianopia
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after stroke andwho are aware of the condition” (NICE 2013): our
updated review does not directly support this recommendation.
Our review is in agreement with the conclusions in other reviews
that the evidence relating to the effectiveness of visual restora-
tion therapy is inconsistent and of poor quality (Barrett 2009;
Bouwmeester 2007), and that few studies have assessed functional
ability in activities of daily living as an outcome.
Our review is in agreement with narrative reviews of evidence for
interventions for visual problems after stroke (Lane 2008, Hanna
2017), which have concluded that there is a need for high-quality
studies of the effectiveness of interventions for visual field defects.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is limited low-quality evidence that compensatory scanning
training may improve an important outcome (quality of life) in
patients with visual field defects following stroke, but further re-
search is very likely to have an important impact on our confidence
in the estimate of effect and is likely to change the estimate. There
is insufficient evidence to reach a conclusion about the impact of
compensatory scanning training on other outcomes.
There is insufficient evidence to reach generalised conclusions
about the benefits of visual restitution therapy (restitutive interven-
tion), prisms (substitutive intervention), or assessment or screen-
ing interventions for patients with visual field defects after stroke.
Prisms may cause a range of adverse events, particularly headache.
Implications for research
Specific implications for research, based on the findings of this
review, are outlined below.
Are further randomised controlled trials (RCTs)
required?
RCTs are required to determine the effect of:
• compensatory scanning training compared to no treatment,
placebo, or usual care;
• restitutive interventions compared to no treatment, control,
or placebo;
• substitutive interventions compared to no treatment,
control, or placebo;
• assessment or screening interventions compared to standard
care.
Such RCTs must:
• have adequate power (i.e. with an appropriate power
calculation undertaken based on existing trial evidence);
• have adequate allocation concealment, blinding of outcome
assessor, and intention-to-treat analysis;
• clearly define trial participants, with particular care relating
to the diagnosis and inclusion of patients with visual field defects
or visual neglect, or both;
• consider the severity of the visual field defect and plan
subgroup analyses, where appropriate;
• include measures of functional ability in activities of daily
living;
• collect and report data relating to adverse events;
• report clear and usable data.
We recommend that future RCTs concentrate on answering the
specific question relating to the effectiveness of interventions com-
pared to control, placebo, no treatment, or usual care rather than
comparisons with variations of the same ’type’ or category of in-
tervention, or comparisons of different doses, adjuncts to treat-
ment, or modes of delivery. We believe that until such time as
the benefits of interventions for visual field defects compared to
control, placebo, no treatment, or usual care have been established
(or refuted), it is not beneficial to compare the relative effects of
different interventions. We recommend that future RCTs should
include outcomes that are of importance to people affected by this
problem, such as quality of life, confidence, and participation in
social activities and relationships. We recommend that consensus
is reached relating to the important outcome measures which all
future trials of interventions for visual field defects in people with
stroke should assess (i.e. a core outcome set), and that stroke sur-
vivors, carers, health professionals, and researchers are involved in
developing this core outcome set.
A number ofRCTs are currently ongoing.Once they are completed
it will be important to update this review and to re-evaluate the
need for further RCTs of interventions for visual field defects.
Are other primary research studies required?
We do not recommend other study designs aimed at investigating
the effects of visual restitution therapy or prisms, although devel-
opment or pilot studies may be justified to support the design of
a full trial if such work has not previously been completed. Given
the variation in compensatory interventions included in this re-
view, we do recommend that other primary research studies are
considered to explore an optimal scanning training intervention.
Such studies may consider the evaluation of computerised as well
as non-computerised interventions, the effective dosage, and the
role of reading-specific training. However, this work ought to be
done as a prequel to a well-designed RCT of the scanning inter-
vention. Studies evaluating different types of scanning training
should provide clear details of the treatment parameters, including
the eye movements which are being trained by the intervention.
There is a need for further research to identify optimal outcome
measures for usewithin futureRCTs in this area. Such researchmay
consider the relationship between functional measures of activities
of daily living (ADL), measures of vision-related extended ADL
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(such as reading, driving, navigating within an environment), and
laboratory measures of the visual field.
Are further systematic reviews required?
We do not recommend any further systematic reviews aimed at
addressing the effectiveness of interventions for visual field defects
after stroke. We do recommend that this review is updated when
the ongoing RCTs are completed.
Summary of findings
• The quality of evidence summarised in this review is judged
to be low to very low.
• Methodological quality of studies is, in general, poor or
poorly reported, providing insufficient high-quality evidence on
which to reach generalisable conclusions.
• Limited low-quality evidence suggests compensatory
interventions may improve an important outcome (quality of
life) in patients with visual field defects following stroke, but
further research is very likely to have an important impact on our
confidence in the estimate of effect and is likely to change the
estimate. There is insufficient evidence to reach a conclusion
about the impact of compensatory scanning training on
functional activities of daily living, or other outcomes.
• There is insufficient evidence to reach generalised
conclusions about the benefits of vision restoration therapy for
patients with visual field defects after stroke.
• There is insufficient evidence to reach generalised
conclusions about the benefits of prisms for patients with visual
field defects after stroke; there is some low-quality evidence that
prisms may cause adverse events.
• High-quality RCTs are needed to compare compensatory,
restitutive, substitutive, and assessment interventions with
placebo, control, no treatment, or usual care.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aimola 2011
Methods Compensative intervention versus control, placebo, or no intervention
Design: “A randomized, controlled, parallel-group design was used.”
Stratification: no
Randomisation sequence: “participants were randomized equally to 2 groups ... using
parallel trial allocation software”
Comparisons: 2 groups: intervention versus control
Allocation concealment: “Participants were informed about the training types but did
not know to which group they were assigned.”
Blinding: not stated if outcome assessor was blinded
Power calculation: no (feasibility study)
Intention-to-treat analysis: no
Other recruitment details: “recruited from local hospitals or as self-referrals”
Patient and public involvement: not stated
Participants Total study population: randomised 70; “final sample included in analyses consisted of
52 participants; 28 intervention and 24 control”
Withdrawals: 18 “dropped out during the intervention period because of health prob-
lems (n = 7), death (n = 2), or low motivation (n = 9)”
Method of diagnosing VFD: monocular automatic perimetry
Characteristics of population: “chronic hemi-VFDs resulted from any post-chiastmatic
lesion.” Participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: at least 18 years old, no previous access to any formal hemi-VFD
rehabilitation (restoration, substitution or compensation)
Exclusion criteria: “medical instability, inability to provide informed consent, visual
loss as a consequence of prechiasmatic damage or a progressive condition, photosensitive
epilepsy, oculomotor disorders, and severe cognitive impairment. Participants were not
enrolled until at least 3 months after onset to minimize confounding by spontaneous
recovery (range = 3-276 months)”
Baseline comparison of treatment groups: no differences noted at baseline
This study included participants with diagnoses other than stroke
This study included participants with visual field defects and co-existing visual neglect
Method of diagnosing visual perceptual problems: Bells test
Interventions Group 1: home-based compensatory training (n = 28)
Intervention: “the experimental training consisted of reading and exploration compo-
nents; patients completed components sequentially with order randomized.”
Intervention type: compensation. Materials: computer-based: Where can materials
be accessed? not stated. Procedures: “In the visual exploration tasks patients had to
find a target defined by a specific feature (color, shape, size) among an array containing
distractors (i.e. a red letter among blue ones). In the reading task, patients had to detect
a nonword target (ie, vowels) among a varying number of words (i.e. accent), presented
in a single central horizontal line. In both task types participants responded to target
presence using an appropriate computer-mouse press. Computer feedback on speed and
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Aimola 2011 (Continued)
accuracy of responses, and overall progress to date (i.e. difficulty level achieved and
number of training sessions completed), was provided at the end of each block of trials.”
Provided by: “at the start of the intervention period the experimenter demonstrated the
training, during which the computer was set up ... Participants were encouraged to train
in a similar manner, though adherence cannot be guaranteed” .Delivery: home-based
(Table 1). Regimen: “Patients could perform a maximum of 14 blocks per day. Each
block contained 120 trials. They completed 294 exploration and 196 reading blocks.
” Tailoring: “For both training components difficulty level was dynamically adjusted
based on both accuracy and speed of previous performance. If patients were ≥ 90%
accurate then difficulty would increase to the next level, whereas with accuracy < 75%
difficulty would drop to an easier level. In exploration tasks difficulty was increased by
enlarging the spatial zone within which a target could appear and by making targets and
distractors more similar. For the reading task the word length and number of distractor
words increased (up to a maximum of 7). For both tasks, presentation time was directly
related to previous response times, that is, the faster the participant, the shorter the
successive presentation time”. Modification: see tailoring. Adherence: “There were 18
withdrawals, 9 due to lowmotivation. A total of 89% of the low-motivation withdrawals
were in the control group. Recommended training duration was 5 weeks. However, only
3 patients met this requirement; the mean completion time for the experimental training
was 9.3 weeks (SD = 6.0).”
Group 2: control (n = 24)
Intervention: “This training consisted of a number of tasks requiring visual attention
but no systematic exploration or large horizontal eye movements.” Intervention type:
placebo/attention control. Materials: computer-based. Where can materials be ac-
cessed? not stated. Procedures: “The randomly presented tasks included a Go/No-Go
task, centrally presented sequential search, Sternberg task, and a ”rabbit hunting“ task.
” Provided by: “at the start of the intervention period the experimenter demonstrated
the training, during which the computer was set up ... Participants were encouraged to
train in a similar manner, though adherence cannot be guaranteed”.Delivery: home-
based (Table 1). Regimen: “Patients were instructed to complete 10 blocks per day in
approximately 1 hour, with a total of 350 blocks.” Tailoring: “Difficulty was adjusted
dynamically depending on performance by reducing presentation time or increasing at-
tentional load.” Modification: see tailoring. Adherence: “There were 18 withdrawals,
9 due to low motivation. A total of 89% of the low-motivation withdrawals were in the
control group. Recommended training duration was 5 weeks. However, only 3 patients
met this requirement; the mean completion time for the experimental training was 9.3
weeks (SD = 6.0).”
Outcomes See Table 4
Perimetry (Esterman)
Visual search (find the number)
Reading (corrected reading speed)
Tasks simulating ADL: 1) driving hazard perception (mean score per hazard), 2) obstacle
avoidance (completion time), 3) visuomotor search (time)
Attention tasks: 1) sustained attention to response (mean percentage error score), 2) test
of everyday attention
Subjective questionnaires: Visual Functioning Questionnaire (VFQ-25), Subjective Rea-
sons Questionnaire
Time points when outcomes were assessed: before and after intervention
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Aimola 2011 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Stated “using parallel trial allocation soft-
ware”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Participants were informed about the
training types but did not know to which
group they were assigned.” Not stated if
outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk “There were 18 withdrawals, 9 due to low
motivation.”
Other bias Low risk No other issues noted
Bainbridge 1994
Methods Substitutive intervention versus substitutive intervention
Design: parallel RCT
Stratification: not stated
Randomisation sequence: not stated
Comparisons: Full Field plastic press-on 15-diopter Fresnel prisms (base towards the
deficit) versus Half Field prisms cut to cover the respective homonymous field
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 18 (stroke only) participants who had hemianopsia or visual
neglect, or both
Withdrawals: none
Method of diagnosing VFD: confrontation; method of diagnosing visual perceptual
problems: confrontation
Characteristics of population: participant details are listed in Table 2
Type and severity of visual problems: participant details are listed in Table 3
Inclusion criteria: not stated
Exclusion criteria: not stated
Baseline comparison of treatment groups: not stated
Interventions Group 1: Full field prism (n = 10)
Intervention type: substitution. Materials: Full field prism. Where can materials be
accessed? not stated. Procedures: 15 dioptre full-field plastic press-on Fresnel prisms
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Bainbridge 1994 (Continued)
(base towards the deficit). Provided by: not stated. Delivery: face-to-face, individual,
location not stated (Table 1). Regimen: used the prisms while awake for 4 weeks. Tai-
loring: not stated. Modification: not stated. Adherence: not stated
Group 2: Hemi-field prism (n = 8)
Intervention type: substitution.Materials:Hemi-field 15 diopter Fresnel prism.Where
can materials be accessed? not stated. Procedures: Hemi-field prisms cut to cover the
respective field. Provided by: not stated.Delivery: face-to-face, individual, location not
stated (Table 1). Regimen: used the prisms while awake for 4 weeks. Tailoring: not
stated. Modification: not stated. Adherence: not stated
Outcomes See Table 4
Motor visual perception score
Line Bisection Test
Line Cancellation test
Harrington-Flocks Visual Field score
Time points when outcomes were assessed: baseline and at 4 weeks
Adverse events? not stated
Notes Insufficient information to assess for any confounding variables (abstract)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Quote “patients were randomized”. Insuf-
ficient information available in the abstract
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Insufficient information available in the ab-
stract
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information available in the ab-
stract
Other bias Unclear risk Insufficient information available in the ab-
stract
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Bowers 2014
Methods Substitutive intervention versus control, placebo or no intervention
Design: RCT (cross-over, with a “counterbalanced AB/BA design (AB = real first, BA =
sham first)”. The “real” prisms could be either “oblique” or “horizontal” peripheral prism
glasses, meaning that there were 4 possible treatment allocations for each participant)
Stratification: see below (minimisation)
Randomisation sequence: participants were assigned using minimisation. “The first
participant was assigned randomly, with each subsequent participant assigned in such a
way as to minimize imbalances among the 4 treatment allocations. We could realistically
balance for only 2 factors. Study site was the primary factor (because continuation rates
varied significantly across sites in our first multicenter study) and side of hemianopia
(right or left) was the second factor (because the side of the lesion could potentially affect
performance with the prism glasses). We did not balance for age because it was not a
significant factor affecting continuation rates in our previous study.”
Comparisons:oblique peripheral prismglasses, horizontal peripheral prismglasses, sham
prism glasses
Allocation concealment: yes
Blinding: “Double-maskingwas used,with participants anddata collectors beingmasked
as far as possible. In addition, the principal investigator who conducted data analyses was
masked. However, it was impossible to mask all study personnel; there was an unmasked
practitioner at each site who fitted the prism glasses and dealt with clinical aspects of
patient care.”
Power calculation: yes (data from previous trial used to calculate minimum sample size;
led to “plan to enrol at least 68 participants”)
Intention-to-treat analysis: no
Other recruitment details: “Data were collected at 13 study sites, including the Peli
laboratory at Schepens, 11 vision rehabilitation clinics in the United States, and 1 in the
United Kingdom. The clinics included university, hospital, and private practice clinics.
Each site recruited a median of 7 participants (range, 3-12). Participants were recruited
by practitioners at each study site.”
Patient and public involvement: not stated
Participants Total study population: 73 randomised
Withdrawals: 6 (before the start of the cross-over)
Method of diagnosing VFD: visual field mapping extended to at least 50° from fixation
in all directions andwas performedusingGoldmannperimetry (V4e target), aHumphrey
Field Analyzer 120-point full-field screening test, or similar tests, depending on the
equipment available at each clinic
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3
Inclusion criteria: “Complete homonymous hemianopia of greater than 3 months’
duration, no visual neglect (Bells test and Schenkenberg Line Bisection test), and no
history of having worn peripheral prism glasses. In addition, participants had corrected
monocular visual acuity of at least 20/50 in each eye, refractive error within the −5
diopter (D) to +5D range, no strabismus, no significant cognitive decline (Short Portable
Mental Status Questionnaire), and no balance problems or other deficits that could
impair ability to walk or use the prism glasses. To ensure that study inclusion criteria
were uniformly applied, screening data were sent to the principal investigator (A.R.B.),
who determined eligibility”
Exclusion criteria: none listed
Baseline comparison of treatment groups: yes (mobility questionnaire)
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Bowers 2014 (Continued)
Interventions Group 1: Prism glasses (total n = 37)
Group 1a. Real oblique prism glasses (n = 19)
Group 1b. Real horizontal prism glasses (n = 18)
Intervention type: substitution.Materials: peripheral prism glasses of 57 prism dioptres
(intervention) versus 5 prism dioptres (sham).Where can materials be accessed? From
vision specialists; for the study these were manufactured by “Chadwick Optical, Inc.
(White River Junction, Vermont)”. Procedures: participant fitted and provided with
prism glasses to be worn for the following 4 weeks. “Training in how to use the prism
glasses was conducted by the practitioner.” “Participants were taught to view through the
central prism-free area of the spectacle lens at all times and to turn the head and eyes to
fixate objects of interest that were initially detected from the prism image in peripheral
vision. A simple ”reach and touch“ training exercise was used to familiarize participants
with the relationship between the apparent and real positions of objects detected from the
prism image; this exercise was also encouraged for home-training. Participants were given
verbal and written instructions about how to use the prism glasses and were encouraged
to wear them as much as possible each day. They were advised not to use the peripheral
prism glasses for driving or prolonged reading.” Provided by: “practitioner”. Delivery:
face-to-face, individual, clinic appointment to be provided with the glasses, then to
be worn by participant (Table 1). Regimen: first pair of prisms glasses 4 weeks; then
cross-over and use of second pair of prism glasses for another 4 weeks (see procedures).
Tailoring: not stated. Modification: not stated. Adherence: not stated
Group 2: Sham prism glasses (total n = 36)
2a. Sham oblique prism glasses (n = 17)
2b. Sham horizontal prism glasses (n = 19)
Intervention: control. Intervention type: placebo control. Materials: sham prism
glasses.Where can materials be accessed? For the study these were manufactured by
“Chadwick Optical, Inc. (White River Junction, Vermont)”. Procedures: as for real
prisms. Provided by: “practitioner”.Delivery: face-to-face, individual, clinic appoint-
ment to be provided with the glasses, then to be worn by participant (Table 1).Regimen:
first pair of prisms glasses 4 weeks; then cross-over and use of second pair of prism glasses
for another 4 weeks (see procedures). Tailoring: not stated. Modification: not stated.
Adherence: not stated
Outcomes See Table 4
The proportion of participants fitted with each type of prism glasses for whom the
decision is to continue using the glasses
Difference in perceived mobility (i.e. rating of how helpful each type of prism glasses are
in avoidance of obstacles when walking)
Time points when outcomes were assessed: at the end of each cross-over period
Notes Data presented for the first phase (i.e. before the cross-over) is presented for “real” versus
“sham” prisms, i.e. with data from the oblique and horizontal groups combined: “there
were no statistically significant differences between the oblique and horizontal groups
for any of the outcome measures ... therefore, data were pooled across the 2 groups for
the main analyses”
Risk of bias
Bias Authors’ judgement Support for judgement
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Bowers 2014 (Continued)
Allocation concealment (selection bias) Low risk “The clinical coordinator at Schepens as-
signed participants to 1 of 4 possible treat-
ment allocations (real oblique AB/BA and
real horizontal AB/BA) using minimiza-
tion”. Allocation was done by central clin-
ical co-ordinator
Blinding (performance bias and detection
bias)
All outcomes
Low risk Outcome assessor was blinded. The per-
sonnel fitting the prism were not blinded:
“Double-masking was used,with partici-
pants and data collectors being masked as
far as possible. In addition, the principal
investigator who conducted data analyses
was masked. However, it was impossible to
mask all study personnel; there was an un-
masked practitioner at each site who fit-
ted the prism glasses and dealt with clinical
aspects of patient care”. In the debriefing,
61% (37/61) of participants reported that
they thought that one pair of glasses might
have been a sham; of these, 92% (34/37)
correctly identified the sham
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for dropouts were reported and
were balanced across the groups
Other bias High risk Authors have disclosed conflicts of interest:
“Dr Peli has financial interest in a patent
related to the peripheral prism glasses (as-
signed to Schepens Eye Research Institute)
. Ms Keeney has licensed that patent for
Chadwick Optical, Inc. Chadwick Opti-
cal, Inc funded the study in part from
National Institutes of Health (NIH) grant
EY014723 through a subcontract with
Schepens Eye Research Institute. Dr Peli
was a paid consultant toChadwickOptical,
Inc on the design of the permanent prisms.
No other financial interests were reported.
”
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De Haan 2015
Methods Compensative intervention versus control, placebo or no intervention
Design: RCT
Stratification: minimisation (”minimised regarding gender, side of field defect (left or
right), side of field defect (hemianopia versus quadrantanopia), age (younger versus older
than 55), and time since onset (shorter versus longer than 12months - because time since
onset was assumed less important than the other variables, this variable was weighted
less heavily than the others)
Randomisation sequence: randomisation software
Comparisons: 2 groups, training group and control group
Allocation concealment: no, “author GH entered the characteristics of the patient into
the randomisation software ... which resulted in allocation to the training group or the
waiting list control group”
Blinding: “Assessors were blinded to participants’ group allocation”.
Power calculation: yes
Intention-to-treat analysis: no; some participant data excluded from analysis due to
deviations from study protocol (“too low compliance with training protocol”, “time
period between T1 and T2 longer than acceptable”)
Other recruitment details: patients were recruited at Royal Dutch Visio and Bartiméus,
the two centers of expertise for blind and partially sighted people in the Netherlands
Patient and public involvement: not described
Participants Total study population: 54 randomised; training group (n = 30), control group (n =
24)
Withdrawals: at follow-up immediately after training; training group (n = 28), control
group (n = 24). Additional participants excluded from analysis, so in analysis: training
group (n = 26), control group (n = 23)
Method of diagnosing VFD: specific method not clear: “patients underwent extensive
and standardized ophthalmological and neuropsychological assessments at the centers
mentioned above prior to participation in the study.”
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: “The main inclusion criterion was presence of a hemi-VFD, at least a
quadrantanopia, restricted to one half of the visual field, due to acquired postchiasmatic
brain injury ... To be included, patients required a minimum binocular visual acuity of
Snellen 0.5 (6/12 or 20/40, LogMAR 0.3), a stable neurological and ophthalmological
condition, non-disturbed eye and head motility, ability to walk at least 50 meters, and a
Mini Mental State Examination (MMSE) score 24 out of 30.”
Exclusion criteria: “Exclusion criteria were ocular diseases affecting the visual field or
binocular visual acuity, signs of severe physical impairments or (neuro)psychological
disorders. Neglect was excluded based on the Balloons, Drawings, Line Bisection and
Rey Complex Figure Test.”
Baseline comparison of treatment groups: yes
Interventions Group 1: InSight-Hemianopia Compensatory Scanning Training (IH-CST) (n = 26)
Intervention type: compensation. Materials: “The full training protocol is available
at Visio and Bartimeus for occupational therapists trained for applying the protocol”.
Electronic software was needed: “software was needed in order to implement the exercises
... this software was developed by the faculty of Behavioural and Social Science at the
University of Groningen”.Procedures: “The aim of the IH-CST is to teach patients
with HVFD to compensate for their visual field defect during a wide range of mobility-
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related activities ... The compensation strategy taught in the IH-CST is to apply a
scanning rhythm consisting of a triad of saccades. First a large saccade towards the blind
side is made in order to receive information from the periphery. This is followed by a
second saccade back towards the seeing side to prevent overcompensation. Third, a small
saccade is made back to the starting point of looking straight forward ... The training
program consists of exercises for improving awareness of the visual field defect and its
consequences for daily life, exercises to learn the scanning rhythm, and practice of the
scanning rhythm in daily life mobility situations”.Provided by: occupational therapists:
“Thirty occupational therapists ... experienced in working with brain injured patients
were schooled in providing the IH-CST ... ”. Delivery: “Training according to the
protocol was provided in Dutch at nine locations of Royal Dutch Visio and one location
of Bartimeus in the Netherlands.” “Homework assignments are included in the training
protocol”. (Table 1). Regimen: 15 individual sessions of 60 to 90 minutes each, 18.5
hours of face-to-face training in total during a period of 10 weeks. Tailoring: yes (stated
“not applicable” in author’s checklist, but stated that “... the patient proceeds to the
next exercise once the predefined targets or an exercise are accomplished. This creates
flexibility for individual needs and progress and can cause the training to take more or
less than 15 sessions”).Modification: no. Adherence: “patients are asked to keep a diary
of their practice at home and the therapist asks about the progress of the homework
assignment at the beginning of every training session”
Group 2:Wait-list control (n = 23)
Intervention type: control. Materials: none. Where can materials be accessed? NA.
Procedures:NA. Provided by:NA.Delivery:NA. (Table 1) Regimen: NA. Tailoring:
NA.Modification: NA. Adherence: NA.
Outcomes See Table 4
Tests for visual functions (Goldman perimetry)
Reading tests
Basic scanning tests
Hazard perception test
Tracking task
Obstacle course
Questionnaires for activity and participation
Time points when outcomes were assessed: participants in the training group were
assessed the week before training (T1) and the week after training (T2); participants in
the control group were assessed at the same time points (T1 and T2)
Notes Trial registration details: ISRCTN Registry (ID ISRCTN16833414); Central Com-
mittee on Research Involving Human Subjects (CCMO; registration number NL31718.
042.10)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Random allocation, using randomisation
software. Researcher (GH) was aware of al-
location, but was not involved in providing
treatment or assessment
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Outcome assessors were blinded. Personnel
providing training and participants could
not be blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis. Final analy-
sis completed only on those who completed
training, and who complied with the train-
ing programme
Other bias High risk Control group received no treatment or
contact with personnel. Therefore, high
risk of bias due to attention received by
training group
Elshout 2016
Methods Restitutive intervention versus control, placebo or no intervention
Design: randomised cross-over trial
Stratification: not stated
Randomisation sequence: ”For each cohort of 10 patients, numbers (J01-J40), the
training stimuli (FloworPoint), and the order of training rounds [Test (defect) round
first or Control (intact) round first] were randomly assigned to a patient number ... The
patients were included in order of registration on our website. Thus, the assignment of
a patient to a patient number (with corresponding training scheme: stimulus type and
the training order) was determined prior to the first inclusion, completely random and
not based on selection.“
Comparisons: 2 groups: ”(1) test (high contrast training of the affected field) and (2)
control (low-contrast training of the intact visual field)“
Allocation concealment: see randomisation sequence
Blinding: ”We applied both Humphrey (blinded) and Goldmann perimetry (not
blinded, because of insufficient staffing).“ Not stated for reading tests
Power calculation: not stated
Intention-to-treat analysis: no. ”Three patients dropped out during the first training
round for personal reasons and were excluded from analyses“
Other recruitment details: ”This study was part of a larger project ... Forty stroke
patients with visual field defects due to post-chiasmatic stroke were included following
written informed consent. Patients throughout the Netherlands could signup for our
study voluntarily by filling in a form on our website.“ However after 3 cohorts of 10
patients, the training procedure was modified ”because in some patients the control
training reversed the increase of the visual field of the preceding defect training“. This
study therefore only reported the first 3 cohorts of participants
Patient and public involvement: not stated
Participants Total study population: 30 patients with post-chiasmatic lesions
Withdrawals: 3 patients dropped out ”for personal reasons“. They were excluded from
analyses
Method of diagnosing VFD: Goldmann perimetry measurement
Characteristics of population: participant details are listed in Table 2.
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Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: ”Patients in the chronic phase of stroke (> 10 months post CVA)
were included if they showed no signs of visual neglect (line bisection test). Patient age
was between 18 and 75 years, and they were able to undergo (f )MRI scanning.“
Exclusion criteria: visual neglect (see above)
Baseline comparison of treatment groups: not stated
Interventions Group 1: defect training (high contrast stimuli offered within the field defect along its
border) (n = 15 for first phase, before cross-over)
Intervention type: restitution - high-contrast stimuli in affected hemifield. Materials:
”Each patient received a training unit at home to create a controlled training environ-
ment.This unit consists of a container, to be placed on a table, with a top cover and side
covers to present a dark visual surround for the training stimuli with the exclusion of
stray light.Mini Mac computer, keyboard, andmouse, a support with 24“ LEDmonitor,
webcam, and chin/headrest were positioned inside the matte black container”. Where
can materials be accessed? not stated. Procedures: “Viewing distance was fixed at 40
cm. The subject’s face was indirectly lighted with a TL light for eyetracking with the
webcam. The computer was prepared with eyetracking software, and training programs
that were adjusted to the particular visual field defect of the patient.” “For both stimuli,
the patient maintained fixation binocularly on a ring (diameter = 0.5°) at the center
of the screen. During stimulus presentation (7s),patients shifted attention covertly (i.e.
without shifting eye fixation) toward the stimulus and responded using the keyboard.
Only the fixation point was shown during the intertrial interval of 2s”. “To cue the stim-
ulated target location and to perform a discrimination task, a line was presented simul-
taneously with the point extending from the fixation target into the trained hemifield.
The meridional angle of the line differed by 10° from the training point.The patient
made a forced-choice response whether the point stimulus was presented clockwise or
counterclockwise relative to the presented line”. Provided by: Not stated. Delivery: In
patients home. (Table 1). Regimen: “1h a day, 5 days a week during 8 weeks to com-
plete at least 40h of training per hemifield”. “The length of one training session was on
average 12min (depending on the number of trials set per session and amount of fixation
errors). The number of trials in a session ranged between 60 and 100, depending on
the shape and quality of the visual field defect. The stimuli were randomly presented for
each session”. Tailoring: The number of trials depended on the shape and quality of the
visual field defect. “Point size was at least 0.2° in diameter (at 1° eccentricity) and was
scaled with eccentricity: scale (E) = (0:0006E2 + 0:0448 E + 0:092) = 0:1374”. Modifi-
cation: not stated. Adherence: was monitored: “Throughout the training, fixation was
monitored via a low-cost commercial webcam and eyetracking software available in the
public domain (www.inference.phy.cam.ac.uk/opengazer/) that was adapted to supply
eye position data to the training program”
Group 2. Control (intact training) (stimuli presented in the intact field about the same
eccentricities as for defect training) (n = 15 for first phase, before cross-over)
Intervention type: placebo/control. Although paper stated: “Following three cohorts of
10 patients, we modified the training procedure, because in some patients the control
training reversed the increase of the visual field of the preceding defect training”. Ma-
terials: as above.Where can materials be accessed? not stated. Procedures: similar to
above defect training: “During intact training, stimuli were presented within the intact
field at about the same eccentricities as for the patient’s defect training ... To offer a
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challenging training during the intact training, the stimulus contrast was reduced (C
< 0.15)”. “Within the entire visual field, a pattern of flow was shown that contracted
on to a training location within the visual field (white points on a dark screen). The
stimulus to be discriminated was placed on a black disk that covered the center of the
contraction pattern, the diameter of which was eccentricity scaled with the same factor
as for the point target. We used a minimal disk size of 1.7° at 1° eccentricity. The origin
of the contraction pattern was the location cue for the flow discontinuity that had to
be detected. The discontinuity stimulus (on the disk) was a flow pattern rotating clock-
wise or counterclockwise about the training location. The patient had to indicate the
direction of rotation”.Provided by: not stated.Delivery: in participant’s home (Table 1)
. Regimen: as above. Tailoring: stimuli were presented at the same eccentricities as for
the defect training, which depended on the shape and quality of the visual field defect.
Modification: not stated. Adherence: as above
Outcomes See Table 4
Perimetry: Humphrey (blinded) and Goldmann perimetry (not blinded because of in-
sufficient staffing)
Reading tests: reading speed
Notes Supplementary material referred to within published paper, but not accessible via we-
blink. Requested from authors February 2019
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Patientswere included in the order inwhich
they registered on the website. Order of
treatment phases was randomly assigned,
and allocated to patient number prior to
patient registrations
Blinding (performance bias and detection
bias)
All outcomes
High risk Noblinding forGoldmannPerimetry (“be-
cause of insufficient staffing”). Humphrey
perimetry was blinded. Not stated for read-
ing tests. Unclear who delivered the inter-
vention and whether they were blind to the
treatment phase
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No intention-to-treat analysis. 3 dropouts
during first phase “for personal reasons”,
but unclear which treatment group they
were in
Other bias Low risk No other issues noted
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Methods Restitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: not stated
Randomisation sequence: not stated
Comparisons: 2 groups
Allocation concealment: not stated
Blinding: stated “blinded”
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 29 patients with post-chiasmatic lesions
Withdrawals: not stated
Method of diagnosing VFD: not stated
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated
Exclusion criteria: not stated
Baseline comparison of treatment groups: not stated
Interventions Group 1: non-invasive brain stimulation using alternating current stimulation (ACS) (n
= 15)
Intervention type: restitution - alternating current stimulation. Materials: not stated.
Where can materials be accessed? not stated. Procedures: not stated. Provided by: not
stated.Delivery: face-to-face, individual, location unclear (Table 1). Regimen: 10 days.
No other details reported. Tailoring: not stated. Modification: not stated. Adherence:
not stated
Group 2: sham stimulation (n = 14)
Intervention type: placebo/control.Materials: not stated.Where can materials be ac-
cessed? not stated. Procedures: not stated.Provided by: not stated.Delivery: face-to-
face, individual, location unclear (Table 1).Regimen: 10 days. No other details reported.
Tailoring: not stated. Modification: not stated. Adherence: not stated
Outcomes See Table 4
Perimetric thresholds within areas of residual vision
Subjectively perceived visual functioning/vision-related quality of life (composite score
of National Eye Institute Visual Function Questionnaire 39)
Health-related quality of life (Short Form Health Survey SF-12)
Time points when outcomes were assessed: baseline and post-intervention (time point
not stated)
Notes Insufficient information to assess for any confounding variables (abstract)
Risk of bias
Bias Authors’ judgement Support for judgement
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Allocation concealment (selection bias) Unclear risk Insufficient information available in the ab-
stract
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Insufficient information available in the ab-
stract
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information available in the ab-
stract
Other bias Unclear risk Insufficient information available in the ab-
stract
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Methods Assessment or screening intervention versus control, placebo or no intervention
Design: pilot RCT
Stratification: none
Randomisation sequence: “randomized into one of two groups using a computer-
generated randomization table”
Comparisons: 2 groups: Group A (control) and Group B (experimental)
Allocation concealment: not stated (“randomization process was administered by a
researcher at the University of Liverpool, who was not involved in data collection but
was involved in the later data analysis”)
Blinding: participants were blinded (“participants were masked to group allocation”),
“assessors were not masked” (“findings from the visual assessment were withheld from
the therapy staff in group A (control group). In comparison the visual assessment details
were made available to the therapy staff for participants in group B (experimental group)
”
Power calculation: feasibility study (“prospective observation cohort study in the UK
suggested that of all stroke patients referred with suspected visual impairment, 85%
were found to have an identifiable visual impairment (Rowe 2007). On the basis of
this preliminary data, this pilot study aimed to screen 100 patients in order to recruit a
minimum of 70 participants”)
Intention-to-treat analysis: no (“All data analysis was conducted based on the recruited
patients to each group with full FIM data collection for both baseline and 6-week follow-
up assessment”)
Other recruitment details: “Participants were prospectively recruited between February
2008 and July 2009”. “Specified members of the health care team (nurses, stroke physi-
cians, physiotherapists and occupational therapists) on the stroke unit were required
to screen patients against these criteria to identify potential participants. Staff used a
screening form with questions to identify visual signs (head turning, strabismus, ptosis)
and symptoms (diplopia, loss of vision, field loss). This was adapted from the screening
form used in the Visual In Stroke (VIS) study (Rowe 2010)”.“If visual impairment was
noted, the screening form was sent to the orthoptist and hence, it doubled as a referral
form”. “Where necessary, for example when a potential participant had communication
difficulties, adaptations were made to the consent process”
Patient and public involvement: not stated
Participants Total study population: 64
Withdrawals: 13 died before full baseline assessment (Group A: 4; Group B: 9). Another
10 cases ( Group A: 6, Group B: 4) withdrew (death, early discharge, no follow-up or
DNA follow-up) at follow-up assessment
Method of diagnosing VFD: full visual assessment undertaken by orthoptist. Battery
of routine tests used as part of a previous study (Rowe 2009). It comprised tests of visual
acuity - logMAR (Bailey 1976), ocular alignment - cover test (Pediatric Eye Disease
Investigator Group 2009), ocular motility - saccadic, smooth pursuit and vergence as-
sessment (Holmes 2001), stereopsis - Frisby test (Rosner 1984), visual field - confronta-
tion (Cassidy 2001) and visual inattention - line bisection, star cancellation, and clock
drawing. “The orthoptist did not suggest possible adaptive strategies to be undertaken,
the focus was on alterations made by the therapists based only on the visual assessment
information”
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
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Inclusion criteria: “stroke within 2-6 weeks of being recruited, had a decreased func-
tional ability compared to pre-stroke functioning, had a post-stroke visual impairment,
and were able to understand the research process”
Exclusion criteria: “unable to consent due to cognitive impairment or communication
difficulties, or if they had a visual field impairment pre-existing their stroke”
Baseline comparisonof treatment groups: “no significant difference in the composition
of both groups (x2 test) for gender (P = 0.846), age (P = 0.113), stroke type (P = 0.564)
, stroke area (P = 0.499), stroke laterality (P = 0.396) and handedness (P = 0.268)”
Interventions Group 1: experimental (n = 24 full baseline assessment; n = 20 at follow-up assess-
ment)
Intervention type: assessment or screening.Materials:modified screening form.Where
canmaterials be accessed? Screening form (modified) available from theVisual In Stroke
(VIS) study (Rowe 2010). Procedures: “all participants underwent a full visual assess-
ment by an orthoptist. The findings from the visual assessment were ... made available to
the therapy staff for participants in group B (experimental group)”. “participants in both
groups received occupational therapy and physiotherapy”. “Therapy routinely included
working to regain motor activity and increase ability to achieve valued functional tasks.
The therapists used strategies such as visual scanning and cueing to the affected side as
part of their practice”. Treatment in the experimental group was informed by the re-
sults of the visual assessment. Provided by: orthoptists. No details provided about their
training. Delivery: face-to-face, location Inpatient, stroke unit (Table 1). Regimen: not
stated. Tailoring: yes. Details not supplied. Modification: not stated. Adherence: not
stated
Group 2: control (n = 27 full baseline assessment; n = 19 at follow-up assessment)
Intervention type: control/standard care. Materials: NA.Where can materials be ac-
cessed? NA. Procedures: described above. Treatment in the control group was not in-
formed by results of the visual assessment (“all participants underwent a full visual as-
sessment by an orthoptist. The findings from the visual assessment were withheld from
the therapy staff in group A (control group)”). Provided by:OT, physiotherapy. No de-
tails provided about their training. Delivery: face-to-face, individual, location inpatient
(Table 1). Regimen: NA. Tailoring: NA.Modification: NA Adherence: NA
Outcomes See Table 4
Functional independence measure (FIM)
Timed 10 m walk
Non-validated questionnaire (“Therapist with themost contact with each participant was
asked to complete a non-validated questionnaire giving qualitative information about
their treatment approach.” “Two versions of this questionnaire. The group A question-
naire asked the therapist to justify their treatment approach. The group B questionnaire
required the therapist to comment on whether their treatment approach had been influ-
enced by the visual assessment”)
Time points when outcomes were assessed: “baseline and at 6 weeks after baseline (or
on discharge if this occurred earlier)”
Notes Review author Fiona Rowe was involved in this trial.
Risk of bias
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Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “computer generated randomization table.
The randomization process was adminis-
tered by a researcher at the University of
Liverpool, who was not involved in data
collection but was involved in the later
data analysis. Participants were masked to
group allocation, but the assessors were not
masked in this trial”
Blinding (performance bias and detection
bias)
All outcomes
High risk “Participants were masked to group alloca-
tion, but the assessors were not masked in
this trial.”
“The qualitative study indicated an inher-
ent bias had been introduced to this trial,
due to the inability to blind carers, and
assessors to group allocation. The health
care team perceived that the presence of
a full baseline vision assessment enhanced
their awareness of the effect of visual deficits
following stroke. This was regardless of
whether or not the full visual assessment
details were available.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No intention-to-treat analysis. Dropouts
were clearly reported, but reason for not at-
tending was not clear and could be related
to the intervention
Other bias Low risk No other concerns noted
Jobke 2009
Methods Restitutive intervention versus restitutive intervention
Design: RCT (cross-over)
Stratification: no
Randomisation sequence:nodetails reported (”randomly assigned them into 2 groups“)
Comparisons:2groups, extrastriate vision restoration therapy versus conventional vision
restoration therapy
Allocation concealment: not stated
Blinding: ”double-blind“
Power calculation: no
Intention-to-treat analysis: no
Other recruitment details: none
Patient and public involvement: no
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Participants Total study population: 21 (mixed population) participants, with visual field defects,
lesions over 1 year old
Group 1: 8 participants, Group 2: 10 participants. The study included a mixed popula-
tion
Withdrawals: ”Three patients had to be excluded from the analysis. One male patient
(patient 19) used another vision therapy program not included in this study. Another
patient (patient 20) was excluded because he discontinued the training for more than 4
weeks during the trial and a female patient (patient 21) showed poor fixation performance
(70% rather than the minimally required 90%).“
Method of diagnosing VFD: high-resolution perimetry and ”common static perimetry
diagnosis at their own ophthalmologists office“. Method of diagnosing visual perceptual
problems: not stated
Characteristics of population: participant details are listed in Table 2
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: at least 6 months prior experience of vision restoration therapy
Exclusion criteria: none listed
Baseline comparison of treatment groups: yes
Interventions Group 1: extrastriate vision restoration therapy (VRT) (n = 8)
Intervention type: restitution. Materials: extrastriate vision restoration therapy - not
stated where this could be accessed/acquired
Procedures: stimulation of the ”entire blind area with a massive moving spiral“, plus
standard VRT in areas of residual vision. ”The spiral consisted of concentric circles which
moved with a frequency of 2.5 Hz, and increased in width to generate the perception
of motion“. ”Additionally, areas of residual vision (relative defects) were stimulated by
standard VRT, i.e. the common single-point stimulation paradigm. Just like in standard
VRT, the patient had to respond to the white target stimuli presented at random locations
in areas of residual vision.“ Provided by: not stated. Delivery: training carried out at
home by participants (Table 1). Regimen: extrastriate VRT, 1/2 hour daily for 90 days
Tailoring: Yes. ”The size of the training area varied from patient to patient according to
the size of the visual field defect“.Modification: Yes: ”Every week the patients completed
a self-administered diagnostic test at home and sent their data to the institute for updating
the training region if necessary. Adherence: “Training breaks of longer than 2 weeks led
to exclusion of the patient.”
Group 2: conventional vision restoration therapy (VRT) (n = 10)
Intervention type: restitution.Materials: standard visual restoration therapy - not stated
where this could be accessed/acquired. Procedures: standard vision restoration therapy
consisted of single white target stimuli, presented at random in areas of residual vision.
The participant had to respond to the white target stimuli presented at random locations
in areas of residual vision. Provided by: not stated. Delivery: training carried out at
home by participants (Table 1). Regimen: conventional vision restoration therapy, 1/2
hour daily for 90 days. Tailoring: see above. Modification: see above. Adherence: see
above
Outcomes See Table 4
High-resolution perimetry
Perimetry: common static perimetric diagnosis at own ophthalmologist
Near visual acuity: Radner reading test
NEI-VFQ
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Zahlen-Verbindungs test: speed of connecting numbers in a paper-pencil test
Time points when outcomes were assessed: before and after each cross-over period
Notes 1. “All patients had used VRT for at least 6 months (range from 6-36 months) prior
to study entry and were therefore experienced participants. We were aware that this
might reduce the power of the therapy because of a possible ’ceiling effect’. To eliminate
training bias, no patient carried out VRT during the 6 months preceding the study”. But
this also means that this was potentially a very selective group of patients, i.e. those who
were motivated to continue using VRT after an initial experience. Therefore, it may be
inappropriate to generalise from this study to the general population of patients with
visual function defects. There was no data on the type or length of each participant’s
previous VRT (just the range of 6 to 36 months), and if there were previous changes
in the functions measured in this test. In his previous paper on VRT, (Kasten 2001)
concluded that patients can be split into 3 main types after scanning training: 1) those
whose field increases both during and after training, 2) those whose field increases during
training, but decrease afterwards, and 3) those who show no change at all. If true, this
would impact on the results of this study, as types 1) and 3) do not benefit from further
training
2. Participants did not use their glasses for treatment and measurements. Measurements
included ameasure of near visual acuity; given the age of patients,mostwill be presbyopes,
so will struggle with this task, dependent on age and prescription
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Quote “random assignment”, no further
details given
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind” was in the title, but no fur-
ther information appeared in the paper
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants excluded from analysis and
not included in demographic details. “One
patient used another vision therapy pro-
gram not included in this study. Another
patient was excluded because he discontin-
ued the training formore than 4weeks dur-
ing the trial and a patient showed poor fix-
ation performance (70% rather than the
minimally required 90%).” Some of these
dropouts may have occurred because of an
issue directly associated with the interven-
tion studied
Also, missing data for standard perimetry
measures
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Other bias High risk Researchersmay have had financial interest
in intervention being investigated. Poggel
2004 stated “BA Sabel and E Kasten are in-
ventors. BA Sabel is a consultant and share-
holder of NovaVision Inc, and has equity
in excess of $10,000.”
Kasten 1998
Methods Restitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: not stated
Randomisation sequence: not stated; correspondence with author did not provide any
further detail
Comparisons: visual restitution training (computer-based training) versus placebo (fix-
ation training program)
Allocation concealment: stated “randomly assigned (double-blind)”; no further details
Blinding: “double-blind”
Power calculation: no
Intention-to-treat analysis: no (1 dropout from placebo group)
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 19
Withdrawals: 1 (“one patient from the placebo group failed to meet the requirement to
train for 150 h. This patient dropped out of the study”)
Method of diagnosing VFD: high-resolution perimetry and Tubinger automated
perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: “patients had to have both a visual-field defect and post-chiasmatic
or optic nerve damage as shown by CT, MRI, surgical records or ophthalmoscopic
documentation of optic nerve atrophy”
Exclusion criteria: insufficient fixation ability, neglect, non-optic nerve heteronymous
visual field defect, disorders of the eye, no residual vision, no visual deficit, age > 75
years, age < 18 years, died, lesion age < 12 months, epilepsy or photosensitivity, cognitive
deficits, not willing to participate in trial, no shows after initial screening
Baseline comparison of treatment groups: baseline comparison was presented for
combined groups of 19 post-chiasmatic injury participants and 19 participants with
optic nerve injury (see notes below)
Interventions Group 1: visual restitution therapy (n = 9)
Intervention type: restitution.Materials: computer-based training. Procedures: during
vision restoration therapy, the participant maintained fixation on a central fixation spot,
with their “visual border zone” stimulated by repetitive stationary stimuli of varying
luminance presented in a random location within this border zone. Provided by: not
stated. Delivery: training was carried out on a personal computer placed in a darkened
room at home. (Table 1).Regimen: 1 hour per day, 6 days per week for 6 months (a total
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of 150 hours required). Tailoring: yes “compliance checks and adjustments of training
difficulty level were done monthy”.Modification: yes “we used an individually adapted
training protocol, which was determined by the characteristics of the transition zone”.
Adherence: a total of 150 hours was required (compliance checks done monthly)
Group 2: placebo (fixation training) (n = 10)
Intervention type: placebo.Materials: computer-based training.Procedures: the fixa-
tion training program required “eye movements to stimuli near the foveal region for a
comparable amount of time”. Provided by: not stated.Delivery: training was carried
out on a personal computer placed in a darkened room at home. (Table 1). Regimen:
1 hour per day, 6 days per week for 6 months (a total of 150 hours required).Tailor-
ing: not stated.Modification: not stated. Adherence: a total of 150 hours was required
(compliance checks done monthly)
Outcomes See Table 4
Visual field: high-resolution perimetry
Visual field: Tubinger automated perimetry
Visual acuity: Landolt ring to give minimum angle of resolution
Quality of life questionnaire
Notes 1. Reports of this trial combined data from the trial of 19 post-chiasmatic injury partic-
ipants with data from a trial of 19 participants with optic nerve injury. However, within
the paper it did state “The data reported here are from two independent clinical trials
each with an experimental and a control group. In the first trial, two groups of optic
nerve injury patients ... In the second trial, patients with post chiasmatic injury were
randomly assigned ...”. It is the second trial which is included in this review. However,
baseline characteristics (age, gender, size of visual field deficit) were only available for the
2 trials combined ... i.e. from 38 participants, 19 of whom had optic nerve injuries and
who were not relevant to this trial/review
2. This study included a mixed population of patients and there was no separate data
for stroke. There was an uneven distribution of stroke patients between the groups, with
only 2/9 in Group 1 and 8/10 in Group 2
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Stated that participants were randomly as-
signed (double-blind). No further details
of method of randomisation. Correspon-
dence with the author gave the further de-
tail that while participating in the study
the participants did not know which of the
treatments were expected to produce effects
Blinding (performance bias and detection
bias)
All outcomes
Low risk Stated “(double-blind)”, but no further in-
formation provided in the paper. Corre-
spondence with the author stated that it
was a different person performing the tests
than the person who gave the training
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One patient who failed to meet the re-
quirement to training for a total of 150
hours. This patient dropped out from the
study”. Data for this participant appeared
to be included in baseline data but did not
say if included in final assessment data; the
implication was no. Visual acuity reported
to be performed but no datawere presented
Other bias High risk Researchers may have financial interest
in intervention being investigated. Poggel
2004 stated “BA Sabel and E Kasten are in-
ventors. BA Sabel is a consultant and share-
holder of NovaVision Inc, and has equity
in excess of $10,000”
Kasten 2007
Methods Restitutive intervention versus restitutive intervention
Design: RCT
Stratification: not stated
Randomisation sequence: “Patients were assigned randomly to one of 3 groups”,
method of randomisation not stated. Correspondence with author did not provide any
further detail
Comparisons: “Three experimental groups: Group I: parallel co-stimulation (n = 7);
Group II: moving co-stimulation (n = 7); and Group III: single stimulation (n = 9)”
Allocation concealment: not stated: (“Patients were informed that the effectiveness of
three different programs for visual field training was being studied and that there was no
placebo group”
Blinding: not clear: Correspondence with the author stated that it was a different person
performing the tests than the person who gave the training
Power calculation: no
Intention-to-treat analysis: no (“A total of 5 patients had to be excluded after baseline
examinations for one or more of the following reasons: fixation deficits, noncompliance
to the training procedure, other treatments that may have had influenced their training,
or illness during the trial.”)
Other recruitment details: not stated
Patient and public involvement: no
Participants Total study population: 28 considered; data available for 23
Withdrawals: “A total of 5 patients had to be excluded after baseline examinations for
one or more of the following reasons: fixation deficits, noncompliance to the training
procedure, other treatments that may have had influenced their training, or illness during
the trial.”
Method of diagnosing VFD: high-resolution perimetry and Tubinger automated
perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3
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Inclusion criteria: patients aged 18 to 75 years with a stable homonymous visual field
defect resulting from CNS lesion, of greater than 6 months. Visual fields had to have
matching deficits of both eyes on monocular perimetry plus structural damage of post-
chiasmic visual system as documented by MRI/CT or medical reports
Exclusion criteria: total blindness, central scotomata, lesions of the optic nerve or chi-
asma, insufficient fixation, other visual diseases, visual neglect, motor disturbances, cog-
nitive deficits, psychotic episodes, or epilepsy. Method of diagnosing visual perceptual
problems: “Zahlen-Verbbinbungd test” and “alters-Konzentrationstest”
Baseline comparison of treatment groups: 23 causes of lesions were: 14 with vascular
disease, stroke, cerebral haemorrhage or ischaemia; 8 with trauma; 1 with inflammation
Interventions Group 1: parallel co-stimulation (n = 7)
Intervention type: restitution (2 stimuli presented simultaneously).Materials: training
programs ran on commercially available personal computers. Procedures: “visual field
training was completed at home after initial examinations and instruction sessions were
carried out in our laboratory”. Provided by: not stated. Delivery: “All three training
conditions had the following features in common: While the patient had to watch a
fixation control, a target stimulus (adjustable between about 0.5°and 1.5° diameter, 100
cd/m2) was presented repeatedly in a predetermined intact part of the border region of
the dark screen (adjustable between < 1 cd/m2 up to 50 cd/m2). Upon detection of the
target stimulus, the patient was required to respond as soon as possible by pressing the
spacebar of the computer keyboard. Then the stimulus moved some degrees towards
the blind area. If the patient still perceived the stimulus, this had to be acknowledged
by pressing the spacebar again; the stimulus then moved again some degrees into the
direction of the blind area and so forth. This procedure was repeated until the patient
was unable to see the stimulus in the absolute blind field. At this “blind” position
the stimulus was then presented 10 times. Thereafter, stimulation started at another
predetermined position of the border region (see also “transition zone”, Kasten 1998b)
, and the stepwise stimulation process moving from intact to blind visual field regions
was repeated. Standardized variables throughout training procedures in all patients were
size and luminance of stimuli and background luminance.” (Table 1). Regimen: 30
minutes twice per day for threemonths.Tailoring: yes. “the trained area was individually
adjusted to the patient’s visual field border”. “Other variables were adjusted individually
according to the visual defect - for example, the location of fixation control, the location
to start stimulation, the direction of stimulation, the frequency of fixation controls, and
whether feedback upon responding was accompanied by a tone. Accordingly, training
parameters were adjusted to the individual pattern of residual vision.”
Modification: yes “Each month (if necessary even more often), results stored on the
disc were analyzed, and the training area was readjusted, based on the progress of the
patients”. Adherence: “After each session, data were saved automatically on a disk to
control compliance”
Group 2: moving co-stimulation (n = 7)
Intervention: restitution (2 stimuli presented, with 1 nearer the blind area “running”
continually between intact and lost field). All other intervention details as Group 1
Group 3: single stimulus (n = 9)
Intervention: Restitution (only a single stimulus was presented). All other intervention
details as Group 1
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Outcomes See Table 4
Visual field: high-resolution perimetry (number of hits, learning effects, fixation ability,
false hits)
Visual field: Tubinger automated perimetry at 30 and 90 degrees (no of hits, fixation
ability)
Eye movements: “Chronos Vision Eye Tracker”
Visual acuity
Subjective visual ability questionnaire
Attention: “Zahlen-Verbindungs Test” of visuo-spatial attention
“Alters-Konzentrationstest” attention test for older people
“testbatterie zur Aufmerksamkeitspruefung” ability to improve attention
Notes 1. This study included a mixed population of patients and there was no separate data
for stroke
2. Visual acuity at 40 cm was measured without glasses.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Quote “participants were randomly as-
signed to one of three experimental
groups”, no further informationonmethod
given. Correspondence with the author
gave the further detail that participating the
patients did not know which of the treat-
ments were expected to produce effects
Blinding (performance bias and detection
bias)
All outcomes
Low risk Correspondencewith the author stated that
it was a different person performing the
tests than the person who gave the training
Incomplete outcome data (attrition bias)
All outcomes
High risk “A total of 5 patients had to be excluded
after baseline examinations for one or more
of the following reasons: fixation deficits,
non-compliance to the training procedure,
other treatments that may influence train-
ing, illness during the trial”. No data were
provided for these participants
Other bias High risk Researchers may have had financial in-
terests in intervention being investigated.
Poggel 2004 stated “ BA Sabel andEKasten
are inventors. BA Sabel is a consultant and
shareholder of NovaVision Inc, and has eq-
uity in excess of $10,000”
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Methods Compensative intervention versus compensative intervention
Design: parallel-group RCT
Stratification: “To achieve a nearly balanced number of patients with quadrantanopia
in each group, the assignment of quadrantanopic patients between treatment groups was
alternated, resulting in 3 patients in the AVT group and 4 patients in the VST group”
Randomisation sequence: random number algorithm
Comparisons: 2 groups, audiovisual stimulation training (AVT) versus visual stimula-
tion training (VST)
Allocation concealment: not stated
Blinding: no detail provided about blinding of patients, caregivers or assessors
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 20 with unilateral lesions of the occipital lobe confirmed by
MRI. Not all participants had VFD as a result of stroke. 18/20 stroke; 1/20 tumour and
1/20 TBI
Withdrawals: none
Method of diagnosing VFD:Goldmann perimeter examination. Visual field assessment
was done using the kinetic method with suprathreshold checks. Measured before and
after training. “Pre-post comparisons of visual field defects were classified as stable in all
patients”
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: “left- or right-sided visual field deficits primarily caused by stroke”
(as confirmed by MRI). Normal bilateral hearing measured by audiometry with no
asymmetry between ears, normal or corrected binocular visual acuity
Exclusion criteria: visual neglect or signs of aphasia (“Patients were initially tested with
3 different neglect tests (line bisection, Mesulam test, draw a clock face test) and the
token test”)
Baseline comparison of treatment groups: “Both groups were comparable with regard
to demographic and clinical variables before treatment”
Interventions Group 1: audiovisual exploration training (AVT) (n = 10)
Intervention type: compensation. Materials: red light-emitting diodes (LEDs), piezo-
electric loudspeakers, white-noise generator, laptop computer using a custom-made soft-
ware for this purpose.Where can materials be accessed? not stated.Procedures: “train-
ing sessions were conducted in a dimly illuminated room. The patients sat in chairs
60 cm in front of the apparatus, with their eyes adjusted to the center of the appara-
tus. Stimuli to the blind visual field and intact visual field were presented in random
sequence. Patients were instructed to detect the presence of visual targets by pressing a
response button as fast as possible. To prevent patients from reacting to false positives,
20% catch trials with solely acoustic stimulation were implemented in each training
session. Whenever patients responded to a catch trial, a computer-generated ’nickering’
of a horse sounded. Patients were explicitly instructed to execute eye movements with
their head held straight forward. Training was carried out under binocular conditions”.
Provided by: not stated.Delivery: face-to-face, individual, location inpatient (Table 1).
Regimen: 20 therapy sessions (each session lasting 30 minutes) over 3 weeks. Tailoring:
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yes. Based on type of VFD (“For patients with homonymous hemianopia, 70% of all
stimuli were presented in the blind visual field. For patients with quadrantanopia, 70%
of the stimuli were presented in the 2 upper or 2 lower rows of the affected side”).Mod-
ification: yes, “whenever a patient complained of tiredness, the training was interrupted
for 1 minute”. Adherence: not stated
Group 2: visual exploration training (VET) (n = 10)
Intervention type: compensation.Materials: as described for AVT.Where can materi-
als be accessed? not stated. Procedures: “settings of stimuli presentation were identical
as for the AVT, with the exception that the sound was turned off during all training
sessions and catch trials were not needed”. Provided by: not stated. Delivery: face-to-
face, individual, location inpatient (Table 1). Regimen: 20 therapy sessions (each session
lasting 30 minutes) over 3 weeks. Tailoring: yes. Based on type of VFD (“For patients
with homonymous hemianopia, 70% of all stimuli were presented in the blind visual
field. For patients with quadrantanopia, 70% of the stimuli were presented in the 2
upper or 2 lower rows of the affected side”). Modification: yes, “whenever a patient
complained of tiredness, the training was interrupted for 1 minute”. Adherence: not
stated
Outcomes See Table 4
Visual field: Perimetry - Goldmann kinetic and suprathreshold
Visual exploration test
Reading test
Search task
Evaluation of ADL
Electro-oculography
Time points when outcomes were assessed: before and after treatment
Definitions relevant to outcomes: “Changes in visual fields defects were established by
comparing the pretraining visual field with the post-training visual field. Changes were
classified as better, stable, or worse. Better or worse were defined by differences of more
than 5° horizontally or vertically”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Random number algorithm used to assign
participants. However, it was also stated
that “To achieve a nearly balanced num-
ber of patients with quadrantanopia in each
group, the assignment of quadrantanopic
patients between treatment groups was al-
ternated, resulting in 3 patients in the AVT
group and 4 patients in the VT group”.
This suggests that allocation was not con-
cealed for these participants
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information was given on blinding of
participants, or outcome assessors. It is un-
likely that personnel could be blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of any dropouts
Other bias Low risk No other concerns noted
Modden 2012
Methods Restitutive intervention versus compensative intervention
Design: prospective randomised controlled, single-blind, single-center treatment study
Stratification: no
Randomisation sequence: ”Patients were randomly assigned to receive either CT, RT,
or OT. Randomization by throwing dice and allocation took place before starting with
the initial assessment of neuropsychological tests“
Comparisons: compensatory therapy (CT) versus restorative computerised training
(RT) versus standard occupational therapy (OT)
Allocation concealment: no
Blinding: no (”All patients were recruited and assigned to treatment groups by a neu-
ropsychologist. The same neuropsychologist also tested the patients before (time point
T1) and after (time point T2) the treatment and was not blinded to the type of training.
The training itself was performed by a psychological assistant or by the occupational
therapists not involved in the study, and they provided the test results at T1 and T2.“
Power calculation: yes
Intention-to-treat analysis: no dropouts
Patient and public involvement: not stated
Participants Total study population: 45 patients randomised
Withdrawals: 0
Method of diagnosing VFD: ”a perimetry test from the Test Battery of Attentional
Performance, the latter having a sensitivity and specificity for visual field defects similar
to the Goldmann perimetry.“
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous hemianopia with a posterior cerebral artery stroke
Exclusion criteria: visual neglect, eye-movement disorders, neuropsychological disor-
ders like aphasia, dysexecutive syndromes, memory deficits, or higher order motor im-
pairments like apraxia
Baseline comparison of treatment groups: ”At baseline, the 3 groups did not differ in
demographic and neuropsychological measures“
Interventions Group 1: restitution therapy (RT) (n = 15)
Intervention: RT - computer-based stimulation of visual field
Intervention type: restitutive. Materials: computer-based restitution therapy: ”A ther-
apy-integrated perimeter program (provided by Teltra company)“. Procedures: ”A ther-
apy-integrated perimeter program (provided by Teltra company) created the exact mea-
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surement of the individual visual field border. Using that measurement, a series of colored
targets appeared on a blue screen anywhere at 1 of 10 positions on the border line. A
randomly presented first fixation target (a rotating arrow) announced the second stimu-
lus target in the hemianopic border zone (basic principle of covert attention shift). The
patients were instructed to respond (by pressing a key) to each stimulus target (colored
and flickering frames, beams, and spots) as soon it was perceived. The program contained
no adaptive difficulty levels. Eye movements were not allowed, and this was controlled
by the assistant“. Provided by: ”The training itself was performed by a psychological
assistant or by the occupational therapists not involved in the study“. Delivery: face-
to-face, individual, location rehabilitation centre: ”The participants in both PC-based
therapy groups were seated 60 cm away from the screen (19-inch monitor) and had to
perform the tasks binocularly. As during testing, the head was fixed by a chin rest, the
sessions were always controlled by the assistant to make sure that the instructions were
followed.“ (Table 1). Regimen: 30 minutes/day for 15 sessions. Tailoring: no: ”The
program contained no adaptive difficulty levels.“Modification: no. Adherence: stated
”no-one dropped out because of problems with compliance“
Group 2: compensatory therapy (CT) (n = 15)
Intervention: CT - computer-based stimulation of visual field
Intervention type: compensatory. Materials: computer-based: ”The ’Exploration’ task
(from RehaCom, provided by HASOMED GmbH, Magdeburg, Germany)“. Proce-
dures: ”The “Exploration” task . . . . . . . . . . . was adapted individually according to the
side of the hemianopia. On a dark background, different bright stimuli arranged in rows
and columns were presented. A ring (diameter of 2 cm) moved line by line (interlaced)
on a matrix unit over the field. The participant was instructed to follow the ring (start-
ing point to an outmost fixation in the blind side) by eye movements and to identify a
critical targeted icon. The targets were not always distributed homogeneously but were
clustered in the blind side. Thus, the exploration in the hemianopic field was further
promoted. The patients had to respond (by pressing a key) when the targeted icon was
perceived in the circle. Provided by: “The training itself was performed by a psychologi-
cal assistant or by the occupational therapists not involved in the study”.Delivery: face-
to-face, individual, location rehabilitation centre: “The participants in both PC-based
therapy groups were seated 60 cm away from the screen (19-inch monitor) and had to
perform the tasks binocularly. As during testing, the head was fixed by a chin rest. The
sessions were always controlled by the assistant to make sure that the instructions were
followed.” (Table 1). Regimen: 30 minutes/day for 15 sessions. Tailoring: yes: “The
program contained several difficulty levels. In levels 1 to 20, all lines were completely
filled with symbols, whereas there were omissions in the rows of symbols in levels 21
to 30 to increase the difficulty.” Modification: not clear. Adherence: stated “no-one
dropped out because of problems with compliance”
Group 3. occupation therapy (OT) (n = 15)
Intervention: OT - standard occupational therapy
Intervention type: compensatory. Procedures: “After a standardized assessment of daily
living activities, the therapy consisted of individually adapted stimulation of daily activity
tasks to compensate via eye-, head-, and bodymovements. These compensation strategies
included aspects of spatial and body perception, searching or arranging objects, pen and
paper searching task, readingmaps or newspapers, and self-care activities. The participant
was instructed to perform systematic eye movements toward the lost visual field. The
interventions were carried out in the treatment rooms, on the wards, in a kitchen or a
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bathroom, outside in the park, or in a supermarket.”Provided by:occupational therapist.
Delivery: face-to-face, individual, location rehabilitation centre: (Table 1). Regimen:
30 minutes/day for 15 sessions. Tailoring: yes: “After a standardized assessment of daily
living activities, the therapy consisted of individually adapted stimulation of daily activity
tasks”. Modification: not clear. Adherence: stated “no-one dropped out because of
problems with compliance”
Note: “Patients receiving RT and CT did not receive OT in the context of their standard
rehabilitation treatment.”
Outcomes See Table 4
Visual field expansion - test battery of attentional performance visual field assessment
Visual search performance - cancellation
Reading performance - Weschler memory tests
ADL - Extended Barthel Index
Time points when outcomes were assessed: after completion of training
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Randomisation was by throwing a dice: no
allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding: “All patients were recruited
and assigned to treatment groups by a neu-
ropsychologist. The same neuropsycholo-
gist also tested the patients before (time
point t1) and after (time point t2) the treat-
ment and was not blinded to the type of
training. The training itself was performed
by a psychological assistant or by the oc-
cupational therapists not involved in the
study, and they provided the test results at
t1 and t2.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Other bias Low risk No other concerns noted
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Methods Restitutive intervention versus restitutive intervention
Design: “Randomised controlled, double-blind pilot trial”
Stratification: no
Randomisation sequence: “Participants were randomly assigned using a predetermined
enrollment sequence to 1 of 2 arms”. Method of randomisation not stated. Correspon-
dence with the author provided the information that “as subjects were admitted, they
were randomly assigned to one of two groups based on an a priori generated random-
ization strategy.”
Comparisons: 2 groups: vision restoration therapy with active transcranial direct current
stimulation (VRT + tDCS) and vision restoration therapy with sham transcranial direct
current stimulation (VRT + sham)
Allocation concealment: yes: “Participants and investigators analyzing visual field out-
comes were blinded to the tDCS mode (active versus sham).”
Blinding: yes: “Participants and investigators analyzing visual field outcomes were
blinded to the tDCS mode (active versus sham).”
Power calculation: not stated
Intention-to-treat analysis: no
Other recruitment details: “A total of 150 potential participants were screened. Fol-
lowing comprehensive neurological and ophthalmological screening, 12 patients ... were
enrolled”
Patient and public involvement: not stated
Participants Total study population: 12
Withdrawals: 4
Method of diagnosing VFD: high-resolution perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: “Patientswith unilateral postchiasmal visual field loss following stroke
or brain damage, who were in the chronic phase of recovery (> 3 months post-lesion)
”. Participants were “aged over 18, with deep hemianopic field loss as defined and con-
firmed by monocular perimetry along with established structural damage of the post-
charismatic visual system as documented by standard neuroimaging techniques (CT or
MRI), medical reports, or a combination of these. Participants also had cognitive, lan-
guage and motor function sufficient to understand the experiments and follow instruc-
tions, had given informed written consent to participate in the study and hadmotivation
to participate in the VRT program.”
Exclusion criteria: “Any ocular visual pathology or contraindication to noninvasive
brain stimulation and tDCS. Specific criteria drawn from safety guidelines pertaining to
the use of noninvasive cortical stimulation include 1) the presence of any metallic, me-
chanical, or magnetic implant in the head or implantable device (e.g. cardiac pacemaker)
; 2) prior history of seizure or familial history of seizure disorder in a first degree relative,
and 3) chronic use of neuroactive medication (e.g. neurostimulants, anticonvulsants, or
antidepressants).”
Baseline comparison of treatment groups: not stated. Baseline data were provided, but
no statistical comparison. Time since stroke did not appear to be comparable, with the
VRT + tDCS group mean, 20.8 months (SD 26.6, range 3 to 72 months), and VRT +
sham group mean, 58.7 months (SD 72.9, range 10 to 192 months)
This study appeared to include participants with visual field defects only (no visual
neglect), although the method of ensuring no visual neglect was unclear
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Method of diagnosing visual field defect: “monocular perimetry”, no further details
of method
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: visual restoration therapy + transcranial Direct Current Stimulation (VRT +
tDCS) (n = 6; data available for n = 4)
Intervention: computer-based stimulation of the visual field with active transcranial di-
rect current stimulation, 30-minute sessions twice per day, 3 times per week for 3months
of vision restoration therapy and concurrent transcranial direct current stimulation of 2
mA/minute
Intervention type: restorative. Materials: computer-based restitution therapy: “Vision
Restoration Therapy (VRT; Novavision Inc, Boca Raton, Florida)”, transcranial Direct
Current Stimulation: “tDCS was applied using two 5 × 7 cm2 saline-soaked sponge
electrodes connected to a 9-V battery-driven stimulator (IOMED Inc. Salt Lake City,
Utah)”.Procedures: vision restoration therapy: “Briefly, participants were seated in front
of a computer screen at a constant viewing distance and instructed to detect (signaled
by a key press) the presence of a flashed light stimulus while maintaining fixation on a
central target. Built-in fixation monitoring required patients to respond to a color change
of the central fixation target occurring at random intervals. Target stimuli were presented
primarily in the region of the transition zone (identified by a prior visual field test; see
details on high-resolution perimetry), and the spatial parameters of customized therapy
were determined based on weekly progress and results of monthly tests.” Transcranial
direct current stimulation: “tDCS was applied using two 5 × 7 cm2 saline-soaked sponge
electrodes connected to a 9-V battery-driven stimulator delivering a constant current of 2
mA for the entire duration of the training procedure. Following the 10-20 International
EEG co-ordinate system, the anode was placed at the occipital pole and the cathode
(reference) was positioned at the vertex. Electrodes were then secured using nonlatex
rubber straps, and an identical montage was worn by all patients throughout training.”
Provided by:University eye clinic.Delivery: face-to-face, individual, locationUniversity
eye clinic (Table 1). Regimen: “We used a contracted VRT regimen lasting 3 months (2
half-hour sessions, separated by a 30-minute rest interval, for 3 d/wk).” Tailoring: not
stated. Modification: not stated. Adherence: not stated
Group 2: visual restoration therapy + sham transcranial Direct Current Stimulation
(VRT + sham) (n = 6; data available for n = 4)
Intervention: computer-based stimulation of the visual field with sham transcranial
direct current stimulation, 30-minute sessions twice per day, 3 times per week for 3
months of vision restoration therapy, transcranial direct current stimulation turned on
for 30 seconds then ramped down to zero and turned off. Intervention type: restorative.
Materials: see above. “Experimental blinding with respect to active or sham transcranial
direct current stimulation was implemented according to standard protocol guidelines
described previously”. Procedures: see above. Provided by: see above. Delivery: see
above (Table 1). Regimen: see above. Tailoring: not stated. Modification: not stated.
Adherence: not stated
Outcomes See Table 4
Visual field - high-resolution perimetry: position of visual field border and stimulus
detection accuracy
Visual field - subjective topograhic measure of perceived visual field deficit
Extended ADL - Veterans Affairs Low Vision-Visual Functional Questionnaire (LV-
VFQ)
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QoL - Vision Impairment (IVI) profile
Other - independent measure of fixation performance during training and HRP testing
Time points when outcomes were assessed: baseline and at completion of training (3
months)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Participants were randomly assigned us-
ing a predetermined enrollment sequence
to 1 of 2 arms”. Method of randomisation
not stated. Correspondence with the au-
thor provided the information that “as sub-
jects were admitted, they were randomly
assigned to one of two groups based on an
a priori generated randomization strategy.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Correspondence with the author stated
“the investigators assessing the visual
field results (primary outcome) were also
blinded to patient group assignment. Once
visual field assessment was complete, they
were provided with an encrypted copy of
the data without any identifying informa-
tion”
Correspondence with the author stated
“Blinding to stimulation (i.e. sham) was
maintained by exploiting the inherent
properties of tDCS. All patients wore the
electrode montage regardless of the group
they were relegated to. When the tDCS
unit is turned on, current is slowly ramped
up until the target current level is reached.
During this time, patients will typically re-
port a tingling or itching sensation beneath
the surface of the anode electrode (over-
lying the occipital cortex). This sensation
subsides shortly after a couple of minutes
of habituation. Thus, in the experimental
group, the current remains on but in the
sham control group, the current is turned
off. In either case, the patient is not aware
of this happening. This fact is exploited for
the purposes of experimental blinding since
patients in the VRT + tDCS group can not
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perceive sensation of stimulation and nei-
ther can those patients who are in the VRT
+ sham tDCS group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 4 dropouts who were not in-
cluded in data analysis. Reasons for drop-
outs were provided, and were even between
the groups. The author supplied the fol-
lowing information: “Out of 12 patients
who were enrolled into the study, 4 (i.e. 2
from each group), were excluded or could
not complete the study. Here are the rea-
sons: VRT + tDCS group: Patient 1 - ex-
cluded soon after randomization as she had
an unrelated adverse event that excluded
her from participation; Patient 2 - excluded
from analysis due to technical issues that
could not allow us to ascertain whether
sufficient tDCS current was being deliv-
ered throughout the training period. VRT
+ sham tDCS group: Patient 1: did not re-
ceive allocated intervention due to onset
of medication use that was contraindicated
with tDCS; Patient 2 - discontinued due to
onset of amedical condition that precluded
her from further participation.”
Other bias Low risk No other concerns noted
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Methods Restitutive intervention versus restitutive intervention
Design: prospective RCT
Stratification: no
Randomisation sequence: stated participants were “assigned randomly” but no details
given. Correspondence with author did provide any further detail
Comparisons: 2 groups - visual restoration therapy (VRT) with attentional cueing, VRT
without attentional cueing
Allocation concealment: no - “Patients were not told which type of training they re-
ceived; a double-blind control was not possible owing to staff limitations.”
Blinding: no
Power calculation: no
Intention-to-treat analysis: no. 1 dropout, for whom no data was presented. Stated:
“Patient 5 did not participate in the training procedure owing to time constraints and is
not listed here.”
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 20 recruited (data available for 19)
Withdrawals: 1 (“Patient 5 did not participate in the training procedure owing to time
constraints and is not listed here.”)
Method of diagnosing VFD: high-resolution perimetry and standard Tu bingen Au-
tomated Perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous visual field defects after postgenicular lesions, age 18
to 75 years. Visual field size, assessed by high-resolution campimetry, had to be stable;
that is, patients were included only if visual field size increased or decreased by < 2%
over at least 4 weeks before the study started“
Exclusion criteria: optic nerve, retinal or other ophthalmic disorders; mental deficits;
impaired attention and neglect; psychiatric disorders; epilepsy and diseases with obvious
visual or cognitive effect
Baseline comparison of treatment groups: not stated
This study included patients with visual field defects only (no visual neglect)
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: visual restitution therapy (VRT) with attentional cueing (n = 10)
Intervention: computer-based stimulation of visual field, with cueing
Intervention type: restitution
Materials: computer-based vision restoration therapy (Nova Vision, Magdeburg, Ger-
many).Procedures: a high-resolution computer-based campimetric test (high-resolution
perimetry [HRP]; Nova Vision, Magdeburg, Germany) was used to assess visual field
size and to determine ARVs.Training stimuli appeared on a dark computer screen, each
target increasing in brightness in four steps from dark gray (30 cd/m2) to bright white
(96 cd/m2) over 2000 milliseconds. Stimulus size, fixation control, mode of response,
and viewing distance were identical to those used for HRP. For vision restoration therapy
with attentional cueing, the training stimulus was preceded by a large (12° x 12° visual
angle) dim gray cue frame enclosing a predetermined segment in the upper visual field
that included parts of the intact and blind fields as well as ARVs. The frame appeared
for 200 milliseconds and was followed at a randomised interval (mean stimulus onset
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asynchrony: 1000 milliseconds, range 750 to 1250 milliseconds) by a training stimulus
presented in the area that had been stimulated by the cue frame (the attention field). In
each training session, patients received 500 training stimuli. In the experimental group,
approximately one-third of the trials, that is, those where the target was to be presented
in the attention field, were preceded by a cue. Targets were presented at random locations
within the upper and the lower visual fields. Depending on the percentage of stimuli
detected, the duration of each training session was approximately 30 to 35 minutes.”
Provided by: not stated.Delivery: training completed at home using computer (Table
1). Regimen: “Patients performed the training in six training units, each lasting approx-
imately 1 month. A unit consisted of 56 sessions, with two sessions per day.” Tailoring:
yes: “Each patient’s ARV was determined based on five HRP tests. The training area was
then adjusted to the visual field border of that individual.” Modification: not stated.
Adherence: not stated (“Data from each session were saved on a disk”)
Group 2: visual restitution therapy (VRT) with no attentional cueing (n = 9)
Intervention: computer-based stimulation of visual field
Intervention type: restitution
Materials: see above.Procedures: see above.Provided by: see above.Delivery: see above.
(Table 1). Regimen: see above. Tailoring: see above. Modification: see above. Adher-
ence: see above
Outcomes See Table 4
Change in size of visual field:
Tubinger automated perimetry (TAP)
High resolution perimetry (HRP)
Time points when outcomes were assessed: at the end of each training unit (HRP),
and after the 6th training unit (HRP and TAP)
Notes Training and measurement were essentially the same thing.
Authors referred to Kasten 2001 as proof that control was not needed. They did not
address his conclusions on effects of training when recruiting from an already trained
group - see Jobke 2009 above.
Outcome data was largely presented for all patients combined (control and experimental
groups combined)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk “Patients were not told which type of train-
ing they received; a double-blind control
was not possible owing to staff limitations”
- the paper did not state what methods (if
any) were used to conceal the allocation
from those enrolling and assigning partici-
pants and correspondence with the author
did not provide any further information
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Blinding (performance bias and detection
bias)
All outcomes
High risk “Patients were not told which type of train-
ing they received; a double-blind control
was not possible owing to staff limitations”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 participant did not participate, none of
his data were included in final analysis. The
co-author was not totally clear on the rea-
son for non-participation, but believed it
to be another stroke
Other bias High risk Researchers had financial interest in inter-
vention being investigated: “BA Sabel and
E Kasten are inventors. BA Sabel is a con-
sultant and shareholder of NovaVision Inc,
and has equity in excess of USD 10,000”
Rossi 1990
Methods Substitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: no
Randomisation sequence: “randomly assigned”. Method of randomisation not stated
Comparisons: 2 groups; 15 diopter Fresnel prisms and control (no prisms)
Allocation concealment: no
Blinding: no, as the prism group wore their prisms during testing
Power calculation: no
Intention-to-treat analysis: not stated (not clear if any dropouts)
Other recruitment details: “39 patients with either homonymous heminaopia or uni-
lateral visual neglect were recruited from an inpatient stroke rehabilitation unit”
Patient and public involvement: not stated
Participants Total study population: 39
Withdrawals: none
Method of diagnosing VFD: tangent screen (inability to reliably detect a 1 cm red target
on tangent screen examination in a homonymous field pattern) and Harrington Flocks
visual field screener
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous hemianopia or unilateral visual neglect and a diagnosis
of stroke based on clinical history, neurological exam and neuroimaging
Exclusion criteria: visual acuity worse than 20/200, unable to comprehend and co-
operate with visual field assessment, disabling cardiac, pulmonary or rheumatologic
problems
Baseline comparison of treatment groups: yes
The study included only stroke patients.
This study included patients with visual field defects and/or visual neglect
Method of diagnosing visual perceptual problems: neglect was confirmed by inability
to reliably detect bilateral tachistoscopically presented targets using theHarringtonFlocks
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Visual Screener
Interventions Group 1: 15 diopter Fresnel prisms (n = 18)
Intervention: prisms
Intervention type: substitution
Materials: plastic, press-on Fresnel prisms (stated these are “commercially available”).
Procedures: “Plastic press-on Fresnel prisms were trimmed to fit on the inside of the
patients’s spectacle lenses. Each prism was cut to the shape of a half circle overlaying
only the affected hemifield, with the base of the prims toward the affected field”. Pro-
vided by: not stated (university neurology department),Delivery: face-to-face, individ-
ual, location inpatient (Table 1). Regimen: “Patients wore the prisms for all daytime
activities. Prism position and cleanliness were checked daily by study personnel. Patients
were restricted to ambulation ’with assessance only’ for at least 1 day after the fitty of the
prisms”. Also “participated in a routine stroke rehabilitation program including physi-
cal, occupational, and speech therapy ... ADL training and table-top visual perception
retraining tasks”. Tailoring: no. Modification: no. Adherence: not stated (stated “In
practice, most patients tolerated the Fresnel prisms well after a day or two”)
Group 2: control (n = 21)
Intervention: no prisms
Intervention type: control
Materials: NA. Procedures: NA.Provided by: NA.Delivery: NA. Regimen: “partici-
pated in a routine stroke rehabilitation program including physical, occupational, and
speech therapy ... ADL training and table-top visual perception retraining tasks”. Tai-
loring: NA.Modification: NA. Adherence: NA
Outcomes See Table 4
Modified Mini Mental Status Examination
Motor free visual perception test
Line bisection task
Line cancellation task
Harrington Flocks Visual Screener
Tangent Screen Examination
Barthel ADL score
Frequency of falls
Time points when outcomes were assessed: baseline, 2 weeks and 4 weeks
Notes 1. The length of time that the prisms were worn may vary considerably for different
patients, as this was for “all day time activities”
2. States that diagnosis of homonymous hemianopia precludes diagnosis of neglect - this
is not current thinking so must question diagnostic criteria especially with respect to
neglect
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Patients were “randomly assigned” but
methodology not stated
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Blinding (performance bias and detection
bias)
All outcomes
High risk “the study was not performed in a blinded
fashion”, however for Tangent Screen Ex-
amination “results were plotted onto tem-
plates and judged by observer unaware of
the patient’s group assignment ...”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete data mentioned
Other bias Low risk No other sources of bias noted
Roth 2009
Methods Compensative intervention versus restitutive intervention
Design: RCT
Stratification: no
Randomisation sequence: paper stated “an equal number of patients assigned randomly
to either the EST or the FT group”; and correspondence with the author stated that “the
patients were randomized according to a pre-existing list”
Comparisons: 2 groups; compensatory “exploratory saccadic training (EST)” and con-
trol (“flicker-stimulation training (FT), which is unlikely to affect visual-search be-
haviour”)
Allocation concealment: no
Blinding: not stated
Power calculation: no
Intention-to-treat analysis: no
Other recruitment details: participants, aged 18 to 80 years, with post-chiasmatic le-
sions of greater than 6 months duration and visual field defects that are isolated homony-
mous hemianopias or quadrantanopias. The study included a mixed population (mainly
stroke)
Patient and public involvement: not stated
Participants Total study population: 30 participants recruited (data analysed for 28)
Withdrawals: “Two FT patients droppped out because of illness and insufficient com-
pliance”
Method of diagnosing VFD: not stated.
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: visual field defects must not cross the vertical midline, but reach
within 5 degrees of it and there must be no other visual field defects, or visual acuity
deficit
Exclusion criteria: other visual field defects, visual acuity less than 0.6 (20/33), other
diseases of eye or brain, motor impairments hampering computer use, other neurologic
impairments (particularly epilepsy or hemineglect)
Baseline comparison of treatment groups: “The groups did not differ regarding age,
diagnoses or duration of disease”
This study included a mixed population (mainly stroke). Group 1: 15 participants (12
stroke or haemorrhage, 3 other), Group 2: 15 participants (14 stroke or haemorrhage, 1
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other)
This study included patients with visual field defects only (no visual neglect)
Method of diagnosing visual perceptual problems: clock drawing and line bisection
test
Interventions Group 1: explorative scanning training (n = 15)
Intervention: computer-based scanning training
Intervention type: compensation
Materials: laptop.Where canmaterials be accessed? “A custom software program (Bor-
land Delphi 7.0) was used to generate a random array of digits....”. Procedures: random
digits were presented with equal distribution in blind and seeing fields: patients had to
find these digits with positive feedback provided for a correctly found number. Provided
by: not stated. Delivery: face-to-face, individual, location home-based training (Table
1). Regimen: training was performed for 30 minutes, twice per day, 5 days per week for
6 weeks at home, on a laptop set at 30 cm.Tailoring: no.Modification: no. Adherence:
protocols were used to attempt to ensure standardisation and patients were instructed
to avoid head movements. However, it is not know whether this standardisation and in-
structions were adhered to. There may, therefore, be some inconsistencies in the delivery
of the intervention. Errors in aspects such as laptop position, etc. could impact on the
position of the stimuli viewed and subsequently the explorative eye movements
Group 2: flicker-stimulation training (n = 15)
Intervention: computer-based training, “designed to stimulate the blind hemifield”
Intervention type: restitution (note - author stated this is ’potential’ restitution training)
Materials: laptop.Where can materials be accessed? “Borland Delphi 7.0 was used to
generate the flicker stimulus”. Procedures: letters flickering at 10 Hz were presented at
21.8 degrees eccentricity, with proportion 3:1 blind:seeing field. Participant to maintain
central fixation but identify peripheral letter: positive feedback given of correctly iden-
tified letter. Provided by: not stated. Delivery: “The patients trained at home, using
our laboratory’s laptops to ensure standard training conditions (screens, fixed viewing
distance, and visual-field area trained)” (Table 1). Regimen: training was performed for
30 minutes, twice per day, 5 days per week for 6 weeks at home, on a laptop set at 30 cm.
Tailoring: no. Modification: no. Adherence: patients were instructed to fixate. There
appears to have been no attempt to control or measure fixation
Outcomes See Table 4
Digit search task (response time)
Natural search task (response time)
Natural scene exploration and fixation stability (video eye tracker)
Perimetry (Tubinger automated perimeter)
Reading speed
QoL - World Health Organisation questionnaire WHOQOL-BREF
Time points when outcomes were assessed: baseline, post-treatment, follow-up
Notes Inclusion criteria stated visual field defect with “duration exceeding 6months”. However,
1 patient in group 2 was reported to have a 4-month-old homonymous hemianopia.
Possibility of spontaneous recovery. Furthermore, this discrepancy casts doubt on the
application of the selection criteria
Risk of bias
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Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Correspondencewith the author stated that
“the patients were informed that probably
each method could be effective, one by eye
movement training (EST), the other by vi-
sual field stimulation (FT). FT was sup-
posed to be a potential restitution training.
Therefore, the patients of both groups per-
formed a potentially effective training - but
with quite different approaches”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details in the paper or by contacting
the author of whether or how assessor was
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Stated “twoFT (Group2) patients dropped
out because of illness and insufficient com-
pliance. Finally data from 15 EST and
13 FT patients were included”. Data from
these participants were included in base-
line characteristics, but not included in fi-
nal analyses
Other bias Low risk No other cause of bias noted
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Methods Substitutive intervention versus compensative intervention versus control, placebo
or no intervention
Design: “Randomized controlled, multicentre pilot trial”
Stratification: “Randomization lists were generated using block randomization stratified
by centre and degree of hemianopia (partial or complete) with treatment allocation ratio
of 1:1:1.”
Randomisation sequence: “Participants were individually randomized to one of three
treatment groups using a secure (24-hour) web-based randomization programme.”
Comparisons: 3 groups: Group 1 - Fresnel prisms; Group 2 - visual search training;
Group 3 - control (standard care/information only)
Allocation concealment: treatment allocationwas disclosed to the patient by the treating
clinician: “The local PI (orthoptist) obtained the treatment allocation and subsequently
assigned the participant to the treatment arm.”
Blinding: outcome assessors for visual field assessment and reading speed were blind to
treatment allocation. “due to the nature of the intervention, it is not possible to blind
other study personnel or the participant.”
Power calculation: no - pilot trial; designed to enable sample size calculation for future
trials
Intention-to-treat analysis: “Outcome data were analysed according to the intention-
to-treat principle.”
Other recruitment details: “Participants were recruited from stroke units based in
15 United Kingdom (UK) National Health Service (NHS) trusts. Potentially eligible
participants were identified by stroke research nurses, and screened for inclusion by a
local principal investigator (a qualified orthoptist registered with the Health and Care
Professions Council, UK). Participants eligible for inclusion, and providing consent,
attended for a baseline assessment, which included assessment and documentation of
patient demographics, visual signs and symptoms, visual acuity measures, any additional
ocular problems, comorbidity, severity of stroke and level of disability”
Patient and public involvement: protocol stated: “This trial has involved a stroke
survivor directly in the development of this protocol (JR) and will liase closely with her
for advice and direction throughout the conduct of the trial and in the dissemination
process. Involvement of stroke survivors in oversight committees is also planned for this
trial”
Participants Total study population: 87 participants randomised. 71 participants at 26-week follow-
up
Withdrawals: 2 “complete withdrawal” (“patients withdrawn from all data analysis and
follow-up”). 9 “partial withdrawal” (“patients withdrawn from follow-up”). 5 loss to
follow-up
Method of diagnosing VFD: “Stable homonymous hemianopia (partial or complete)
induced by recent stroke, defined following WHO guidelines”. “The visual field assess-
ment will be conducted by a qualified Orthoptist at baseline and at the 6-week, 12-
week and 26-week follow-up visits. An Esterman strategy is to be used for quantitative
visual field assessment. This can be performed using either: The Esterman programme
on Humphrey or Octopus perimetry; The III4e target on Goldmann with additional
checks of static points in the central visual field.”
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: “a. 18 years of age or older; b. best corrected visual acuity of 0.5 or
better in each eye at distance; c. stable homonymous hemianopia (partial or complete)
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induced by recent stroke, defined following WHO guidelines, present over 2 weeks (to
exclude rapid recovery cases) but less than 26 weeks prior to randomization; d. refractive
error within ± 5 dioptres; e. willing and able to give consent for the study; f. prior to
stroke able to read and understand English.”
Exclusion criteria: “a. unable to consent due to severe cognitive impairment; b. assessed
to have ocular motility impairment and/or visual inattention in addition to the visual
field impairment; or c. had pre-existent visual field impairment due to previous stroke.”
Baseline comparison of treatment groups: “There were no notable differences at base-
line between three arms.”
This study included patients with visual field defects only (no visual neglect)
Method of diagnosing visual perceptual problems: “as assessed by the orthoptist”
Interventions Group 1: prisms (n = 27)
Intervention: Fresnel prisms (40 prism dioptre strength)
Intervention type: substitution
Materials: “Participants were assessed and given sector Fresnel prisms of 40 prismdioptre
strength on their glasses (or plain glasses if not already worn). Separate prism segments
were used as a mechanical displacement to expand the upper and lower quadrants.
” Where can materials be accessed? In the UK: NHS supplies for Fresnel prisms.
Procedures: “The participant will be instructed to maintain central fixation through
their glasses. They will then be instructed to use head movements to explore their field
to the affected side when they become aware of an object of interest through the prism.
The first prism will be placed at the participant’s first visit; if possible the second prism
will also be fitted at this time. However, if the participant is not comfortable with both
prisms being fitted at once, the second prism can be placed at a second visit (2 weeks
later, ± 1 week) if no adaptation difficulties to the first prism have occurred. If adaption
difficulties have occurred the patient can continue with only the first prism and this will
be captured on the case report forms.” Provided by: orthoptist. Delivery: face-to-face,
clinic location (patients could be in or outpatients). (Table 1) Regimen: “The prisms
should be worn for a minimum of 2 h daily from prism affixation until 6-week follow-
up visit as a minimum, after this the patient can elect to continue treatment if they wish.
” Tailoring: no. Modification: no. Adherence: “There were 73 protocol deviations in
58 patients (68.2% overall: 77% in the Fresnel prisms arm, 93% in the visual search
arm and 34.5% in the standard care arm). The majority of deviations (n = 41, 56.2%)
related to lack of compliance in the intervention arms (e.g. prism not worn a minimum
of 2 hours daily for 6 weeks or visual exercises not carried out for 30 minutes daily for 6
weeks). Compliance level was similar across the intervention arms. Patients in the Fresnel
prisms arm wore the prisms during 27 days on average.”
Group 2. scanning training (n = 30)
Intervention: “visual search training”
Intervention type: compensatory (scanning) training
Materials: “Comprised an A4 landscape card with horizontal and diagonal numbered
circles radiating out from a central fixation target.” Where can materials be accessed?
From author. Procedures: “The participant will be instructed to hold this at a distance
of 8 inches from their eyes (to ensure a wide field of vision is utilised), glasses can be
worn as required. Participants will be asked to transfer gaze quickly between printed
targets on the A4 card. The targets are printed off centre to the right and left sides
along the horizontal as well as oblique planes to ensure stimulation of a wide area in
the blind and seeing parts of the visual field.” Provided by: instructions provided by
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orthoptist. Training carried out at home by patients. “Participants will be instructed
on the scanning exercises following randomisation to ensure their understanding of the
procedure of doing this training. In addition, printed instructions will be provided with
the visual training target card”. Delivery: home (self-adminstered) (Table 1). Regimen:
“Participants will be instructed to continually scan between the various targets for 30min
daily from baseline until their 6-week follow-up, after which they can elect to continue
treatment if they wish.” Tailoring: no. Modification: no. Adherence: “There were 73
protocol deviations in 58 patients (68.2% overall: 77% in the Fresnel prisms arm, 93%
in the visual search arm and 34.5% in the standard care arm). The majority of deviations
(n = 41, 56.2%) related to lack of compliance in the intervention arms (e.g. prism not
worn a minimum of 2 hours daily for 6 weeks or visual exercises not carried out for 30
minutes daily for 6 weeks). Compliance level was similar across the intervention arms .
.. patients in the visual search training arm followed the visual search exercises 28 days
on average.”
Group 3: standard care (n = 30)
Intervention: advice only (“all three arms will receive the same information leaflets”)
Intervention type: control
Materials: “Participants were given information leaflets from the UK Stroke Association
and the UK Royal National Institute for the Blind about visual impairment following
stroke.” Where can materials be accessed? UK Stroke Association and the UK Royal
National Institute for the Blind. Procedures: standard care.Provided by:NA.Delivery:
NA (Table 1). Regimen: NA. Tailoring: NA.Modification: NA. Adherence: NA
Outcomes See Table 4
Visual field assessment
Reading ability (Radner reading test)
Visual function questionnaire (VFQ 25-10)
Rivermead mobility index
Nottingham extended activities of daily living assessment
ED-5Q (a standardised instrument for measuring health outcome)
Short Form-12 (SF-12)
Adverse events
Time points when outcomes were assessed: baseline, 6-week, 12-week, and 26-week
follow-up
Notes Review authors Fiona Rowe and Alex Pollock were involved in this study
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Participants were individually random-
ized to one of three treatment groups using
a secure (24-hour) web-based randomiza-
tion programme. Randomization lists were
generated using block randomization strat-
ified by centre and degree of hemianopia
(partial or complete) with treatment alloca-
tion ratio of 1:1:1. The local PI (orthoptist)
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obtained the treatment allocation and sub-
sequently assigned the participant to the
treatment arm.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and clinical personnel unable
to be blinded due to the nature of the in-
tervention. Blinded outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data all accounted for. Inten-
tion-to-treat analysis (where possible)
Other bias Low risk No other cause of bias noted
Schuett 2012
Methods Compensative intervention versus compensative intervention
Design: randomised cross-over trial
Stratification: no
Randomisation sequence: ”randomly allocated“
Comparisons: 2 groups, Group A (VET followed by RT) and Group B (RT followed
by VET)
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 36: Group A: 17/18 stroke and Group B: 17/18 stroke. The
study included a mixed population
Withdrawals: none
Method of diagnosing VFD: not stated
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated (although the authors reported that ”none of the patients
had visual neglect as assessed by tests in accordance with the Behavioural Inattention
Test (line bisection, letter and star cancellation, figure and shape copying, drawing from
memory; Halligan 1991).“ and ”All patients were native German speakers and had at
least 5 years of education. All patients complained of moderate to severe difficulties in
reading and visual exploration and showed impaired performance in both domains“
Exclusion criteria: cerebral visual disorders, including reduced visual acuity (< 0.90
for near and far binocular vision), impaired spatial contrast sensitivity (Vistech contrast
sensitivity test, 1988), visual adaptation, disturbances of the anterior visual pathways or
of the oculomotor system, macular disease (according to ophthalmologic examination),
aphasia, premorbid reading disorders, pure alexia (vertical word reading test; Zihl 1995;
Zihl 2011), impairments of visual-lexical numerical processing (horizontal and vertical
number reading; Zihl 1995; Zihl 2011), or verbal memory deficits
Baseline comparison of treatment groups: none (”before treatment, there were no
differences between groups either for demographic and clinical variables or for reading
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and visual exploration performance“.) However, more participants with hemianopia in
Group A compared with Group B (Table 3)
This study included patients with diagnoses other than stroke
This study included patients with visual field defects only (i.e no neglect)
Method of diagnosing visual perceptual problems: ”Behavioural InattentionTest (line
bisection, letter and star cancellation, figure and shape copying, drawing from memory;
Halligan 1991).“
Interventions Group 1: visual exploration training (VET) (n = 18)
Intervention type: compensation
Intervention: ”Visual exploration training: for improving visual exploration, we used
standardized versions of the visual search paradigm (parallel and serial search mode).“
Materials: software-based reading and visual exploration training programmes (devel-
oped by Zihl 2011); training material was presented using a LCD monitor with a stim-
ulus display
Where can materials be accessed? not stated (but references provided). Procedures:
”Patients were systematically trained to use larger saccadic eye movements to gain a
quick complete visual overview as well as to develop and use a more efficient oculomotor
visual exploration or scanning strategy that can be flexibly adapted to the visual-spatial
structure of the respective scene or environment. Training material consisted of visual
search displays extending 50° horizontally and 42° vertically. We used different target
and distractor letters of varying similarity as stimuli. Stimulus size was 2.5°, and we used
the same colours for the training material and the monitor background as in the reading
training. Each training trial was composed of the presentation of a visual search display.
Patients were instructed to fixate on a cross in the centre of the monitor and to search,
after its offset, for a single target letter (e.g. ‘T’) among distractor letters (e.g. ‘O’s) as
accurately and quickly as possible. In target-present trials, the patient was asked to press
the left mouse button, in target-absent trials, the right mouse button. Presentation and,
thus, visual search timewas unlimited (exhaustive visual search).“Provided by: treatment
was administered and supervised by the experimenter. No details about the training or
experience of the experimenter.Delivery: not clear (Table 1). Regimen: ”An individual
training session lasted ~45 min consisting of 10-15 practice units (20 trials each) and
short or, if required, longer breaks between units. Training was completed when patients
reached a defined criterion (at least 90% correct responses) for any level of difficulty
used. Patients required on average 12 training sessions, which were carried out within 2-
3 weeks for each patient. . . .Visual exploration training: Group A: 12.3 sessions (SD 3.4)
.“ Tailoring: ”In addition to varying letter similarity during the course of training, visual
search difficulty was also systematically increased by increasing the visual display size, i.e.
the number of stimuli, not the display area (15-20-item displays). This training protocol
was adjusted to individual reading performance and training progress. Modification:
(see tailoring). Adherence: “Training was completed when patients reached a defined
criterion (at least 90% correct responses) for any level of difficulty used”
Group 2: reading training (RT) (n = 18)
Intervention type: compensation
Intervention: reading training
Materials: “The treatment was performed using the software-based reading and visual
exploration training programmes as developed by Zihl 2011; training protocol and
procedure were similar to our previous studies (Schuett 2008; Zihl 1995; Zihl 2011).
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Training material was presented using a LCDmonitor with a stimulus display extending
50! horizontally and 42! vertically at a viewing distance of 115 cm.”Where canmaterials
be accessed? not stated. Procedures: “single words of different lengths, ranging from
3 to 12 letters, were used as training material. Letter and digit size was 2.5, and width
subtended 1° ; spacing between letters (text material) was 0.4°. We used yellow for the
training material and a dark blue for the background. These size and colour specifications
have been shown to allow for comfortable reading and oculomotor training (Schuett
2008; Zihl 1995; Zihl 2011). Each training trial was composed of the time-limited
presentation of one single word in the centre of the screen. Patients were instructed to
perceive each word as a whole before reading it aloud by intentionally shifting their gaze,
as quickly as possible, from the screen’s centre to the beginning (in cases with left-sided
visual field loss) or to the end (in cases with right-sided visual field loss) of each word.
This paradigm allows reading-related eye movements to be trained and reinforced by the
patient’s normal internal visual feedback and feedback given by the experimenter. During
the course of training, the length of the presented words was systematically increased
from 3- to 13-letter words. When a patient was able to read at least 90% of the words
of a given length correctly, presentation time was reduced from 1000 ms to 300-400
ms. The final training stage involved the randomized presentation of words of different
lengths. By adopting this procedure, patients were forced to make quicker and more
efficient saccades in order to perceive and read the whole word before its disappearance.
In addition, patients learned to flexibly adjust the size of saccades according to word
length”. Provided by: treatment was administered and supervised by the experimenter.
Nodetails about the training or experience of the experimenter.Delivery:not clear (Table
1). Regimen: “an individual training session lasted ~45 min; it consisted of 10 practice
units (30 trials each) and short or, if required, longer breaks between units. Training was
completed when patients reached a defined criterion (at least 90% correct responses)
for any level of difficulty used. Patients required on average 12 training sessions, which
were carried out within 2-3 weeks for each patient ... Group B (12.6 sessions, SD 2.
4).” Tailoring: “training protocol was adjusted to individual reading performance and
training progress”.Modification: not stated.Adherence: “Training was completed when
patients reached a defined criterion (at least 90% correct responses) for any level of
difficulty used”
Outcomes See Table 4
Reading test (reading time and errors)
Visual exploration (cancellation task - time and errors)
Visual field assessment (Kinetic perimetry using a standard Tubingen perimeter)
Time points when outcomes were assessed: this was a cross-over trial. Time points
before the cross-over were: T1, initial assessment; T2, before treatment; T3, after the
first training component. (Additional time points - after the cross-over were: T4, after
the second training component; T5, after a follow-up interval). “Visual field assessment
was carried out before and after treatment (T2 and T4).”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Allocation concealment (selection bias) Unclear risk Stated “randomly allocated”. No further
details onmethodof randomisationor con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk It was unclear whether there was partic-
ipant and/or outcome assessor blinding.
However the “experimenter” delivered the
intervention, and may therefore have taken
the outcome measures
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No flow diagram, and no details of recruit-
ment or retention
Other bias Low risk No other issues noted
Spitzyna 2007
Methods Compensative intervention versus control, placebo or no intervention
Design: randomised cross-over trial.
Stratification: “Because of the small number of patients entering the study, we wished to
ensure that the two treatment groups did not become unbalanced on a few key variables
so patients were allocated using a modified minimization technique where cumulative
measures of two factors (text reading speed (≤ 90 or >90 wpm) and degrees of sparing
of right foveal/parafoveal (0 or 2 degrees) vision) were used to minimize the difference
between the two groups.”
Randomisation sequence: modified minimisation technique: “The weighting used for
allocation to the group with the lowest total was one. We describe the minimisation
as modified because the first subject was not allocated randomly to either group, but
deterministically placed in Group 1.”
Comparisons: “Two-armed study with two therapy blocks in each arm: one group
practiced reading moving text (MT) that scrolled from right-to-left, daily for two four
week blocks (group 1), while the other had sham therapy (spot-the-difference) for the
first block and then crossed over to MT for the second.”
Allocation concealment: personal communication with authors: “The allocation was
concealed from the persons recruiting into the study but not from the tester. The recruiter
(s) did not know that the first subject would be placed in group 1 but the tester did”
Blinding: personal communication with authors: “The tester was the first author (a
psychologist). She was not blind to the therapy. It was not possible to blind her to this
as it was a behavioural therapy and she was ’dispensing’ this at each time point.”
Power calculation: no
Intention-to-treat analysis: no
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 22 participants recruited, data for 18
Withdrawals: “three dropped out before completing therapy”.
Method of diagnosing VFD: “Perimetry was performed twice, before and after comple-
tion of the therapy blocks (B and T4). Static fields were measured using the automated
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Humphrey field analyser II (Carl Zeiss Group, California, USA) analysis of the central
10 degrees of vision (central 10-2 threshold test). Dynamic fields were also measured
using a Goldmann perimeter (Haag Streit, Köniz, Switzerland) when there were con-
cerns over subject’s performance with the automated procedure (a false positive or false
negative response rate greater than 15%). The procedures for determining the amount
of field sparing were as reported previously. In the event of a discrepancy between the
static and dynamic fields or pre- and post-therapy changes, the opinion of the orthoptist
who performed the tests (Ms Bronia Unwin) was sought. The precision of the static
perimerty is two degrees and all the patients fell into one of two groups, either 0 or 2
degrees spared to the right of fixation.”
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated, but described as “participants with fixed homonymous
right-sided visual field defect that interfered with reading (hemianopic alexia).” “All the
patients had a fixed homonymous defect that had been present for at least 3 months”
Exclusion criteria: not stated
Baseline comparison of treatment groups: some discrepancies between baseline char-
acteristics of groups. Length of time since symptom onset - all participants in Group
1 were over 1 year since onset of symptoms; 4 participants in Group 2 were less than
1 year since onset (3 are 6 months or less). Average age at time of symptom onset was
43 years for group 1 (range 5 to 67 years) and 63 years for group 2 (range 39 to 78
years). “There were no differences between the groups on all of the variables” for general
neuropsychological assessments
The study included a mixed population.
This study included patients with visual field defect only (no visual neglect)
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: optokinetic nystagmus inducing reading therapy (n = 11)
Intervention type: compensation
Intervention: horizontal scrolling text from right to left to “induce small-field optoki-
netic nystagmus”
Materials: “The tapes were made by animating freely available text from a variety of
SherlockHolmes stories (www.citsoft.com/holmes3.html) across a computer screen from
right-to-left (i.e. horizontal motion was from the patients’ blind field into their seeing
field), so-called Times Square presentation. After some minor preparations, such as
deleting hyphens and adding a few spaces after each sentence, custom-written software
was used to animate the text across the screen at a variable rate. The output from the
graphics card was connected to the video-input on a VHS video recorder to produce
the tapes. Tape speeds of: 85, 105, 143, 173, 205, 240, and 275 wpm were made with
the text presented in Times New Roman font, 24-point, black on white, scrolling across
the middle of the screen.” Where can materials be accessed? not stated. Procedures:
participants were instructed to read and try to follow a line of text scrolling horizontally
from right to left in the middle of a computer screen at speeds of 85 to 275 words per
minute. “Patients were instructed to read the story on the tapes and try to follow it,
although no tests of comprehension were made to check this.” Provided by: not stated.
Delivery: not clear. Patient-led therapy. (Table 1). Regimen: “treatment blocks lasted
for 4 weeks each” and participants were asked to record how long they spent on the
tasks each day. “The aim was to achieve a minimum of 400 minutes of rehabilitation
(20 sessions x 20 minutes) over approximately 4 weeks”. Tailoring: “patients contacted
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one of us (G.A.S.) when they required a new (usually faster) tape.” Modification: no.
Adherence: “There were no differences between the two groups in total time spent on
rehabilitation tasks across both treatment blocks in minutes (range), 914 (865-955); 901
(840-1000), t-test, t (10) 0.50, P = 0.628”
Group 2: control (n = 11)
Intervention type: control
Intervention: sham training; “spot the difference”
Materials: “’Spot-the-difference’ tests were taken from a children’s puzzle booklet; the
original cartoons were altered to remove text. The number of differences on each page
varied between eight and 12.”
Where can materials be accessed? not stated. Procedures: “Patients were instructed
to look for as many differences as possible between the two pictures, but were not told
how many to expect, completing at least two cartoons over 20 min. Between 40 to 60
examples were selected randomly for each patient (out of a total of the 70 prepared tests)
, depending on their speed.” Provided by: not stated. Delivery: not clear. Patient-led
therapy. (Table 1). Regimen: “treatment blocks lasted for 4 weeks each” and participants
were asked to record how long they spent on the tasks each day. “The aim was to
achieve a minimum of 400 minutes of rehabilitation (20 sessions x 20 minutes) over
approximately 4 weeks”. Tailoring: not stated. Modification: no. Adherence: “There
were no differences between the two groups in total time spent on rehabilitation tasks
across both treatment blocks in minutes (range), 914 (865-955); 901 (840-1000), t-test,
t (10) 0.50, P = 0.628”
Outcomes See Table 4
Text reading speeds (passages from Neale analysis of reading)
Single word reading speeds (words taken from MRC psycholinguistic battery)
Eye movement characteristics - spatial characteristics of saccadic amplitude, incoming
saccade amplitude and landing position
- temporal characteristics
Perimetry - Humphrey field analyser
- Goldmann perimetry
Time points when outcomes were assessed: T1, initial assessment; T2, before treat-
ment; T3, after the first training component. (Additional time points - after the cross-
over were: T4, after the second training component; T5, after a follow-up interval)
Notes Did not state whether visual correction using glasses was used during training or testing
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Modified minimisation technique of se-
quence generation. Personal communica-
tion with authors: “The allocation was con-
cealed from the persons recruiting into the
study but not from the tester. The recruiter
(s) did not know that the first subject would
be placed in group 1 but the tester did”
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Blinding (performance bias and detection
bias)
All outcomes
High risk Personal communication with authors:
“The tester was the first author (a psychol-
ogist). She was not blind to the therapy. It
was not possible to blind her to this as it
was a behavioural therapy and she was ’dis-
pensing’ this at each time point.”
Incomplete outcome data (attrition bias)
All outcomes
High risk “Three patients dropped out before com-
pleting therapy” (all from group 2) and
“data from these subjects were excluded
from analyses”
Other bias Low risk No other potential bias noted
Szlyk 2005
Methods Substitutive intervention versus substitutive intervention
Design: randomised cross-over design
Stratification: not stated
Randomisation sequence: “randomly assigned” but method not given
Comparisons: participants in Group 1 received Gottlieb prism during the first 3-month
phase of the study, and participants in Group 2 received Fresnel prisms during the first
3-month phase of the study. Participants then crossed over to receive the other treatment
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 10 participants.
Withdrawals: no information (7 participants provided follow-up data at 2 years - 3
could not be contacted)
Method of diagnosing VFD: not stated.
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: stated “The patients were screened to include patients with only
occipital lobe strokes”. Participants described as having “Hemianopsia because of cere-
bral vascular accidents”. All included participants were male, but unclear if this was an
inclusion criterion
Exclusion criteria: not stated.
Baseline comparison of treatment groups: yes
The study included a mixed population.
It was assumed that participants did not have neglect (as this is unlikely in occipital
lesions)
Method of diagnosing visual perceptual problems: not stated - it was not stated
whether the patients may have had visual neglect (although neglect is unlikely in occipital
lesions)
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Interventions Group 1: Gottlieb Visual Field Awareness System (VFAS) (n = 5)
Intervention type: substitution
Intervention: Gottlieb VFAS prism
Materials: 18.5 dioptre Gottlieb VFAS prism
Where can materials be accessed? “Rekindle(R), Stone Mountain, GA, USA”. Proce-
dures: 18.5 dioptre Gottlieb VFAS prism drilled into one lens. Positioned just off pupil
centre - generally on the same eye as side of field loss, on same side as field loss, base
out. Provided by: low-vision specialist for laboratory and outdoor training, kinesiother-
apist for on-road training. Delivery: laboratory and out-door training within university
grounds, and on-road (driving) training on a road course within a medical centre (Table
1). Regimen: training of 4 x 2 to 3-hour sessions indoors with low vision specialist and
8 x 2-hour outdoor sessions behind the wheel. The lenses were then worn for 3 months.
Tailoring: not stated. Modification: not stated. Adherence: no information (whether
prism was still worn at time of follow-up was recorded as never/occasionally/frequently)
Group 2: Fresnel prisms (n = 5)
Intervention type: substitution
Intervention: Press-OnTM Fresnel 20 Diopter Prisms
Materials: Press-OnTM Fresnel 20 Diopter Prisms.Where can materials be accessed?
“3M Health Care, St. Paul, MN, USA”. Procedures: 20 dioptre press-on Fresnel prisms
attached to posterior surface of 1 spectacle lens. Positioned just off pupil centre - generally
on the same eye as side of field loss, on same side as field loss, base out. Provided by:
low-vision specialist for laboratory and outdoor training, kinesiotherapist for on-road
training.Delivery: laboratory and out-door training within university grounds, and on-
road (driving) training on a road course within a medical centre (Table 1). Regimen:
training of 4 x 2 to 3 hour sessions indoors with low-vision specialist and 8 x 2-hour
outdoor sessions behind the wheel. The lenses were then worn for 3 months. Tailoring:
not stated. Modification: not stated. Adherence: no information (whether prism was
still worn at time of follow-up was recorded as never/occasionally/frequently)
Outcomes See Table 4
Goldmann visual field
Visual acuity
Contrast sensitivity
Lab assessment - indoor functional assessment
Outdoor function assessment
Driving skills assessment - indoor and on-road
Pyschophysical assessment
- attentional visual acuity
- attentional motion sensitivity
Self-report (satisfaction)
Time points when outcomes were assessed: before and after each cross-over. Continued
use of devices assessed at 2-year follow-up
Notes 1. Data were presented after the cross-over, for both groups combined - no first phase
data were available
2. Stated: “For each assessment task for each individual in the test-retest period, we
computed the change in score from the initial baseline testing to the repeat baseline
testing. We then averaged these change scores across subjects for each task”. For each task
If the change from baseline to training exceeded the test-retest change it was scored as
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’improved’, if it was less than or equal it was scored as ’no change’. The sum of improved
tasks across the test battery was then computed
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Stated “randomly assigned into one of two
experimental groups” but no details of
method provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details of blinding included
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete data issues apparent, how-
ever, scores have been combined so it is dif-
ficult to tell if there are any missing out-
comes
Other bias Low risk No other cause of bias noted
AB/BA:ref erstoorderof interventionswithincross−overtrial,whereAandBdenotediff erentinterventionsandABorBAtheorderofdelivery
ACS: alternating current stimulation
ADL: activities of daily living
ARV: area of residual vision
AVT: audiovisual exploration training
cd/m2: candela per square meter (standard unit of luminance)
CNS: central nervous system
CT: computerised tomography
CVA: cerbrovascular accident
EEG: electroencephalogram
EQ-5D:standardised EuroQol health-related quality of life instrument
FIM: Functional Independence Measure
FT: flicker stimulation training
HRP: high resolution perimetry
HVFD: homonymous visual field defect
IH-CST: InSight Hemianopia - Compensatory Scanning Training
IVI: impact of visual impairment
LCD: liquid crystal display (high definition monitor)
LEDs: light emitting diodes
LV-VFQ: Low Vision - Visual Function Questionnaire
MMSE: Mini Mental State Examination
MRC: Medical Research Council
MRI: magnetic resonance imaging
MT: moving text
n: number
NA: not applicable
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NEI-VFQ: National Eye Institute Visual Function Questionnaire
OT: occupational therapy
PI: principal investigator
QoL: quality of life
RCT: randomised controlled trial
RT: restitution therapy
SD: standard deviation
SF-12: Short-Form Health Survey
T1/T2/T3/T4/T5: outcome asssessment timepoint 1, 2, 3, 4 or 5
TAP: Tubinger automated perimetry
TBI: traumatic brain injury
tDCS: transcranial direct current stimulation
TL: tube luminescent
VET: visual exploration training
VFAS: visual field awareness system
VFD: visual field defect
VFQ-25: visual functioning questionnaire
VIS: Visual In Stroke (study name)
VRT: vision restoration therapy
VST: visual stimulation training
WHOQOL-BREF:
wpm: words per minute
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akinwuntan 2005 The protocol for this review was to include “any intervention that is specifically targeted at improving
the visual field defect, or improving the ability of the participant to cope with the visual field loss”.
Although this randomised controlled intervention study did measure visual, neurophysical and driving
outcomes, the intervention targeted a person’s decreased ability to drive, not specifically due to their
visual field defect, but by all the “motor, visual, cognitive, and perceptual deficits ... experienced after
stroke”, and thus was ineligible
Akinwuntan 2010 Not VFD
Akinwuntan 2012 Not VFD
Alber 2015 Not RCT
Balconi 2013 Not VFD
Beasley 2013 Not VFD
Bowers 2012 Not RCT
Braga 2018 Not RCT
Brandt 2009 Not RCT
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Brigui 2014 Not RCT
Cameirao 2012 Not vision
Carter 1983 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field defects:
this study included 33 participants, all of whom had a diagnosis of stroke. The 2011 version stated:
“this study did not diagnose visual field defects but instead relied on clinical identification of a ’visual
scanning problem’. Visual scanning problems are likely to be due to visual neglect as well as visual field
defects, thus we have to assume that the participants in this study had a combination of problems.
However, it could be possible that the participants had visual neglect problems but not visual field
defects, and vice versa.”
Carter 1988 The protocol for this review was to include “any intervention that is specifically targeted at improving
the visual field defect, or improving the ability of the participant to cope with the visual field loss”.
The intervention in this study was cognitive skills retraining and ADL retraining; it included visual
scanning training within a large battery of training activities, but this was not specifically targeted at
visual field loss
Chen 2013 Not stroke
ChiCTR-OON-15006688 Not RCT
Cho 2015 Not VFD
Courtney-Harris 2015 Aim of study was validation of a vision screening tool; and outcomes were focussed on level of agreement
between tests
Crotty 2009 Not VFD
Cutfield 2011 Not RCT
Dai 2014 Not RCT
Dargie 2012 Not RCT
Davis 2009 Not vision
Fedorov 2010 Not VFD
Ginsberg 2013 Not VFD
Gordon 1985 The method of sequence generation was described as “patients ... were assigned to either experimental
or control condition, depending on the rehabilitation service to which the patient was assigned for
treatment. All patients were accessed from two comparable inpatient services; experimental and control
conditions were alternated every six months between the two services during the time which all patients
on a given service were assigned to the same treatment condition”. Although this was described as
“quasi-random” it did not meet the level of randomisation of sequence generation that was needed for
inclusion
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Hamel 2012 Not RCT
Hazelton 2013 Not RCT
Hollands 2013 Not VFD
Jo 2012 Visual neglect, not VFD
Kang 2009 Not VFD
Kerkhoff 2013 Visual neglect, not VFD
Kerry 2017 Focussed on central alexia (“an acquired reading disorder co-occuring with a generalised language deficit
(aphasia)”)
Ko 2011 Not RCT
Lane 2010 The method of sequence generation in this study of compensation interventions was stated as “ the
first 23 were assigned to Group A, and the last 23 to Group B” and thus was non-random
Lee 2013a Visual neglect, not VFD
Lee 2013b Not RCT
Loverro 1988 The method of sequence generation in this study of bed orientation was stated as “assigned to rehabil-
itation hospital beds based on bed availability” and thus was non-random
Machner 2012 Visual neglect, not VFD
Mancuso 2012 Visual neglect, not VFD
Markowitz 2010 This was a comment on a study: Bergsma DP and Van der Wildt G. British Journal of Ophthalmology
2010; 94:88-96, which was not a randomised controlled trial
NTR5637 Not RCT
Olma 2013 Not RCT
Opolka 2013 Visual neglect, not VFD
Padula 2009 Not RCT
Park 2013 Not VFD
Rosenberg 2011 Not VFD
Sabel 2009 This study looked at visual restitution in optic nerve disorder. The consensus of the Advisory Group
for this review was that the review should be limited to post-chiasmal visual field loss only, so this study
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was not included
Saposnik 2013 Not VFD
Scholomov 2010 Not RCT
Taylor 2011 Not RCT
Teasell 2011 Visual neglect, not VFD
Thurtell 2010 Not VFD
Van Wyk 2011 Not VFD
Van Wyk 2016 Not VFD (eye movement disorders)
Weinberg 1977 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field defects.
Weinberg 1977 and Weinberg 1979 both included participants with the same inclusion criteria. The
2009 version stated: “These studies included only people with right-sided cerebrovascular accident.
However, from the limited information available in the published papers, it does appear that the
diagnosis of visual field defect (or visual neglect) was not an inclusion criterion for entry to these studies.
The authors appear to assume that this patient group will have visual neglect as they have right-sided
brain damage. It is worth noting that in these two studies the participants were divided into subgroups
of ’mild’ and ’severe’ based on ”presence of visual field defect on confrontation and performance on
visual cancellation“, and that we can therefore be confident that the ’severe’ subgroup contained people
with visual field defects, while it is not confirmed whether all the ’mild’ subgroup had a visual field
defect. Arguably, therefore, the ’severe’ subgroups are more relevant to our review question than the
’mild’ subgroups. There was substantial heterogeneity when we included the ’mild’ subgroups in the
analyses. Exploring this heterogeneity using subgroup analyses found that the ’severe’ subgroup had
a greater response to the intervention than the ’mild’ subgroup, for all outcomes ... Arguably it was
inappropriate to have included the ’mild’ subgroups within any of the analyses, as it is possible that
participants in this group did not have a visual field defect. However, due to the uncertainty we felt it
was appropriate to include the ’mild’ subgroup but to further explore the effect of removing them from
the analyses.”
Weinberg 1979 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field defects.
Weinberg 1977 and Weinberg 1979 both included participants with the same inclusion criteria. The
2009 version stated: “These studies included only people with right-sided cerebrovascular accident.
However, from the limited information available in the published papers, it does appear that the
diagnosis of visual field defect (or visual neglect) was not an inclusion criterion for entry to these studies.
The authors appear to assume that this patient group will have visual neglect as they have right-sided
brain damage. It is worth noting that in these two studies the participants were divided into subgroups
of ’mild’ and ’severe’ based on ”presence of visual field defect on confrontation and performance on
visual cancellation“, and that we can therefore be confident that the ’severe’ subgroup contained people
with visual field defects, while it is not confirmed whether all the ’mild’ subgroup had a visual field
defect. Arguably, therefore, the ’severe’ subgroups are more relevant to our review question than the
’mild’ subgroups. There was substantial heterogeneity when we included the ’mild’ subgroups in the
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analyses. Exploring this heterogeneity using subgroup analyses found that the ’severe’ subgroup had
a greater response to the intervention than the ’mild’ subgroup, for all outcomes ... Arguably it was
inappropriate to have included the ’mild’ subgroups within any of the analyses, as it is possible that
participants in this group did not have a visual field defect. However, due to the uncertainty we felt it
was appropriate to include the ’mild’ subgroup but to further explore the effect of removing them from
the analyses.”
While we were confident that the ’severe’ subgroup from this study contained some participants with
visual field defects, this was not the focus of this trial, which was focused on participants with right
brain damage only. Further, we cannot be certain that all participants in this group had visual field
defects (there is a chance that some had severe visual neglect but no visual field defect)
White 2010 Not VFD
ADL:activitiesof dailyliving
RCT: randomised controlled trial
VFD: visual field defect
Characteristics of studies awaiting assessment [ordered by study ID]
Ghandehari 2011
Methods Methods described this as a “prospective, observational study”
Results described as a “randomised controlled trial”, and included a study flowchart
No details of randomisation were provided.
Participants 40 participants: “stroke patients with posterior cerebral artery territory infarction” with “pure homonymous hemi-
anopia without neglect”
Interventions Group 1: Neuroaid (MLC601)
Group 2: Piracetam
Outcomes Visual field (standard perimetry)
Notes Study carried out in Iran during 2009-2010
Authors emailed in 2015, but no reply
Sand 2017
Methods Conference abstract: “Patients were randomised ...”
ClinicalTrials.gov: “observational” study
Participants Stroke patients - not clear if VFD was an inclusion criteria
Interventions Experimental: “training with vision teacher with individually adapted training program”
Control: no training
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Outcomes Visual field defect
Visual function
Quality of life
National Institute of Health Stroke Scale (NIHSS)
Notes ClinicalTrials.gov Identifier: NCT02307981
Unclear if this was an RCT or not
NIHSS:NationalInstituteof HealthStrokeScale
RCT: randomised controlled trial
VFD: visual field defect
Characteristics of ongoing studies [ordered by study ID]
Feldon 2017
Trial name or title Visual restoration for hemianopia
Methods RCT
Participants Adults (21 to 75 years); lesion in the occipital lobe of the brain (18 to 90 days previously); stable homonymous
hemianopia
Interventions Experimental: training in the blind field: A computer software and chin-rest necessary to perform visual
training will be loaned to each participant to use at home. They will perform 1 to 2 daily training sessions
in their home, consisting of 200 to 300 trials each. The visual task performed repetitively will involve
discriminating the direction of motion of a small cloud of dots located at a predetermined location in the
blind field. The computer program will automatically create a record of participant performance during each
home training session. They will train daily (about 40 to 60 minutes total), 5 to 7 days per week, for at least
24 weeks
Control: training in the intact field (as above)
Outcomes Primary outcome measure: 24-2 Humphrey PMD - Change in the perimetric mean deviation (PMD) from
24-2 Humphrey perimetry between baseline and post-training
Starting date March 2018
(Estimated completion: May 2019)
Contact information lisa blanchard@urmc.rochester.edu
Notes ClinicalTrials.gov Identifier: NCT03350919
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Gall 2015
Trial name or title Restoration of vision after stroke (REVIS)
Methods “Randomised”
Participants Adults aged 18 to 75 years; > 6 months post stroke; hemianopia or quadrantopia confirmed by standard
automated perimetry
Interventions Experimental: active tDCS (transcranial direct current stimulation)
Control: sham stimulation
Outcomes Primary outcome: improved detection in the visual field, measured using high resolution perimetry
Secondary outcome: change in extent of visual fields using standard automated perimetry
Starting date April 2015
(study completion: April 2017)
Contact information turgut.tatlisumak@hus.fi
Notes ClinicalTrials.gov Identifier: NCT02405143
Hayes 2010
Trial name or title Retraining following hemianopia in acquired brain injury following stroke
Methods Comparison of 2 intensities of scanning training
Participants 20 participants
Interventions Visual scanning training using a light panel
Outcomes Includes quality of life measures and functional vision skills
Starting date
Contact information ahayes@nvtsystems.com.au
Notes Unpublished. Recruitment has ended. ACTRN12610000494033
ISRCTN16023965
Trial name or title Home-training for hemianopia (partial blindness)
Methods RCT (3 groups)
Participants Adults (aged at least 18) suffering with a nonprogressive visual field defect for at least 3 months caused by a
brain injury
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ISRCTN16023965 (Continued)
Interventions Group 1 (intervention group 1): use the DREX program on a touchscreen tablet
Group 2 (intervention group 2): use the DREX program on a computer
Group 3 (control group): given their usual care and any treatments given by their doctors or therapists
Outcomes “Reading and visual search abilities and also their quality of life”
Starting date June 2015
(study completion: December 2017)
Contact information azuwan.musa@durham.ac.uk
Notes ISRCTN16023965
Komm 2009
Trial name or title Rehabilitation outcome in chronic neglect patients with associated visual field loss: results of a blinded
randomized cross-over study
Methods Masked randomised cross-over study
Participants Stroke patients with persistent neglect and visual field loss 6 months post-onset
Interventions Computer-aided visual restitution training versus compensatory eye movement training
Outcomes Visual field and neglect measures
Starting date
Contact information bernhard.sabel@med.ovgu.de
Notes Currently in press. Results not available for this review
NCT02737930
Trial name or title Fluoxetine for visual recovery after ischemic stroke (FLUORESCE)
Methods RCT
Participants MRI-confirmed acute ischaemic stroke resulting in an isolated homonymous visual field loss
Estimated enrolment: 40 participants
Interventions Experimental: fluoxetine - 20 mg fluoxetine capsule by mouth once daily for 90 days
Placebo comparator: placebo
Outcomes Primary outcome measure: improvement in size of visual field deficit (degrees)
Secondary outcome measures:
Improvement in size of visual field deficit (square degrees)
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NCT02737930 (Continued)
Improvement in parametric mean deviation
Functional field score
Visual Function Questionnaire-25 score
Patient Health Questionnaire-9 score
Modified Rankin Scale score
Post-stroke changes in cortical visual representation as measured by functional magnetic resonance imaging
Post-stroke changes in retinal nerve fibre layer thickness
Starting date May 2016
(Estimated study completion: June 2020)
Contact information bogachan sahin@urmc.rochester.edu
Notes ClinicalTrials.gov identifier: NCT02737930
NCT02886663
Trial name or title Visual field restoration in patients with post-stroke homonymous hemianopsia (REVOIR)
Methods Randomised cross-over design
Participants Adults, 3 to 36 months post-stroke; presence of a homonymous visual field amputation after vascular retro-
chiasmatic lesion of the occipital region (visual cortex alone or with optical radiations or with other associated
occipital areas)
Anticipated recruitment: 104 participants
Interventions Experimental: immediate rehabilitation (“a stimulus, in the blind field of hemianopsic patients, to restore the
vision of patients with homonymous hemianopsia consecutive to stroke”)
Control: delayed rehabilitation
Outcomes Primary outcome measure: change in the sensitivity of detection of a visual stimulus after rehabilitation
Starting date September 2016
Contact information lsalomon@for.paris
Notes ClinicalTrials.gov Identifier: NCT02886663
DREX:DurhamReading&Exploration
PMD: perimetric mean deviation
RCT: randomised controlled trial
tDCS: transcranial direct current stimulation
VFD: visual field defect
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D A T A A N D A N A L Y S E S
Comparison 1. Restitutive interventions versus control, placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Visual field 1 19 Mean Difference (IV, Random, 95% CI) 1.02 [-1.37, 3.41]
2 Quality of life 1 30 Odds Ratio (M-H, Random, 95% CI) 13.0 [2.07, 81.48]
Comparison 2. Compensative interventions versus control, placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Visual field 2 95 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.92, 0.70]
1.1 Participants with visual
field defects (no visual neglect)
2 95 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.92, 0.70]
1.2 Participants with visual
field defects and (possibly) co-
existing visual neglect
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Extended activities of daily living 2 87 Std. Mean Difference (IV, Random, 95% CI) 0.49 [-0.01, 0.99]
2.1 Participants with visual
field defects (no visual neglect)
2 87 Std. Mean Difference (IV, Random, 95% CI) 0.49 [-0.01, 0.99]
2.2 Participants with visual
field defects and (possibly) co-
existing visual neglect
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Reading 4 162 Std. Mean Difference (IV, Random, 95% CI) 0.26 [-0.05, 0.58]
3.1 Participants with visual
field defects (no visual neglect)
3 110 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.20, 0.56]
3.2 Participants with visual
field defects and (possibly) co-
existing visual neglect
1 52 Std. Mean Difference (IV, Random, 95% CI) 0.45 [-0.10, 1.00]
4 Quality of life 2 96 Mean Difference (IV, Random, 95% CI) 9.36 [3.10, 15.62]
4.1 Participants with visual
field defects (no visual neglect)
2 96 Mean Difference (IV, Random, 95% CI) 9.36 [3.10, 15.62]
4.2 Participants with visual
field defects and (possibly) co-
existing visual neglect
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Scanning - cancellation 2 97 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.40, 0.39]
5.1 Participants with visual
field defects (no visual neglect)
1 48 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.45, 0.68]
5.2 Participants with visual
field defects and (possibly)
visual neglect
1 49 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.69, 0.44]
6 Adverse events 2 108 Odds Ratio (M-H, Random, 95% CI) 5.18 [0.24, 112.57]
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Comparison 3. Substitutive interventions versus control, placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functional Activities of Daily
Living
1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Participants not wearning
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Participants wearing
prisms during assessment
1 39 Mean Difference (IV, Random, 95% CI) -4.0 [-17.86, 9.86]
2 Visual field 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Participants not wearing
prisms during assessment
1 46 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.46, 0.70]
2.2 Participants wearing
prisms during assessment
1 39 Std. Mean Difference (IV, Random, 95% CI) 1.12 [0.44, 1.80]
3 Extended activities of daily living 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Participants not wearing
prisms during assessment
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.44, 0.85]
3.2 Participants wearing
prisms during assessment
1 61 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.26, 0.75]
4 Reading 1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Participants not wearing
prisms during assessment
1 45 Mean Difference (IV, Random, 95% CI) 2.80 [-7.13, 12.73]
4.2 Participants wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Falls 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Participants not wearing
prisms during assessment
0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Participants wearing
prisms during assessment
1 39 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.26, 5.76]
6 Quality of life 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Participants not wearing
prisms during assessment
1 43 Mean Difference (IV, Random, 95% CI) 8.40 [-4.18, 20.98]
6.2 Participants wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Scanning - cancellation 1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Participants not wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Participants wearing
prisms during assessment
1 39 Mean Difference (IV, Random, 95% CI) 9.80 [1.91, 17.69]
8 Adverse events 1 59 Odds Ratio (M-H, Random, 95% CI) 87.32 [4.87, 1564.
66]
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Comparison 4. Assessment or screening versus control, placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ADL 1 37 Mean Difference (IV, Random, 95% CI) -6.97 [-23.78, 9.84]
Analysis 1.1. Comparison 1 Restitutive interventions versus control, placebo or no intervention, Outcome
1 Visual field.
Review: Interventions for visual field defects in people with stroke
Comparison: 1 Restitutive interventions versus control, placebo or no intervention
Outcome: 1 Visual field
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kasten 1998 (1) 9 3.94 (3) 10 2.92 (2.21) 100.0 % 1.02 [ -1.37, 3.41 ]
Total (95% CI) 9 10 100.0 % 1.02 [ -1.37, 3.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours restitutive
(1) TAP border postion in degrees of visual angle from zero vertical meridian
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Analysis 1.2. Comparison 1 Restitutive interventions versus control, placebo or no intervention, Outcome
2 Quality of life.
Review: Interventions for visual field defects in people with stroke
Comparison: 1 Restitutive interventions versus control, placebo or no intervention
Outcome: 2 Quality of life
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kasten 1998 (1) 13/18 2/12 100.0 % 13.00 [ 2.07, 81.48 ]
Total (95% CI) 18 12 100.0 % 13.00 [ 2.07, 81.48 ]
Total events: 13 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours restitutive
(1) Dichotomous variable (improve or not improved) - derived from percentage of those who reported subjective improvements of vision
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Analysis 2.1. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 1 Visual field.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 1 Visual field
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants with visual field defects (no visual neglect)
De Haan 2015 (1) 26 57.75 (6.74) 23 62.58 (11.13) 50.2 % -0.52 [ -1.10, 0.05 ]
Rowe 2010 (2) 24 0.0815 (0.1488) 22 0.04 (0.1502) 49.8 % 0.30 [ -0.28, 0.89 ]
Subtotal (95% CI) 50 45 100.0 % -0.11 [ -0.92, 0.70 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 3.97, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Participants with visual field defects and (possibly) co-existing visual neglect
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 50 45 100.0 % -0.11 [ -0.92, 0.70 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 3.97, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours compensative
(1) Functional Field Score (NB: Significant difference between training and control group at baseline assessment)
(2) Relative change in visual field area
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Analysis 2.2. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 2 Extended activities of daily living.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 2 Extended activities of daily living
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants with visual field defects (no visual neglect)
De Haan 2015 (1) 26 -2.04 (0.56) 23 -2.51 (0.72) 54.0 % 0.72 [ 0.14, 1.30 ]
Rowe 2010 (2) 22 15.2 (4.4) 16 14.1 (6) 46.0 % 0.21 [ -0.44, 0.86 ]
Subtotal (95% CI) 48 39 100.0 % 0.49 [ -0.01, 0.99 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Participants with visual field defects and (possibly) co-existing visual neglect
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 48 39 100.0 % 0.49 [ -0.01, 0.99 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours compensatory
(1) Independent mobility questionnaire (multiplied by -1 as low result indicates positive outcome)
(2) Change in EADL from baseline
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Analysis 2.3. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 3 Reading.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 3 Reading
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants with visual field defects (no visual neglect)
De Haan 2015 (1) 24 159 (33) 21 147 (34) 27.9 % 0.35 [ -0.24, 0.94 ]
Rowe 2010 (2) 25 13 (13.1) 21 14.6 (11.9) 28.9 % -0.13 [ -0.71, 0.46 ]
Spitzyna 2007 (3) 11 102.49 (34.68) 8 85.99 (22.89) 11.3 % 0.52 [ -0.41, 1.45 ]
Subtotal (95% CI) 60 50 68.1 % 0.18 [ -0.20, 0.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Participants with visual field defects and (possibly) co-existing visual neglect
Aimola 2011 (4) 28 132.46 (50.16) 24 109.13 (52.63) 31.9 % 0.45 [ -0.10, 1.00 ]
Subtotal (95% CI) 28 24 31.9 % 0.45 [ -0.10, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 88 74 100.0 % 0.26 [ -0.05, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.098)
Test for subgroup differences: Chi2 = 0.63, df = 1 (P = 0.43), I2 =0.0%
-10 -5 0 5 10
Favours control Favours compensative
(1) Radner average reading speed (words per minute)
(2) change in Radner reading speed
(3) Reading speed
(4) Mean corrected reading speed (words per minute)
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Analysis 2.4. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 4 Quality of life.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 4 Quality of life
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants with visual field defects (no visual neglect)
De Haan 2015 (1) 29 71.98 (10.07) 23 62.39 (15.06) 76.3 % 9.59 [ 2.43, 16.75 ]
Rowe 2010 (2) 25 68.4 (20) 19 59.8 (22.7) 23.7 % 8.60 [ -4.27, 21.47 ]
Subtotal (95% CI) 54 42 100.0 % 9.36 [ 3.10, 15.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
2 Participants with visual field defects and (possibly) co-existing visual neglect
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 54 42 100.0 % 9.36 [ 3.10, 15.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours compensatory
(1) NEI-VFQ-25 total score
(2) VFQ-25 total score
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Analysis 2.5. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 5 Scanning - cancellation.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 5 Scanning - cancellation
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants with visual field defects (no visual neglect)
De Haan 2015 (1) 23 2224 (838) 25 2140 (545) 49.5 % 0.12 [ -0.45, 0.68 ]
Subtotal (95% CI) 23 25 49.5 % 0.12 [ -0.45, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 Participants with visual field defects and (possibly) visual neglect
Aimola 2011 (2) 25 101 (53) 24 107 (40) 50.5 % -0.13 [ -0.69, 0.44 ]
Subtotal (95% CI) 25 24 50.5 % -0.13 [ -0.69, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 48 49 100.0 % -0.01 [ -0.40, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
-10 -5 0 5 10
Favours compensative Favours control
(1) Parallel search test, reaction time (ms)
(2) Visuomotor search - time to complete (seconds)
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Analysis 2.6. Comparison 2 Compensative interventions versus control, placebo or no intervention,
Outcome 6 Adverse events.
Review: Interventions for visual field defects in people with stroke
Comparison: 2 Compensative interventions versus control, placebo or no intervention
Outcome: 6 Adverse events
Study or subgroup
Compensative
intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Haan 2015 0/26 0/23 Not estimable
Rowe 2010 (1) 2/30 0/29 100.0 % 5.18 [ 0.24, 112.57 ]
Total (95% CI) 56 52 100.0 % 5.18 [ 0.24, 112.57 ]
Total events: 2 (Compensative intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours compensative Favours control
(1) Number of reported adverse events. (NB there were 7 adverse events within 2 participants).
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Analysis 3.1. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
1 Functional Activities of Daily Living.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 1 Functional Activities of Daily Living
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearning prisms during assessment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Participants wearing prisms during assessment
Rossi 1990 (1) 18 50 (21.21) 21 54 (22.91) 100.0 % -4.00 [ -17.86, 9.86 ]
Subtotal (95% CI) 18 21 100.0 % -4.00 [ -17.86, 9.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours substitutive
(1) Barthel Index (standard deviations calculated by review authors from reported P value for difference between the groups)
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Analysis 3.2. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
2 Visual field.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 2 Visual field
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearing prisms during assessment
Rowe 2010 (1) 24 0.0524 (0.134) 22 0.04 (0.1502) 100.0 % 0.12 [ -0.46, 0.70 ]
Subtotal (95% CI) 24 22 100.0 % 0.12 [ -0.46, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Participants wearing prisms during assessment
Rossi 1990 (2) 18 -5.8 (4.24) 21 -14.2 (9.17) 100.0 % 1.12 [ 0.44, 1.80 ]
Subtotal (95% CI) 18 21 100.0 % 1.12 [ 0.44, 1.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Chi2 = 4.83, df = 1 (P = 0.03), I2 =79%
-10 -5 0 5 10
Favours control Favours substitutive
(1) Relative change in visual field area
(2) Harrington Flocks Visual Screener error scores - improvement from baseline at 4 weeks. The reported outcome was error scores from the Harrington Flocks Visual
Screener, meaning that a lower value was indicative of a better outcome (that is fewer errors are better) so we multiplied the reported values by -1 so that a higher value
was indicative of a better outcome. (Standard deviations calculated by review authors from reported P value for difference between the groups).
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Analysis 3.3. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
3 Extended activities of daily living.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 3 Extended activities of daily living
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearing prisms during assessment
Rowe 2010 (1) 22 15.2 (4.8) 16 14.1 (6) 100.0 % 0.20 [ -0.44, 0.85 ]
Subtotal (95% CI) 22 16 100.0 % 0.20 [ -0.44, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Participants wearing prisms during assessment
Bowers 2014 (2) 33 1.9 (3.3) 28 1.2 (2.2) 100.0 % 0.24 [ -0.26, 0.75 ]
Subtotal (95% CI) 33 28 100.0 % 0.24 [ -0.26, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
-10 -5 0 5 10
Favours control Favours compensative
(1) change in EADL from baseline
(2) Mobility improvement scores (in Logits)
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Analysis 3.4. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
4 Reading.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 4 Reading
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearing prisms during assessment
Rowe 2010 (1) 24 17.4 (21.3) 21 14.6 (11.9) 100.0 % 2.80 [ -7.13, 12.73 ]
Subtotal (95% CI) 24 21 100.0 % 2.80 [ -7.13, 12.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Participants wearing prisms during assessment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours compensative
(1) change in reading speed from baseline
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Analysis 3.5. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
5 Falls.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 5 Falls
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Participants not wearing prisms during assessment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Participants wearing prisms during assessment
Rossi 1990 (1) 4/18 4/21 100.0 % 1.21 [ 0.26, 5.76 ]
Subtotal (95% CI) 18 21 100.0 % 1.21 [ 0.26, 5.76 ]
Total events: 4 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours substitutive Favours control
(1) Number of falls
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Analysis 3.6. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
6 Quality of life.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 6 Quality of life
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearing prisms during assessment
Rowe 2010 (1) 24 68.2 (18.4) 19 59.8 (22.7) 100.0 % 8.40 [ -4.18, 20.98 ]
Subtotal (95% CI) 24 19 100.0 % 8.40 [ -4.18, 20.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 Participants wearing prisms during assessment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours substitution
(1) VFQ-25
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Analysis 3.7. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
7 Scanning - cancellation.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 7 Scanning - cancellation
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Participants not wearing prisms during assessment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Participants wearing prisms during assessment
Rossi 1990 (1) 18 -12.6 (12.54) 21 -22.4 (12.54) 100.0 % 9.80 [ 1.91, 17.69 ]
Subtotal (95% CI) 18 21 100.0 % 9.80 [ 1.91, 17.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours substitutive
(1) Line cancellation errors. Reported mean baseline measures and the improvements made by the experimental group relative to baseline and the control group, and P
values from a student’s test. Using the available data we calculated inferred means for both the control and prism groups. These means and the available P values were
used to calculate the SD for both groups. The calculated SD figures were used for analysis. The reported outcome was line cancellation errors, meaning that a lower value
was indicative of a better outcome (that is fewer errors are better) so we multiplied the reported values by -1 so that a higher value was indicative of a better outcome.
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Analysis 3.8. Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome
8 Adverse events.
Review: Interventions for visual field defects in people with stroke
Comparison: 3 Substitutive interventions versus control, placebo or no intervention
Outcome: 8 Adverse events
Study or subgroup
Compensative
intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rowe 2010 (1) 18/30 0/29 100.0 % 87.32 [ 4.87, 1564.66 ]
Total (95% CI) 30 29 100.0 % 87.32 [ 4.87, 1564.66 ]
Total events: 18 (Compensative intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0024)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours compensative Favours control
(1) Number of participants reporting adverse events. (NB there were 42 adverse events within 18 participants).
Analysis 4.1. Comparison 4 Assessment or screening versus control, placebo or no intervention, Outcome
1 ADL.
Review: Interventions for visual field defects in people with stroke
Comparison: 4 Assessment or screening versus control, placebo or no intervention
Outcome: 1 ADL
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jarvis 2012 (1) 19 97.47 (22.792) 18 104.44 (28.835) 100.0 % -6.97 [ -23.78, 9.84 ]
Total (95% CI) 19 18 100.0 % -6.97 [ -23.78, 9.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours assessment/screen
(1) FIM
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A D D I T I O N A L T A B L E S
Table 1. Demographics of included studies: settings of included studies
Study Country Number of centres Setting for intervention Trial registration
Aimola 2011 UK Multicentre (“from local
hospitals or as self-refer-
rals”)
Community
(participants’ own homes)
UKClinical ResearchNet-
work Portfolio (UKCRN,
ID 7144)
Bainbridge 1994 USA Single NS NS
Bowers 2014 UK, USA Multicentre (13 study
sites)
University, hospital, pri-
vate practice for fitting of
prisms
Then use at home (partic-
ipants’ own homes)
clinicaltrials.gov
NCT00494676
De Haan 2015 Netherlands 2 (“Royal Dutch Visio and
Bartiméus, the two centers
of expertise for blind and
partially sighted people in
the Netherlands”)
Training ... “was provided
in Dutch at nine locations
of Royal Dutch Visio and
one location of Bartiméus
in the Netherlands”
Participants
were also given homework
assignments.
ISRCTN Registry
ISRCTN16833414
Elshout 2016 Netherlands Unclear
(“Patients throughout the
Netherlands could sign up
for our study voluntarily
by filling in a form on our
website”)
Community
(participants’ own homes)
NS
Gall 2013 Not clear NS NS NS
Jarvis 2012 UK Single Stroke unit, Warring and
Halton Hospitals,
NHS Foundation Trust
NS
Jobke 2009 Germany NS NS NS
Kasten 1998 Germany NS Community
(participants’ own homes)
NS
Kasten 2007 Germany NS Community
(participants’ own homes)
NS
Keller 2010 Germany Single Neurological clinic NS
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Table 1. Demographics of included studies: settings of included studies (Continued)
Modden 2012 Germany Single Rehabilitation centre (in-
patients)
NS
Plow 2010 USA Single Outpatient
(University clinic)
clinicaltrials.gov
NCT00921427
Poggel 2004 Germany Single Community
(participants’ own homes)
NS
Rossi 1990 USA Single Rehabilitation
(inpatient)
NS
Roth 2009 Germany NS Community
(participants’ own homes)
NS
Rowe 2010 UK Multicentre (“from stroke
units based in 15 United
Kingdom
(UK)NationalHealth Ser-
vice (NHS) trusts”)
Any (hospital, commu-
nity)
Current Controlled Trials
ISRCTN05956042.
Schuett 2012 Unclear.
Authors from Austria, UK
and Germany. “All partici-
pants were native German
speakers.”
NS NS NS
Spitzyna 2007 UK NS Community
(participants’ own homes)
NS
Szlyk 2005 USA Single; university Outpatient clinic NS
NHS:NationalHealthService
NS: not stated
UK: United Kingdom
USA: United States of America
Table 2. Demographics of included studies: demographics of included participants
Study Number of
participants
Age Gender Time since
stroke/lesion
Initial func-
tional ability
Type of
stroke/lesion
Side of
stroke/lesion
Aimola 2011 70
participants
recruited, 52
participants
included in
Group 1
Mean 61.4
years, SD 10.3
Group 2
Mean 63.0
Group 1
9 F
19 M
Group 2
NS NS Group 1
19 ischaemic
stroke
4
Side of field
defect
Group 1
L 15/R 13
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Table 2. Demographics of included studies: demographics of included participants (Continued)
analyses years, SD 10.9 7 F
17 M
haemorrhagic,
4 traumatic
brain injury
1 tumour
Group 2
20 ischaemic
stroke
2
haemorrhagic
2 traumatic
brain injury
0 tumour
Group 2
L11/R 13
Bainbridge
1994
18 NS NS NS NS NS NS
Bowers 2014 73
randomised;
67 completed
first phase (be-
fore cross-
over); 61 com-
pleted sec-
ond phase (af-
ter cross-over)
For 61 partici-
pants
included after
the cross-over:
me-
dian 58 years
(range 18 to
89)
For 61 partici-
pants
included after
the cross-over:
M 40
F 21
For 61 partici-
pants
included after
the cross-over:
median 18
months (range
3 to 396)
Overall base-
line
mobility diffi-
culty, for 61
participants
included after
the cross-over:
mean -0.17
(SD 2.31) log-
its for n = 31
using oblique
prisms
mean -0.06
(SD 1.89) log-
its for n = 30
using horizon-
tal prisms
For 61 partici-
pants
included after
the cross-over:
hemianopia
was caused by
stroke for 47
(77%)
For 61 partici-
pants
included after
the cross-over:
L hemianopia
39 (64%)
De Haan
2015
54 ran-
domised; data
from 49 anal-
ysed (training
group n = 26,
control group
n = 23)
Training
group 55 ± 10.
1 years
Control group
57±13.0 years
M 32
F 17
Training
group 18 ± 22.
5 months
Control group
22 ± 24.6
months
NS Ischaemic
CVA 36
Haemor-
rhagic CVA 5
Traumatic
brain injury 3
Penetrating
head trauma 1
AVM extirpa-
tion 1
combined 3
L hemianopia
33
R hemianopia
16
Elshout 2016 40 recruited;
data presented
from first 3
cohorts of 10
Mean age 51.
2 years (range
29 to 74)
M 22
F 5
Mean 26.3
months
(range 11 to
NS 5 haemor-
rhagic stroke
22 ischaemic
L-sided field
defect 14
R-sided field
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Table 2. Demographics of included studies: demographics of included participants (Continued)
only (n = 30)
; data from 27
analysed
111) stroke defect 13
Gall 2013 39 (alter-
nating current
stimulation n
= 15, sham n =
14)
NS NS NS NS NS (“patients
with post-chi-
asmatic
visual pathway
lesions”)
NS
Jarvis 2012 64 ran-
domised (ex-
per-
imental group
n = 33, control
n = 31)
Exper-
imental: mean
70.4 years (SD
10.8)
Con-
trol: mean 69.
4 years (SD
14.5)
M 40
F 24
NS NS Ischaemic 56
Haemorrhage
7
Combined 1
R-sided stroke
41
L-sided stroke
19
Bilateral 4
Jobke 2009 21 Group 1
Mean 51.5
years, SD 14.8
Group 2
Mean 47.3
years, SD 13.4
Group 1
M 7
F 1
Group 2
M 6
F 4
Group 1
Mean 89.
0 months, SD
59.9
(range 67 to
225 months)
Group 2
Mean 89.4,
SD 57.6
(range 40 to
236 months)
NS Group 1
5 stroke/
ischaemia
1 brain injury
1 tumour
1 surgery
Group 2
5 stroke/
ischaemia
1 meningitis;
1 injury
3 surgery
NS
Kasten 1998 19
(plus 19 with
pre-chiasmal
damage)
Data are pre-
sented for full
group of 38
Group 1
? Mean 47.7
years, ? SD 12.
9
Group 2
? Mean 55.3
years, ? SD 16.
2
It
is assumed the
data presented
are mean and
SD, but this
was not stated
Group 1
M 11
F 8
Group 2
M 13
F 6
Group 1
? Mean
6.8 months, ?
SD11.4
Group 2
? Mean 7.2
months, ? SD
6.3
It
is assumed the
data presented
are mean and
SD, but this
was not stated
NS 19 par-
ticipants with
post chiasmal
injury;
10 were due to
stroke, 4 due
to trauma and
5 due to other
reasons
NS
Kasten 2007 23 Group 1
Mean 41.1
Group 1
M 5
Group 1
10 to 83
NS Group 1
4 stroke
NS
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Table 2. Demographics of included studies: demographics of included participants (Continued)
years, SD 16.9
Group 2
Mean 39.3
years, SD 10.9
Group 3
Mean 44.3
years, SD 9.1
F 2
Group 2
M 6
F 1
Group 3
M6
F3
months,Mean
34.2*, SD 30.
1*
Group 2
13 to 477
months,Mean
92.7*, SD
170.6*
Group 3
10 to 143
months,Mean
47.6*, SD 54.
4*
1 trauma
1 cere-
bral aneurys-
mal bleeding
1 hypoxia
Group 2
3 stroke
3 trauma
1 surgery
Group 3
3 stroke
2 trauma
1 surgery
1 hypoxia
2 other
Keller 2010 20 Group 1
Mean 54.7
years. SD 20.4
Group 2
Mean 63.6
years, SD 13.8
Group 1
M 6
F 4
Group 2
M 6
F 4
Group 1
Mean 8.5
weeks, SD 6.7
Group 2
Mean 4.2
weeks, SD 2.1
NS Group 1
9 vascular
1 tumour
Group 2
9 vascular
1 traumatic
Group 1
4 left hemi-
anopia
3 right hemi-
anopia
1 UL quan-
drantanopia
1 LL quan-
drantanopia
1 UR quan-
drantanopia
Group 2
3 left hemi-
anopia
3 right hemi-
anopia
3 UL quan-
drantanopia
1 LL quan-
drantanopia
Modden 2012 45 RT Group:
Mean 58.3 ±
11.4 years
CT group:
Mean 57.1 ±
8.3 years
OT group:
Mean 59.0 ±
11.1 years
RT group:
M 10
F 5
CT group:
M 9
F 6
OT group:
M 7
F 8
RT group:
Mean 4.7
weeks
CT group:
Mean 4.9
weeks
OT group:
Mean 4.3
weeks
“Patients were
recruited on
average about
NS RT Group:
occipital 7
temporo-
occipital 2
temporome-
dial 5
parahip-
pocampal 1
CT Group:
occipital 6
temporo-
RT group
L stroke 7
R stroke 8
CT group
L stroke 5
R stroke 10
OT group:
L stroke 5
R stroke 10
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Table 2. Demographics of included studies: demographics of included participants (Continued)
4 weeks after
their stroke.”
occipital 3
temporome-
dial 5
parahip-
pocampal 1
OT Group*:
occipital 4
temporo-
occipital 3
temporome-
dial 5
parahip-
pocampal 1
*numbers pre-
sented in pa-
per do not add
up to 15 (?)
Plow 2010 12 Mean 59.6
years, SEM 3.
5 years
M 5
F 7
Mean 39.8 ±
16.2 months,
range 3 to 192
months
NS Stroke 8 (7 in-
farct, 1 haem-
orrhage)
Surgical
trauma 2
L-affected side
4
R-affected
side 8
Poggel 2004 20 partici-
pants re-
cruited. Base-
line data only
available for
19 (data for
one dropout
not reported)
Group 1
Mean 41.9
years
Range 20 to
67 years
Group 2
Mean 43.2
years
Range 30 to
61 years
Group 1
M 6
F 3
Group 2
M 6
F 4
Group 1
Mean 49.1
months, SEM
?, Range 6.7 to
189.9 months
Group 2
Mean 24.1
months, SEM
5.0, Range 6.8
to 58.3
months
NS Group 1
vascular 1
infarct 8
cortical and
radiations 4
cortical 5
Group 2
vascular 2
infarct 7,
traumatic
brain injury 1
cortical and
radiation 5
cortical 3
radiation 2
Group 1
L 5/R 4
Group 2
L 5/R 5
Rossi 1990 39 Group 1
Mean 72.6
years, SEM 1.
8
Group 2
Mean 63.3
years, SEM 2.
5
Group 1
M 10
F 8
Group 2
M 9
F 12
Group 1
Mean 4.
4 weeks, SEM
0.3
Group 2
Mean 4.
7 weeks, SEM
0.6
NS Group 1
15 infarct
3
haemorrhage
Group 2
18 infarct
3
haemorrhage
Group 1
16 R/2 L
Group 2
13 R/8 L
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Table 2. Demographics of included studies: demographics of included participants (Continued)
Roth 2009 30
participants
recruited
(data available
for 28; 2 drop-
outs)
Group 1
Mean 60.5
years, SD 11.
0, Median 65
Group 2
Mean
60.3 years, SD
11.7,
Median 63
Group 1
4 F
11 M
Group 2
F 7
M 8
Group 1
Mean 39.20
months, SD
54.59,
Median 26
Group 2
Mean 87.87
months, SD
186.66,
Median16
NS Group 1
Stroke 11
Haemorrhage
1
Head injury 1
Abscess 1
AVM 1
Group 2
Stroke 11
Haemorrhage
3
Cyst 1
Affected side
Group 1
L 8/R 7
Group 2
L 7/R 8
Rowe 2010 87
participants
recruited (full
results for 70
participants at
26 weeks)
Group 1
Mean 69.9
years, SD 12.
9, median 68.
8, IQR, 14.4
Group 2
Mean 70.9
years, SD 11.
2, median 72.
9, IQR, 15.2
Group 3
Mean 66.2
years, SD 11.
3, median 68.
2, IQR, 16.2
Group 1
4 F
22 M
Group 2
13 F
17 M
Group 3
9 F
20 M
Group 1
Mean 75.
5 days, SD 45.
3, median 64.
5, IQR 78.0
Group 2
Mean 73.
8 days, SD 49.
2, median 69.
0, IQR 97.0
Group 3
Mean 81.
2 days, SD 48.
0, median 67.
0, IQR 61.0
Barthel Index
score
Group 1
Mean
97.5, SD 5.5,
median 100.0,
IQR 0.0
Group 2
Mean
92.7, SD11.9,
median 100.0,
IQR 15.0
Group 3
Mean
93.3, SD14.7,
median 100.0,
IQR 5.0
Group 1
25 ischaemic
1
haemorrhage
Group 2
28 ischaemic
2
haemorrhage
Group 3
28 ischaemic
1
haemorrhage
Side of infarct
Group 1
L 9/R 16/bi-
lateral 1
Group 2
L 17/R 13/bi-
lateral 0
Group 3
L 11/R 17/bi-
lateral 1
Schuett 2012 36 Group 1
Mean
64.0 years, SD
11.1, range 44
to 81
Group 2
Mean
63.7 years, SD
13.3, range 42
to 83
Group 1
3 F
15 M
Group 2
3 F
15 M
Group 1
Mean 26.6
weeks, SD 14.
5, range 6 to
57
Group 2
Mean 20.1
weeks, SD 18.
8, range 4 to
74
NS Group 1
17 posterior
infarction
1 tumour op-
eration
Group 1
17 posterior
infarction
1 tumour op-
eration
Side of field
loss
Group 1
L 9/R 9
Group 2
L 7/R 11
Spitzyna 2007 22 Age at symp-
tom onset
Group 1
Range 5 to
67 years, mean
42.5*, SD 20.
5*
Group 1
M 6
F 5
Group 2
M 7
F 1
Time since
symptoms on-
set
Group 1
Range 1 to 37
years, mean 7.
5*, SD 10.9*
NS Group 1
3 infarct
1 tuberous
sclerosis
2 traumatic
brain injury, 2
Group 1
All R
Group 2
All R
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Table 2. Demographics of included studies: demographics of included participants (Continued)
Group 2
Range 39 to
78 years, mean
63.1*, SD 12.
2*
Group 2
Range
3 months to 5
years, mean 1.
6*, SD 1.7*
tumour
2
haemorrhage
1 cyst
Group 2
8 infarct
Szlyk 2005 10 Group 1
Range 16 to
74 years, mean
50.6*, SD 22.
5*
Group 2
Range 34 to
73 years, mean
54.0, SD 14.4
Group 1
5 M
Group 2
5 M
NS NS Group 1
4 CVA
1 tumour: all
occipital lobe
Group 2
4 CVA
1 AVM: all oc-
cipital lobe
Group 1
L 3/R 2
Group 2
L 4/R 1
* Figures calculated from raw data supplied in papers
AVM:arteriovenousmalf ormation
CVA: cerebrovascular accident
CT: compensatory training
F: female
IQR: interquartile range
L: left
LL: lower left
M: male
NS: not stated
OT: occupational therapy
R: right
RT: restitutive training
SD: standard deviation
SEM: standard error of the mean
UL: upper left
UR: upper right
Table 3. Demographics of included studies: visual problems of included participants
Study Methods of visual field
assessment
Type/extent of field loss Macular sparing Presence of neglect?
Aimola 2011 Unspecified kinetic
perimeter
Esterman measures of
static superthreshold
Group 1
Hemianopia 20, quadran-
tanopia 8
Group 2
Hemianopia 20, quadran-
tanopia 4
Group 1
Mean 1.92° (SD 1.44)
Group 2
Mean 2.45° (SD 1.85)
Yes: stated “Three pa-
tients (2 in the interven-
tion group, 1 in the con-
trol group) had comorbid
neglect as confirmed with
the bells test”
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
Bainbridge 1994 Harrington Flocks Visual
Screener
Confrontation
Not stated Not stated Yes: no details of inclusion
criteria or participants pro-
vided, but objective stated
“To study the effect of ...
on visual neglect or hemi-
anopsia following stroke”
Bowers 2014 Goldmann perimetry Not stated Not stated No: stated “no visual ne-
glect”. Visual neglect diag-
nosed with Bells test and
Schenkenberg Line Bisec-
tion Test
De Haan 2015 Goldmann perimetry Training group
Functional field score 58 ±
7.8
Quadrantanopia 5
(3 lower left, 1 upper left,
1 lower right)
Hemianopia 21
Control group
Functional field score 64 ±
11.4
Quadrantanopia 5 (3
lower left, 2 upper left)
Hemianopia 18
Not stated No: stated “Neglect was
excluded based on the Bal-
loons, drawings, Line Bi-
section and Rey Complex
Figure Test.”
Elshout 2016 Goldman perimetry
Humphrey perimetry
Right field loss: hemifield
4, incomplete hemifield 5,
quadrant 2, scotoma 1
Left field loss: hemifield
2, incomplete hemifield 9,
quadrant 1, scotoma 2
Bilaterial field loss
Incomplete: 1
“All subjects
had macular sparing of at
least 2°”
No:
patientswith visual neglect
were excluded (based on
line bisection test)
Gall 2013 Standard automated
perimetry
Not stated Not stated Not stated
Jarvis 2012 Confrontation Ocular diagnosis:
low vision 30
visual field loss 38
eye movement deficit 41
perceptual impairment 24
(“Note: patients may have
had an isolated visual im-
pairment or combined vi-
sual deficits”)
Not stated Yes: all patients with a
“post-stroke visual impair-
ment were eligible for in-
clusion”
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
Jobke 2009 Standard automated
perimetry
High resolution perimetry
(HRP)
NB: It did not state
whether participants had
visual neglect or whether
this was diagnosed
Group 1
2 diffuse, 2 full homony-
mous hemianopia, 1 par-
tial homonymous hemi-
anopia, 1 full quadran-
tanopia
2 partial quadrantanopia
Group 2
4 diffuse, 2 full homony-
mous hemianopia, 2 par-
tial homonymous hemi-
anopia, 1 full quadran-
tanopia,
1 partial quadrantanopia
Group 1
7 sparing, 1 not sparing
Group 2
10 sparing
Not stated
Kasten 1998 Tubinger automated
perimetry (TAP)
High resolution perimetry
(HRP)
NB: data were presented
for full group of 38 par-
ticipants (includingpartic-
ipants in parallel trial)
Group 1
TAP 90° - border position,
mean 3.51° (degrees of vi-
sual angle from zero verti-
cal meridian), SEM 1.0
TAP 90° - number of
misses,mean53.0, SEM9.
1
Group 2
TAP 90° - border position,
mean 3.43° (degrees of vi-
sual angle from zero verti-
cal meridian), SEM 0.99
TAP 90° - number of
misses, mean 69.2, SEM
11.2
Not stated No: par-
ticipants with neglect were
excluded. Method of diag-
nosis of neglect not stated
Kasten 2007 Tubinger automated
perimetry (TAP)
High resolution perimetry
(HRP)
TAP 90° (number of blind
stimuli positions)
Group 1
Right eye - mean 46.6, SD
6.9, left eye - mean 43.9,
SD 3.7
Group 2
Right eye - mean 50.3, SD
8.7, left eye - mean 43.1,
Not stated No: par-
ticipants with neglect were
excluded. Method of diag-
nosis of neglect not stated
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
SD 7.6
Group 3
Right eye - mean 32.9, SD
6.8, left eye - mean 37.9,
SD 7.1
.Keller 2010 Goldmann perimetry
Goldmann suprathreshold
Group 1
4 left hemianopia
3 right hemianopia
1 UL quandrantanopia
1 LL quandrantanopia
1 UR quandrantanopia
Group 2
3 left hemianopia
3 right hemianopia
3 UL quandrantanopia
1 LL quandrantanopia
Group 1
6 with 0° macular sparing
4 with < 5° macular spar-
ing
Group 2
6 with 0° macular sparing
4 with < 5° macular spar-
ing
No: participants with ne-
glect were excluded. 3 ne-
glect tests were used: “line
bisection, Mesulam test,
draw a clock face test”
Modden 2012 Vi-
sual field assessment from
the Test Battery of Atten-
tional Performance
RT Group
10 hemianopia
5 quadrantanopia
TAP alertness
without cueing, ms; mean
304.2, SD 80.8
TAP conjunction search,
omissions; mean 9.1, SD
9.0
CT Group
12 hemianopia
3 quadrantanopia
TAP alertness
without cueing, ms; mean
383.7, SD 205.2
TAP conjunction search,
omissions; mean 10.7, SD
6.7
OT Group
10 hemianopia
5 quadrantanopia
TAP alertness
without cueing, ms; mean
308.1, SD 58.6
TAP conjunction search,
omissions; mean 10.3, SD
5.6
RT Group
3/15 participants with less
than 2° sparing
CT Group
3/15 participants with less
than 2° sparing plus 1 par-
ticipant with no sparing
OT Group
3/15 participants with less
than 2° sparing
No: par-
ticipants with neglect were
excluded. Method of diag-
nosis of neglect not stated
Plow 2010 Subjective to-
pographic measure of per-
ceived visual field defect
High resolution perimetry
7 hemianopia
5 quadrantanopia
Not stated Not stated
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
(HRP)
Poggel 2004 Tubinger automated
perimetry (TAP)
High resolution campime-
try
High resolution perimetry
(HRP)
Group 1
Upper attention field (size
of area of residual vision,
%), mean 18.2, SEM 4.0
Lower probe field (size of
area of residual vision, %)
, mean 21.3, SEM 3.1
Total visual field (size of
area of residual vision, %)
, mean 7.3, SEM 1.9
Group 2
Upper attention field (size
of area of residual vision,
%), mean 16.9, SEM 2.4
Lower probe field (size of
area of residual vision, %)
, mean 15.5, SEM 4.0
Total visual field (size of
area of residual vision, %)
, mean 6.7, SEM 1.3
Not stated No: par-
ticipants with neglect were
excluded. Method of diag-
nosis of neglect not stated
Rossi 1990 Harrington Flocks Visual
Screener
Tangent screen measures
Group 1
Homonymous
hemianopia 12
(Visual neglect 6)
Group 2
Homonymous
hemianopia 15
(Visual neglect 6)
Not stated Yes: par-
ticipants with “homony-
mous hemianopia or vi-
sual neglect were recruited
....”. Method of diagnosis
of neglect was Harrington
Flocks Visual Screener
39 participants re-
cruited: 27 had homony-
mous hemianopia; 12 had
visual neglect
Roth 2009 Tubinger automated
perimetry (TAP)
Scanning laser ophthal-
moscopy
Group 1
Homonymous
hemianopia 12, quadran-
tanopia 3
Group 2
Homonymous
hemianopia 12, quadran-
tanopia 3
Not stated No: par-
ticipants with neglect were
excluded. Method of diag-
nosis of neglect was clock-
drawing and line-bisection
tests
Rowe 2010 Goldmann perimetry
Esterman measures of
static superthreshold
Group 1
Homonymous
hemianopia left partial 8,
Homony-
mous hemianopia right
Not stated No: participants with ne-
glect were ex-
cluded.Methodof diagno-
sis was clinical assessment:
“as assessed by the orthop-
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
partial 3, Homonymous
hemianopia left complete
9, Homonymous hemi-
anopia right complete 6
Group 2
Homonymous
hemianopia left partial 5,
Homony-
mous hemianopia right
partial 9, Homonymous
hemianopia left complete
8, Homonymous hemi-
anopia right complete 8
Group 3
Homonymous
hemianopia left partial 8,
Homony-
mous hemianopia right
partial 5, Homonymous
hemianopia left complete
10, Homonymous hemi-
anopia right complete 6
tist”
Schuett 2012 Tubingen kinetic perime-
try
Group 1
Hemianopia 15, quadra-
nopia 1, paracentral sco-
toma 2
Group 2
Hemianopia 10, quadra-
nopia 4, paracentral sco-
toma 4
Group 1
Mean 2.3° (SD 1.4)
Group 2
Mean 2.3° (SD 1.2)
No: participants with ne-
glect were excluded.
Method of diagnosis de-
scribed as: “as assessed by
tests in accordance with
the Behavioural Inatten-
tion Test (line bisection,
letter and star cancellation,
figure and shape copy-
ing, drawing from mem-
ory; Halligan et al, 1991).
”
Spitzyna 2007 Goldmann perimetry
Humphrey automated
perimetry
Group 1
Full homonymous hemi-
anopia 8, partial homony-
mous hemianopia 1, lower
quadrantanopia 1, upper
quadrantanopia 1
Group 2
Full homonymous hemi-
anopia 6, lower quadran-
tanopia 1, upper quadran-
tanopia 1
Macular sparing defined as
2° of sparing
Group 1
Sparing 5, non-sparing 6
Group 2
Sparing 3, non sparing 5
No: only participants with
right-sided homony-
mous hemianopic were in-
cluded; therefore, presence
of neglectwas assumedun-
likely
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Table 3. Demographics of included studies: visual problems of included participants (Continued)
Szlyk 2005 Goldmann perimetry Group 1
Goldmann III4e, range
45.2 to 125, mean 59.12*,
SD 22.07*
Goldmann V4e, range 48.
8 to 115,mean 70.56*, SD
26.15*
Group 2
Goldmann III4e, range
46.8 to 123.8, mean 68.
0*, SD 31.71*
Goldmann V4e, range 50.
67 to 132, mean 73.73*,
SD 33.10*
Figures were calculated for
the affected side only.
Not stated Not stated; however, al-
though it was not stated
whether the participants
may have had visual ne-
glect, neglect is unlikely in
occipital lesions, and only
participants with occipital
lesions were included
* Figures calculated from raw data supplied in papers
combined:combinedetiology
HRP: high resolution perimetry
LL: lower left
LR: lower right
ms: milliseconds
SD: standard deviation
SEM: standard error of the mean
TAP: Tübingen automated perimeter
UL: upper left
UR: upper right
Table 4. Outcome measures within included studies
Study Func-
tional
ability in
ADL
Visual
field
Outcome
category
(measure)
Func-
tional
ability in
EADL
Reading Falls Quality
of life
Visual
scanning
Adverse
events
Other Out-
comes
with data
included
within
meta-
analyses
Aimola
2011
Kinetic
Perimetry
(unspeci-
fied
kinetic
perime-
ter)
Static Su-
Read-
ing (cor-
rected
reading
speed)
1. VFQ
25
2. VIQ -
Visual
Impair-
ments
question-
naire
1. visual
search
- find the
num-
ber (com-
puter -
based)
2. visuo-
Tasks
simulat-
ingADL -
1. driving
hazard
percep-
tion
Reading:
Analysis
2.3
Visual
search:
time to
complete
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Table 4. Outcome measures within included studies (Continued)
perthresh-
old (Es-
terman
mea-
sures of
static su-
perthresh-
old)
(NB not
clear if
recorded
as out-
come or
not;
no results
provided
for visual
field data)
3. Subjec-
tive Rea-
sons
question-
naire
motor
search -
find items
on a shelf
(mean
score per
hazard)
, 2. obsta-
cle avoid-
ance
(comple-
tion time)
, 3. visuo-
mo-
tor search
(time)
Atten-
tion tasks
- 1. sus-
tained at-
tention to
response
(mean
percent-
age error
score), 2.
test of ev-
eryday at-
tention
Analysis
2.5
QoL:
data not
included
as only
available
for indi-
vid-
ual ques-
tionnaire
items
Bain-
bridge
1994
Gross vi-
sual
screen-
ing (Har-
rington-
Flocks
Vi-
sual Field
Score)
Line
Cancella-
tion Test
Motor
Free Vi-
sual Per-
ception
Score
Line Bi-
section
Test
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
Bowers
2014
Mobil-
ity ques-
tionnaire
Ques-
tion: “If
the study
were
to end
today,
would
you
want to
continue
with
these
Func-
tional
ability
in EADL:
Analysis
3.3
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Table 4. Outcome measures within included studies (Continued)
prism
glasses
(i.e. the
prism
glasses
worn
in that
period)?”
De Haan
2015
Kinetic
perimetry
(Gold-
mann
Perime-
try, Func-
tional
Field
score)
Indepen-
dent Mo-
bil-
ity ques-
tionnaire
1. Radner
reading
test;
(a) Rad-
ner aver-
age read-
ing speed
(wpm)
, (b) min-
imal read-
able text
size (Lo-
gRad)
2. Text
reading
test; (a)
text read-
ing speed
(wpm)
, (b) text
correct
answers
1. NEI-
VFQ-25
(Visual
Func-
tional
question-
naire)
2. Cere-
bral Vi-
sual Dis-
or-
ders ques-
tionnaire
1. visual
scanning
- dots test
2. visual
search -
letters
(paral-
lel search
test)
3. visual
search -
let-
ters (serial
search)
Not
reported
as an out-
come
mea-
sure, but
stated no
adverse
events in
either
group
Vi-
sual acu-
ity, con-
trast sen-
sitivity,
hazard
percep-
tion, sim-
ulat-
ing driv-
ing/track-
ing task,
obstacle
course
Vi-
sual field:
Func-
tional
Field
score
Analysis
2.1
Read-
ing: Rad-
ner aver-
age read-
ing speed
Analysis
2.3
Vi-
sual scan-
ning: Par-
al-
lel search
test, time
Analysis
2.5
QoL:
NEI
VFQ
Analysis
2.4
Func-
tional
ability
in EADL:
mobil-
ity ques-
tionnaire
Analysis
2.2
Elshout
2016
Goldman
perimetry
Read-
ing speed
No data
in-
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Table 4. Outcome measures within included studies (Continued)
Humphrey
perimetry
(words
per
minute) -
15 point
Arial
font, 88
and 165
words
cluded (as
data not
available
for before
the cross-
over)
Gall 2013 Static
Thresh-
old
Perime-
try (Stan-
dard au-
tomated
perime-
try)
1. NEI
VFQ 39
(vision-
related)
2. SF-12
(health-
related)
No data
included
in meta-
analy-
ses (as no
suitable
data pre-
sented in
abstract)
Jarvis
2012
FIM 1. Func-
tional
mobil-
ity (timed
walk)
2. Non-
validated
question-
naire giv-
ing quali-
ta-
tive infor-
mation
about
their
treatment
approach
Func-
tional
ability in
ADL:
Func-
tional In-
depen-
dence
Measure
Analysis
4.1
Jobke
2009
Static
Thresh-
old
Perime-
try (Stan-
dard au-
tomated
perime-
try)
Resolu-
tion
Perime-
Rad-
ner read-
ing test
NEI
VFQ
Zahlen-
Verbindungs
test
(ZVT)
for mea-
suring the
speed of
connect-
ing num-
bers in
a paper-
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
(for data
available
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Table 4. Outcome measures within included studies (Continued)
try (High
resolu-
tion
perime-
try)
pencil
test
before the
cross-
over)
Kasten
1998
Resolu-
tion
Perime-
try (High
resolu-
tion
perime-
try)
Static
Thresh-
old
Perime-
try (Tub-
inger au-
tomated
perime-
try)
Qual-
ity of life
question-
naire
Vi-
sual acu-
ity: Lan-
dolt ring
to
give min-
imum an-
gle of res-
olution
Vi-
sual field:
Tub-
inger au-
tomated
perime-
try: bor-
der posi-
tion in
degrees of
visual an-
gle from
zero verti-
calmerid-
ian
Analysis
1.1
Qual-
ity of life
Analysis
1.2
Kasten
2007
Reso-
lution
Perimetry
(High
reso-
lution
perime-
try:
number
of hits,
learning
effects,
fixation
ability,
false hits)
Static
Thresh-
old
Perime-
try (Tub-
inger au-
Sub-
jective vi-
sual abil-
ity ques-
tionnaire
1. Eye
move-
ments:
“Chronos
Vi-
sion Eye
Tracker”
2. Visual
acuity
3.
“Zahlen-
Verbindungs
Test” of
visuo-
spatial
attention
4. “Alters-
Konzen-
tra-
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
(for avail-
able data
compar-
ing group
out-
comes)
146Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Outcome measures within included studies (Continued)
tomated
perime-
try: no of
hits, fixa-
tion abil-
ity)
tionstest”
atten-
tion test
for older
people
5.
“testbat-
terie zur
Aufmerk-
samkeit-
sprue-
fung”
ability to
improve
attention
Keller
2010
Kinetic
Perimetry
(Gold-
mann
perime-
try)
Static Su-
perthresh-
old
(Gold-
mann
suprathresh-
old)
Read-
ing time
(stan-
dard-
ised read-
ing test)
OT
admin-
istered
ques-
tionnaire
(based on
Kerkhoff ’s
self-eval-
uation of
ADL)
1. Visual
explo-
ration test
(number
of omis-
sions)
2. Search
task
(search
time)
Electro-
oculogra-
phy
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
Modden
2012
Extended
Barthel
In-
dex (Ger-
man)
Gross Vi-
sual
Screening
(Test Bat-
tery of At-
tentional
Perfor-
mance:
visual
field as-
sessment)
Reading -
Weschler
memory
tests (er-
rors)
1. Vi-
sual scan:
from the
Test Bat-
tery of At-
tentional
Perfor-
mance
2. Visual
search:
cancella-
tion tasks
from Be-
havioural
Inatten-
tion Test
(BIT)
(omis-
sions)
Atten-
tion: Test
Battery of
Atten-
tional
Perfor-
mance
(alert-
ness)
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
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Table 4. Outcome measures within included studies (Continued)
Plow
2010
Resolu-
tion
Perime-
try (High
resolu-
tion
perime-
try: posi-
tion of vi-
sual field
border
and stim-
u-
lus detec-
tion accu-
racy)
Gross Vi-
sual
Screening
(subjec-
tive topo-
graphic
measure
of per-
ceived vi-
sual field
deficit)
Impact of
Vi-
sion Im-
pairment
(IVI) pro-
file
Low Vi-
sion-
Visual
Func-
tional
Ques-
tionnaire
(LV-
VFQ)
Measure
of fix-
ation per-
formance
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
Poggel
2004
Static
Thresh-
old
Perime-
try (Tub-
inger au-
tomated
perimetry
(TAP))
Static Su-
perthresh-
old (High
reso-
lution
campime-
try)
Resolu-
tion
Perime-
try (High
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
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Table 4. Outcome measures within included studies (Continued)
resolu-
tion
perimetry
(HRP))
Rossi
1990
Barthel
Index
Gross Vi-
sual
Screen-
ing (Har-
rington
Flocks
Visual
Screener)
Static Su-
perthresh-
old
(Tangent
screen
examina-
tion)
Number
of falls
Line can-
cellation
task
Mod-
ifiedMini
Mental
StatusEx-
amina-
tion,
Motor
Free Vi-
sual Per-
ceptual
Test,
Line Bi-
section
Task
ADL:
Barthel
Index:
Analysis
3.1
Vi-
sual Field:
Analysis
3.2
Falls:
num-
ber of falls
Analysis
3.5
Vi-
sual scan-
ning: can-
cellation
Analysis
3.7
Roth
2009
Static
Thresh-
old
Perime-
try (Tub-
inger au-
tomated
perimetry
(TAP))
Resolu-
tion
Perime-
try (Scan-
ning laser
ophthal-
moscopy)
Reading
speed
QoL:
World
Health
Organisa-
tion ques-
tionnaire
WHO-
QOL-
BREF
1. Digit
search
task (re-
sponse
time)
2. Natu-
ral search
task (ta-
ble test)
(response
time)
3. Natu-
ral
scene ex-
ploration
4. Fix-
ation sta-
bility
(video eye
tracker)
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
Rowe
2010
Kinetic
Perimetry
Not-
tingham
Read-
ing abil-
1.
VFQ 25-
Number
of partici-
River-
mead
Visual
Field: rel-
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Table 4. Outcome measures within included studies (Continued)
(Gold-
mann
perime-
try)
Static Su-
perthresh-
old (Es-
terman
mea-
sures of
static su-
perthresh-
old)
extended
activities
of daily
living
(NEADL)
ity (Rad-
ner test)
10 (vision
related)
2. EQ-
5D
3. SF-12
pants and
number
of adverse
events
Mobility
Index
ative
change in
visual
field area
Analysis
2.1 and
Analysis
3.2
QoL:
VFQ 25-
10
Analysis
2.4 and
Analysis
3.6
Adverse
events:
Analysis
2.6;
Analysis
3.8
Schuett
2012
Kinetic
Perime-
try (Tub-
ingen ki-
netic
perime-
try) (NB
not
recorded
immedi-
ately after
first
phase)
Reading
(speed
and
errors)
Cancella-
tion
(speed
and
errors)
No data
included
in meta-
analy-
ses (as no
control
group).
See Table
5
Spitzyna
2007
Kinetic
Perimetry
(Gold-
mann
perime-
try)
Static
Thresh-
old
Perimetry
(Humphrey
10-2
central
1. Text
reading
speeds
2. Single
word
reading
speeds
Eye
move-
ment
charac-
teristics:
- spa-
tial char-
acteris-
tics of sac-
cadic am-
plitude,
incoming
Read-
ing (text
reading
speed)
: Analysis
2.3
Vi-
sual field
-data not
included
as not col-
lected be-
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Table 4. Outcome measures within included studies (Continued)
threshold
pro-
gramme)
(NB not
recorded
immedi-
ately after
first
phase)
sac-
cade am-
plitude
and land-
ing posi-
tion
- tempo-
ral char-
acteristics
fore
cross-
over
Szlyk
2005
Kinetic
Perimetry
(Gold-
man
Perime-
try)
Indoor
func-
tional as-
sessment
Outdoor
func-
tional as-
sessment
Driving
skills as-
sessment
Psy-
chophysi-
cal assess-
ment
Satisfac-
tion
Prisms
use at 2
years
No data
included
in meta-
anal-
yses(as no
control
group).
No data
reported
for before
the cross-
over.
ADL:activitiesof dailyliving
BIT: behavioural inattention test
EADL: extended activities of daily living
EQ-5D:standardised EuroQol health-related quality of life instrument
FIM: Functional Independence Measure
HRP: high resolution perimetry
IVI: impact of vision impairment
LogRad: a scale of reading acuity
LV-VFQ: low vision functional questionnaire
NB: note
NEADL: Nottingham Extended Activities of Daily Living
NEI-VFQ-25: National Eye Institution Visual Function Questionnaire
OT: occupational therapy
QoL: quality of life
SF-12: 12-Item Short Form Health Survey
TAP: tubinger automated perimetry
VFQ: visual function questionnaire
VIQ: visual impairment questionnaire
WHOQOL-BREF: World Health Organisation quality of life questionnaire
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wpm: words per minute
ZVT: Zahlen-Verbindungs test
Table 5. Results of studies comparing two similar active interventions (i.e. two interventions from the same category)
Study Interventions Outcome Mean (or other
reported result if
no mean avail-
able)
Standard devia-
tion
Number of par-
ticipants
Statistical test/
results
Restitution: one restitution intervention versus another restitution intervention
Jobke 2009 Extrastriate VRT Visual
field (high-reso-
lution perimetry,
HRP)
increase from baseline of 5.9% (per-
centage of HRP hits)
8 sig-
nificant increase:
t = -5.262, P = 0.
0005
Standard VRT increase from baseline of 2.9% (per-
centage of HRP hits)
10 sig-
nificant increase:
t = -2.373, P = 0.
021
Kasten 2007 Parallel co-stim-
ulation
Visual field
(high-resolution
perimetry)
increase of 2.4% detected stimuli 7 No significant
differ-
ence “confirmed
by nonparamet-
ric Kruskal-Wal-
lis ANOVA”
Moving co-stim-
ulation
increase of 6.5% detected stimuli 7
Single stimulus increase of 3.9% detected stimuli 9
Plow 2010 VRT + tDCS Visual field
(high-resolution
perimetry)
shift from baseline to post-test from
4.11° ± 1.50° to 8.37° ± 2.29°,
Wilcoxon signed-rank test = 0, P =
0.068
4 Mann-
Whitney U = 0,
P = 0.021 (sig-
nificantly greater
shift in the vi-
sual field bor-
der with VRT +
tDCS than VRT
alone)VRT + sham
tDCS
shift from baseline to post-test from
6.33° ± 2.59° to 7.03° ± 2.51°,
Wilcoxon signed-rank test = 1, P =
0.144
4
VRT + tDCS Functional abil-
ity in ADL (LV-
VFQ)
shift from baseline to post-test from
32.25
± 5.30 to 28.25 ± 5.07; Wilcoxon
signed-rank test = 0; P = 0.068
4 Mann-Whitney
U = 5.5; P = 0.
468 (non-signif-
icant)
VRT + sham
tDCS
shift from baseline to post-test from
28 ± 2.34 to 25.25 ± 1.11;Wilcoxon
signed-rank test = 1; P = 0.285
4
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Table 5. Results of studies comparing two similar active interventions (i.e. two interventions from the same category) (Con-
tinued)
VRT + tDCS Functional abil-
ity in ADL (LV-
VFQ) - 6-month
follow-up
29.00 3.58 5 Wilcoxon
signed-rank test
= 4; P = 0.343VRT + sham
tDCS
26.80 2.11
VRT + tDCS Quality of life -
6-month follow-
up
23.20 7.83 5 Wilcoxon
signed-rank test
= 2.5; P = 0.357VRT + sham
tDCS
16.8 4.62
Poggel 2004 VRT + atten-
tional cueing
Visual
field (high-reso-
lution perime-
try) - percentage
improvement,
attention field
8.3 SEM 1.5 9 P = 0.001 (in
favour of atten-
tional cueing)
VRT with no at-
tentional cueing
2.9 SEM 0.8 10
Compensation: one compensation intervention versus another compensation intervention
Schuett 2012 Visual explo-
ration training
Reading speed 105.3 33.8 18 Not
reported; calcu-
lated as MD -19.
30 (-43.32 to 4.
72) (see Figure 3)
Reading training 124.6 39.5 18
Visual explo-
ration training
Cancellation test
(exploration
time)
18.5 4.9 18 Not
reported; calcu-
lated as MD 18.
30 (14.28 to 22.
32) (see Figure 3)Reading training 36.8 7.2 18
Keller 2010 Audiovisual ex-
ploration train-
ing (AVT)
Functional abil-
ity inADL (ADL
test total score)
1.5 (SE displayed on
graph only)
10 ANOVA P = 0.
036 (in favour of
AVT)
Visual explo-
ration training
5.0 (SE displayed on
graph only)
10
Audiovisual ex-
ploration train-
ing (AVT)
Reading time
(seconds)
75 (SE displayed on
graph only)
10 ANOVA P = 0.
03 (in favour of
AVT)
Visual explo-
ration training
178 (SE displayed on
graph only)
10
Audiovisual ex-
ploration train-
ing (AVT)
Visual scanning
(percentage hits)
85.3 (SE displayed on
graph only)
10 ANOVA P = 0.
01 (in favour of
AVT)
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Table 5. Results of studies comparing two similar active interventions (i.e. two interventions from the same category) (Con-
tinued)
Visual explo-
ration training
64.1 (SE displayed on
graph only)
10
Modden 2012 Computer-
based compensa-
tion therapy
Visual field en-
largement (visual
field
assessment from
Test Battery of
Attentional Per-
formance)
2.9 4.0 15 Pre- to post-
treatment signif-
icant field expan-
sion (P = 0.013)Standard occu-
pational therapy
(compensation)
1.3 4.7 15 Pre- to post-
treat-
ment: no signifi-
cant field expan-
sion (P = 0.316)
Computer-based
compensation
therapy (CT)
Functional abil-
ity in ADL
(improvement in
Extended
Barthel Index)
3.3 3.6 15 “No significant
treatment effects
were found
when comparing
... CT/OT”Standard occu-
pational therapy
(OT) (compen-
sation)
1.8 2.0 15
Computer-based
compensation
therapy (CT)
Reading - Im-
provement
in reading per-
formance, reduc-
tion in number
of errors (from
baseline)
-0.9 1.1 15 “Compared with
OT”...
“CT did not sig-
nificantly reduce
reading errors.”Standard occu-
pational therapy
(OT) (compen-
sation)
-0.7 1.0 15
Computer-based
compensation
therapy (CT)
Visual scanning
- reduction in
number of omis-
sions from base-
line, cancellation
tasks of the Test
Battery of At-
tentional Perfor-
mance
-5.4 5.2 15 “Compared with
OT”... “CT did
not result in su-
perior improve-
ments”
Standard occu-
pational therapy
(OT) (compen-
sation)
-2.3 5 15
Substitution: one substitution intervention versus another substitution intervention
Bainbridge 1994 Full-field Fresnel
Prisms
Visual
Field (Harring-
tonFlocksVisual
Field Score)
2.9 2 10 States full-field
more improved
Hemi-field Fres-
nel Prisms
7.2 3 8
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Table 5. Results of studies comparing two similar active interventions (i.e. two interventions from the same category) (Con-
tinued)
Full-field Fresnel
Prisms
Scanning (Line
cancellation test
errors)
4.7 1.3 10 P < 0.01, Stu-
dent’s t-test (in
favour of full-
field prisms)Hemi-field Fres-
nel Prisms
0.3 0.6 8
Szlyk 2005 18.
5 dioptre Got-
tlieb Visual field
awareness system
prisms
Visual skills cat-
egory assessment
battery
“There was improvement within all
categories with both of the prism sys-
tems ranging from 36% for mobil-
ity (with the Fresnel prisms) to 13%
for recognition (with the Gottlieb
VFAS).”
10 (data only
available for after
cross-over)
“There were no
statistically sig-
nificant dif-
ferences between
improvements
with the Got-
tlieb VFAS com-
pared with the
Fresnel prisms.”
Press-on TM 20
Diopter Fresnel
prisms
ADL:activitiesof dailyliving
ANOVA: analysis of variance (statistical test of )
AVT: audiovisual exploration training
CT: compensation therapy
HRP: high-resolution perimetry
LV-VFQ: Low Vision Visual Functioning Questionnaire
MD: mean difference
OT: occupational therapy
SE: standard error
SEM: standard error of the mean
tDCS: transcranial direct current stimulation
VFAS: visual field awareness system
VRT: visual restitution therapy
Table 6. Results of studies comparing two different types of active interventions (i.e. interventions from different categories)
Study Interventions Outcome Mean (or other
reported result if
no mean avail-
able)
Standard devia-
tion
Number of par-
ticipants
Statistical test/
results
Compensation intervention versus restitution intervention
Modden 2012 Com-
puter-based resti-
tution therapy
Vi-
sual field enlarge-
ment (visual field
assessment from
Test Battery of
Attentional Per-
formance)
3.9 4.9 15 Pre- to post-
treatment signifi-
cant field expan-
sion (P = 0.003)
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Table 6. Results of studies comparing two different types of active interventions (i.e. interventions from different categories)
(Continued)
Computer-
based compensa-
tion therapy
2.9 4.0 15 Pre- to post-
treatment signifi-
cant field expan-
sion (P = 0.013)
Computer-
based restitution
therapy (RT)
Functional abil-
ity in ADL (im-
provement in Ex-
tended Barthel
Index)
1.5 2.8 15 “No significant
treatment ef-
fects were found
when comparing
... RT/CT”Computer-based
compensation
therapy (CT)
3.3 3.6 15
Computer-
based restitution
therapy (RT)
Reading:
improvement in
reading per-
formance, reduc-
tion in number
of errors (from
baseline)
-0.9 2.4 15 “There were no
differences
between RT and
CT.”
Computer-based
compensation
therapy (CT)
-0.9 1.1 15
Computer-
based restitution
therapy (RT)
Visual scanning:
reduction in
number of omis-
sions from base-
line, cancellation
tasks of the Test
Battery of At-
tentional Perfor-
mance
-5.3 10.5 15 “...
the improvement
of the CT com-
pared with the
RTgroup did not
meet the defined
significance level
after Bonferroni
correction (P = .
023).”
Computer-based
compensation
therapy (CT)
-5.4 5.2 15
Roth 2009 Explorative scan-
ning train-
ing (EST) (com-
pensation)
Visual field: Tub-
ingen automated
perimetry
44.4 13.1 15 “Neither
the EST group
nor the FT group
showed any dif-
ferences in their
TAP or SLO out-
comes, quan-
tified as the total
number of stim-
uli detected in
the blind hemi-
field (lowest P =
0.204).”
Flicker stimula-
tion training
(FT)(restitution)
35.7 15.2 13
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Table 6. Results of studies comparing two different types of active interventions (i.e. interventions from different categories)
(Continued)
Explorative scan-
ning train-
ing (EST) (com-
pensation)
Quality
of life (WHO-
QOL-BREF)
12.93 1.67 15 “The EST group
reported
greater improve-
ments (T2 minus
T1 scores) in the
WHOQOL so-
cial-relationships
domain (t test; t
(20) = 2.217, P
= 0.038)” (but no
significant differ-
ences for other
domains)
Flicker stimula-
tion train-
ing (FT) (restitu-
tion)
13.23 1.3 13
Explorative scan-
ning train-
ing (EST) (com-
pensation)
Reading (reading
speed)
99.7 34.7 15 “Al-
though the EST
and FT groups
differed in their
reading speeds at
T1, this dif-
ference remained
unchanged
[main effect
of group, F(1,26)
= 133.074, P <
0.0001, interac-
tion, F < 1]”
Flicker stimula-
tion training
(FT)(restitution)
140.2 20.9 13
Compensation intervention versus substitution intervention
Rowe 2010* Fresnel prisms
(substitution)
Visual Field (rel-
ative change in
visual field area)
0.052 0.1396 24 ANOVA
results: no signif-
icant dif-
ferences between
groups (P = 0.
55, for compari-
son across 3 treat-
ment groups)
Vi-
sual search train-
ing (compensa-
tion)
0.0815 0.1488 24
Fresnel prisms
(substitution)
Extended activi-
ties of daily living
(change
in EADL from
baseline)
15.2 4.8 22 “No evidence of
differences ...”
Vi-
sual search train-
ing (compensa-
tion)
15.2 4.4 22
Fresnel prisms
(substitution)
Reading (change
in Radner read-
ing speed)
17.4 21.3 24 “No evidence of
differences ...”
Vi-
sual search train-
ing (compensa-
tion)
13.0 13.1 25
Fresnel prisms
(substitution)
Quality of
life (VFQ-25 to-
tal score)
68.2 18.4 24 “Visual function
(using the VFQ
25-10) improved
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Table 6. Results of studies comparing two different types of active interventions (i.e. interventions from different categories)
(Continued)
at 26 weeks in
the visual search
training arm (60
[SD 19] to 68.
4 [SD 20]) when
compared to the
Fresnel prisms
(68.5 [SD 16.
4] to 68.2 [18.
4]) and standard
care arms (63.7
[SD 19.4] to 59.
8 [SD 22.7]: Ta-
ble 6, ANCOVA
P = 0.05).”
Vi-
sual search train-
ing (compensa-
tion)
68.4 20.0 25
Fresnel prisms
(substitution)
Adverse events
(number of par-
ticipants
with reported ad-
verse events dur-
ing study)
18 participants 26 “Given the ex-
tent and range of
adverse events re-
ported with
prism wear, cau-
tion must be ex-
er-
cised if prescrib-
ing prism glasses
as an interven-
tion for homony-
mous
hemianopia.”
Vi-
sual search train-
ing (compensa-
tion)
2 participants 30
*Rowe 2010 also had a control (standard care) group, and datawere included in relevantmeta-analyses for compensatory and substitution
interventions versus control.
ADL:activitiesof dailyliving
ANCOVA: analysis of covariance (statistical test of )
ANOVA: analysis of variance (statistical test of )
CT: compensation therapy
EADL: extended activities of daily living
EST: explorative scanning training
FT: flicker stimulation training
RT: restitution therapy
SD: standard deviation
SLO: Scanning Laser Ophthalmoscope
T1: outcome asssessment timepoint 1
T2: outcome assessment timepoint 2
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TAP: Tuebingen automated perimetry
VFQ: visual function questionnaire
WHOQOL-BREF: World Health Organization Quality of Life Instrument
A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) Search Strategy
1. MeSH descriptor Cerebrovascular Disorders, this term only
2. MeSH descriptor Basal Ganglia Cerebrovascular Disease explode all trees
3. MeSH descriptor Brain Ischemia explode all trees
4. MeSH descriptor Carotid Artery Diseases explode all trees
5. MeSH descriptor Intracranial Arterial Diseases explode all trees
6. MeSH descriptor Intracranial Arteriovenous Malformations explode all trees
7. MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
8. MeSH descriptor Intracranial Hemorrhages explode all trees
9. MeSH descriptor Stroke explode all trees
10. MeSH descriptor Brain Infarction explode all trees
11. MeSH descriptor Vasospasm, Intracranial, this term only
12. MeSH descriptor Vertebral Artery Dissection, this term only
13. stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH
14. (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*)
15. (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)
16. MeSH descriptor Hemiplegia, this term only
17. MeSH descriptor Paresis explode all trees
18. hemipleg* or hemipar* or paresis or paretic 1735
19. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18)
20. MeSH descriptor Eye explode all trees
21. MeSH descriptor Visually Impaired Persons explode all trees
22. MeSH descriptor Ocular Physiological Processes explode all trees
23. MeSH descriptor Diagnostic Techniques, Ophthalmological explode all trees
24. MeSH descriptor Optometry explode all trees
25. MeSH descriptor Orthoptics explode all trees
26. MeSH descriptor Eye Diseases, this term only
27. MeSH descriptor Vision Disorders, this term only
28. MeSH descriptor Eye Manifestations, this term only
29. MeSH descriptor Blindness, this term only
30. MeSH descriptor Diplopia explode all trees
31. MeSH descriptor Vision, Binocular, this term only
32. MeSH descriptor Vision, Monocular, this term only
33. MeSH descriptor Visual Acuity explode all trees
34. MeSH descriptor Visual Fields, this term only
35. MeSH descriptor Vision, Low, this term only
36. MeSH descriptor Perimetry, this term only
37. MeSH descriptor Ophthalmology, this term only
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38. MeSH descriptor Vision Screening, this term only
39. MeSH descriptor Eye Diseases, Hereditary explode all trees
40. MeSH descriptor Eye Hemorrhage explode all trees
41. MeSH descriptor Lacrimal Apparatus Diseases explode all trees
42. MeSH descriptor Lens Diseases explode all trees
43. MeSH descriptor Ocular Hypertension explode all trees
44. MeSH descriptor Ocular Hypotension explode all trees
45. MeSH descriptor Ocular Motility Disorders explode all trees
46. MeSH descriptor Optic Nerve Diseases explode all trees
47. MeSH descriptor Orbital Diseases explode all trees
48. MeSH descriptor Pupil Disorders explode all trees
49. MeSH descriptor Refractive Errors explode all trees
50. MeSH descriptor Retinal Diseases explode all trees
51. MeSH descriptor Blindness, Cortical explode all trees
52. MeSH descriptor Hemianopsia explode all trees
53. MeSH descriptor Vitreoretinopathy, Proliferative explode all trees
54. MeSH descriptor Vitreous Detachment explode all trees
55. MeSH descriptor Scotoma, this term only
56. MeSH descriptor Abducens Nerve, this term only
57. MeSH descriptor Oculomotor Nerve, this term only
58. MeSH descriptor Trochlear Nerve, this term only
59. nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder* or retinal or retinopathy or macular
degeneration or glaucoma or cataract* or ophthalmol* or optic nerve
60. intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
61. one near/3 half syndrome
62. (visual* or vision or eye or eyes or eyesight or sight) near/5 (problem* or disorder* or impair* or disabilit* or loss or disease* or
defect* or manifestation* or screening or test* or examination*)
63. hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or
optometr* or ocular or orthoptic*
64. oscillopsia or visual tracking or fresnel prism*
65. III or IV or VI or third or fourth or sixth near/3 nerve palsy
66. (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #
34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #
49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #
64 OR #65)
67. (#19 AND #66)
68. MeSH descriptor Infant explode all trees
69. MeSH descriptor Child explode all trees
70. neonat* or child or children or childhood or juvenile or infan* or toddler
71. MeSH descriptor Neoplasms explode all trees
72. cancer* or carcinoma* or tumor* or tumour* or neoplasm*
73. (#68 OR #69 OR #70 OR #71 OR #72)
74. (#67 AND NOT #73)
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Appendix 2. MEDLINE (Ovid) Search Strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or
cerebral small vessel diseases/ or stroke, lacunar/ or exp intracranial arterial diseases/ or exp intracranial arteriovenous malformations/
or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm,
intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. exp visually impaired persons/
10. exp ocular physiological processes/ or exp diagnostic techniques, ophthalmological/
11. Optometry/ or Orthoptics/
12. eye diseases/ or vision disorders/ or eye manifestations/ or blindness/ or diplopia/
13. vision, binocular/ or vision, monocular/ or exp visual acuity/ or visual fields/ or vision, low/ or perimetry/ or ophthalmology/ or
vision screening/
14. exp ocular motility disorders/ or exp orbital diseases/ or exp pupil disorders/ or exp blindness, cortical/ or exp hemianopsia/ or
scotoma/
15. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
16. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
17. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
18. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
19. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
20. (oscillopsia or visual tracking or fresnel prism$).tw.
21. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
22. or/8-21
23. Randomized Controlled Trials as Topic/
24. random allocation/
25. Controlled Clinical Trials as Topic/
26. control groups/
27. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
28. double-blind method/
29. single-blind method/
30. Placebos/
31. placebo effect/
32. cross-over studies/
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
36. (random$ or RCT or RCTs).tw.
37. (controlled adj5 (trial$ or stud$)).tw.
38. (clinical$ adj5 trial$).tw.
39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
40. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
41. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
42. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
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43. (cross-over or cross over or crossover).tw.
44. (placebo$ or sham).tw.
45. trial.ti.
46. (assign$ or allocat$).tw.
47. controls.tw.
48. or/23-47
49. 7 and 22 and 48
50. exp animals/ not humans.sh.
51. 49 not 50
52. (neonat$ or child or children or childhood or juvenile or infant or toddler).ti.
53. 51 not 52
Appendix 3. Embase Search Strategy
1. cerebrovascular disease/ or exp basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/
or exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp cerebrovascular
malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or stroke unit/ or stroke patient/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/ or paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/ or exp eye disease/ or exp visual disorder/
9. exp visual system examination/ or eye examination/ or exp vision test/
10. exp ophthalmology/ or orthoptics/ or exp visual system/ or exp visual system function/ or depth perception/
11. exp visual aid/
12. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
13. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
14. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
15. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
16. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
17. (oscillopsia or visual tracking or fresnel prism$).tw.
18. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
19. or/8-18
20. Randomized Controlled Trial/ or “randomized controlled trial (topic)”/
21. Randomization/
22. Controlled clinical trial/ or “controlled clinical trial (topic)”/
23. control group/ or controlled study/
24. clinical trial/ or “clinical trial (topic)”/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical
trial/
25. Crossover Procedure/
26. Double Blind Procedure/
27. Single Blind Procedure/ or triple blind procedure/
28. placebo/ or placebo effect/
29. (random$ or RCT or RCTs).tw.
30. (controlled adj5 (trial$ or stud$)).tw.
31. (clinical$ adj5 trial$).tw.
32. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
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33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
34. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
35. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
36. (cross-over or cross over or crossover).tw.
37. (placebo$ or sham).tw.
38. trial.ti.
39. (assign$ or allocat$).tw.
40. controls.tw.
41. or/20-40
42. 7 and 19 and 41
43. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
44. 42 not 43
45. (neonat$ or child or children or childhood or juvenile or infant or toddler).ti.
46. exp Neoplasm/
47. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw.
48. 45 or 46 or 47
49. 44 not 48
Appendix 4. CINAHL Search Strategy
S1. MH “Cerebrovascular Disorders+” or MH “stroke patients” or MH “stroke units”
S2. TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* ) or AB ( stroke or poststroke or post-stroke or cerebrovasc*
or brain vasc* )
S3. TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or intracerebral
)
S4. TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or thrombo*
or emboli* or occlus* )
S5. S3 and S4
S6. TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachmoid ) or AB ( brain* or cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid )
S7. TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed* )
S8. S6 and S7
S9. MH “Hemiplegia”
S10. TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic
S11. S1 or S2 or S5 or S8 or S9 or S10
S12. MH “Eye+” or MH “Rehabilitation of Vision Impaired+” or MH “Optometry” or MH “Eye Diseases+”
S13. MH “Visual Acuity+” orMH “Perimetry+” or MH “Ophthalmology+” orMH “Vision Screening+” orMH “Ocular Physiology+”
S14. TI ( orthoptics or vision, monocular or vision, binocular ) or AB ( orthoptics or vision, monocular or vision, binocular )
S15. TI ( vitreous detachment or hemianopsia or hemianopia or quadrantanopia ) or AB ( vitreous detachment or hemianopsia or
hemianopia or quadrantanopia )
S16. MH “Abducens Nerve” or MH “oculomotor nerve” or MH “troclear nerve” or MH “optic nerve” or MH “nystagmus, pathologic
S17. TI ( smooth pursuit or saccades or gaze disorder* or retinal or retinopathy or ophthalmol* ) or AB ( smooth pursuit or saccades
or gaze disorder* or retinal or retinopathy or ophthalmol*)
S18. TI ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia
or optometry* or ocular or orthoptic* ) or AB ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous
detachment or scotoma or diplopia or optometry* or ocular or orthoptic* )
S19. TI ( oscillopsia or visual tracking or fresnel prism* ) or AB ( oscillopsia or visual tracking or fresnel prism* )
S20. TI ( intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation ) or AB
( intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation )
S21. TI ( visual* or vision or eye or eyes or eyesight or sight ) or AB ( visual* or vision or eye or eyes or eyesight or sight )
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S22. TI ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or test* or
examination* ) or AB ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or
test* or examination* )
S23. S21 and S22
S24. TI ( third or fourth or sixth ) or AB ( third or fourth or sixth )
S25. AB nerve palsy or TI nerve palsy
S26. S24 and S25
S27. S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S23 or S26
S28. S11 and S27
S29. (MH ”Random Assignment“) or (MH ”Random Sample+“)
S30. (MH ”Crossover Design“) or (MH ”Clinical Trials+“) or (MH ”Comparative Studies“)
S31. (MH ”Control (Research)“) or (MH ”Control Group“)
S32. (MH ”Factorial Design“) or (MH ”Quasi-Experimental Studies“) or (MH ”Nonrandomized Trials“)
S33. (MH ”Placebo Effect“) or (MH ”Placebos“) or (MH ”Meta Analysis“)
S34. (MH ”Community Trials“) or (MH”Experimental Studies“) or (MH ”One-ShotCase Study“) or (MH”Pretest-Posttest Design+“)
or (MH ”Solomon Four-Group Design“) or (MH ”Static Group Comparison“) or (MH ”Study Design“)
S35. (MH ”Clinical Research“) or (MH ”Clinical Nursing Research“)
S36. PT clinical trial
S37. PT systematic review
S38. TI random* or AB random*
S39. TI ( singl* or doubl* or tripl* or trebl* ) or AB ( singl* or doubl* or tripl* or trebl* )
S40. TI ( blind* or mask* ) or AB ( blind* or mask*)
S41. S39 and S40
S42. TI ( crossover or cross-over or placebo* or control* or factorial or sham ) or AB ( crossover or cross-over or placebo* or control*
or factorial or sham )
S43. TI ( clin* or intervention* or compar* or experiment* or preventive or therapeutic ) or AB ( clin* or intervention* or compar* or
experiment* or preventive or therapeutic)
S44. TI trial* or AB trial*
S45. S43 and S44
S46. TI ( counterbalance* or multiple baseline* or ABAB design ) or AB ( counterbalance* or multiple baseline* or ABAB design )
S47. TI ( meta analysis* or metaanlaysis or meta-anlaysis or systematic review* ) or AB ( meta analysis* or metaanlaysis or meta-anlaysis
or systematic review* )
S48. S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S41 or S42 or S45 or S46 or S47
S49. S28 AND S48
Appendix 5. AMED Search Strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or cerebral infarction/ or cerebral ischemia/ or cerebrovascular accident/ or stroke/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. eye disease/ or exp ocular motility disorders/ or exp vision disorders/ or optic nerve/
10. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
11. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
12. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
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13. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
14. (oscillopsia or visual tracking or fresnel prism$).tw.
15. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
16. or/8-15
17. clinical trials/ or randomized controlled trials/ or random allocation/
18. research design/ or comparative study/
19. double blind method/ or single blind method/
20. placebos/
21. (random$ or RCT or RCTs).tw.
22. (controlled adj5 (trial$ or stud$)).tw.
23. (clinical$ adj5 trial$).tw.
24. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
25. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
26. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
27. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
28. (cross-over or cross over or crossover).tw.
29. (placebo$ or sham).tw.
30. trial.ti.
31. (assign$ or allocat$).tw.
32. controls.tw.
33. or/17-32
34. 7 and 16 and 33
Appendix 6. PsycINFO Search Strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or hemiparesis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp ”eye (anatomy)“/
9. optometry/ or ophthalmology/ or ophthalmologic examination/
10. exp eye disorders/ or exp eye movements/ or exp vision disorders/
11. binocular vision/ or monocular vision/ or visual acuity/ or visual field/ or peripheral vision/ or exp depth perception/
12. optic nerve/ or abducens nerve/
13. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
14. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
15. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
16. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
17. (oscillopsia or visual tracking or fresnel prism$).tw.
18. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
19. or/8-18
20. clinical trials/ or treatment effectiveness evaluation/ or placebo/
21. (random$ or RCT or RCTs).tw.
22. (controlled adj5 (trial$ or stud$)).tw.
23. (clinical$ adj5 trial$).tw.
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24. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
25. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
26. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
27. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
28. (cross-over or cross over or crossover).tw.
29. (placebo$ or sham).tw.
30. trial.ti.
31. (assign$ or allocat$).tw.
32. controls.tw.
33. or/20-32
34. 7 and 19 and 33
Appendix 7. PQDT Search Strategy
stroke AND hemianopia
OR
stroke AND ”visual field“
OR
cerebrovascular AND hemianopia
OR
cerebrovascular AND ”visual field “
Appendix 8. Trials Registers Search Strategies
US National Institutes of Health Ongoing Trials Register: ClinicalTrials.gov
(www.clinicaltrials.gov):
( hemianopia OR visual field OR vision defect OR eye diseases ) AND ( Brain Infarction OR Intracranial Hemorrhages OR Carotid
Artery Diseases OR Brain Ischemia OR Cerebral Hemorrhage OR Cerebrovascular Disorders OR Stroke ) [DISEASE]
World Health Organization International Clinical Trials Registry Platform
(apps.who.int/trialsearch):
stroke AND hemianopia OR stroke AND visual field
cerebrovascular AND hemianopia OR cerebrovascular AND visual field
WH A T ’ S N E W
Date Event Description
26 February 2019 New search has been performed Review updated, with searches completed inMay 2018.
The review now includes 20 studies; previous (2009)
version included 13 studies. In this updated version,
we have excluded three of the studies from the 2009;
therefore, this updated version includes 10 studieswhich
were included in the previous (2009) version and 10
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(Continued)
new studies, with a total of 547 participants with stroke
11 October 2018 New citation required and conclusions have changed The update of this review has led to changes in the con-
clusions relating to compensatory interventions (with
greater uncertainty around previous, limited evidence of
effectiveness), and has introduced new evidence relating
to adverse events (particularly headache) associated with
substitutive interventions
C O N T R I B U T I O N S O F A U T H O R S
For this version: Alex Pollock led the review update, identified relevant studies, provided methodological expertise, extracted data,
entered data, carried out analyses, and wrote the final drafts. Pauline Campbell ran searches, contributed to screening of titles, provided
methodological expertise, and read and commented on drafts. Christine Hazelton screened titles, identified relevant studies, extracted
data, acted as a second review author, provided content expertise, and contributed to final drafts. Fiona Rowe acted as a second review
author, provided content expertise, extracted and synthesised data relating to outcome measures, and contributed to final drafts. Sven
Jonuscheit and Ashleigh Kernohan applied inclusion criteria to abstracts and full papers, identified relevant studies, extracted data, and
read and commented on drafts. Jayne Angilley, Clair Henderson, and Peter Langhorne read and commented on drafts.
For the previous (2009) version: Alex Pollock led this review, provided methodological expertise, acted as a second review author,
carried out analyses, and wrote the final drafts. Christine Hazelton ran searches, identified relevant studies, acted as first review author,
extracted data, entered data, provided content expertise, and contributed to final drafts. Clair Henderson acted as a second review
author for the identification of relevant studies. Baljean Dhillon, Heather Orr, Katrina Livingstone, Frank AMunro, Fiona Rowe, Uma
Shahani, Jayne Angilley, and Peter Langhorne provided additional content expertise, read and commented on final drafts, and acted as
additional reviewers where there was uncertainty or disagreement. Peter Langhorne also provided additional methodological expertise
where there was uncertainty about the methodological design of studies.
D E C L A R A T I O N S O F I N T E R E S T
Alex Pollock was involved in the VISION trial (Rowe 2010), which was funded by the Stroke Association. No other known interest.
Christine Hazelton has carried out non-randomised studies into the effectiveness of a number of scanning training interventions,
including the intervention studied by Roth 2009, and is developing further project proposals in this area. No other known interest.
Fiona Rowe was the chief investigator for the VISION trial (Rowe 2010), funded by the Stroke Association. She was a co-investigator
for the Jarvis 2012 trial, funded by the University of Liverpool.
Sven Jonuscheit: none known.
Ashleigh Kernohan: none known.
Jayne Angilley: none known.
Clair A Henderson: none known.
Peter Langhorne: none known.
Pauline Campbell: none known.
The work presented here represents the view of the review authors and not necessarily those of the funding bodies.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Royal National Institute of Blind People (RNIB, Scotland), UK.
RNIB (Scotland) funded the first (2009) version of this review.
• Chief Scientist Office, UK.
Alex Pollock and Pauline Campbell are employed by the Nursing, Midwifery and Allied Health Professions Research Unit, which is
funded by the Chief Scientist Office in Scotland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Participants
In the 2011 version of the review, we included studies that investigated the effectiveness of visual scanning training and techniques
even if the population of participants had not been clearly defined as having visual field defects. This decision was made in consultation
with a multidisciplinary group of clinicians (CH, JA, BD,KL, PL, FM, HO, FR, US); the decision was that it was clinically relevant
and useful to include these studies. It is recognised that, in these studies, the visual scanning problems experienced by participants may
have been due to either visual field defects, visual neglect, or a combination of both. The results of these studies were therefore relevant
to the population of patients with ’visual scanning’ problems, regardless of the physiological cause of the scanning problem. Data from
these studies would not be combined with data arising from studies which include a population of patients with visual field defects
but not visual neglect. In this update, this decision was reconsidered, and reversed: populations of participants with ’visual scanning
problems’, but no confirmed visual field defect have been excluded.
Comparisons
In the 2011 version, we included one additional comparison that we did not outline in the protocol. This was a comparison of
compensative intervention versus restitutive interventions. Although not preplanned, discussion amongst the review authors led to the
conclusion that this was a clinically relevant comparison and ought to be included in this review. However, for this updated review, we
reached consensus that we should adhere to the prestated comparisons, but that we should include a summary of results data from any
studies which compared two active interventions (i.e. studies with no control group). This has been added as Table 5 and Table 6 and
a narrative synthesis included under Effects of interventions.
Subgroup analyses
The following subgroup analyses were listed as planned in the protocol and previous versions of this review, but have been removed,
as Cochrane guidance recommends restricting the number of subgroup analyses as large numbers can lead to spurious explanations of
heterogeneity (Higgins 2011):
• age (under 60 years, 60 years and over);
• gender (men, women);
• side of stroke (left, right, bilateral);
• presence of age-related visual problems (presence, absence);
• presence of eye movement disorders (presence, absence);
• level of motor impairment (mild, moderate, severe);
• level of cognitive impairment (mild, moderate, severe).
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Search strategy
Due to available time and resources for this latest update, and following a detailed consideration of the comprehensiveness of other
databases:
• we searched, for the 2011 version of this review, the following databases, but did not search them for this updated version:
◦ British Nursing Index (searched 1985 to 31 December 2009);
◦ PsycBITE (Psychological Database for Brain Impairment Treatment Efficacy) at www.psycbite.com (last searched
December 2009).
◦ Trials Central ( www.trialscentral.org) (last searched February 2010).
• for the 2011 version, but not for this updated version, we also:
◦ searched the references supplied by commercial companies providing interventions aimed at restoration of visual field
defect (including NovaVision®);
◦ performed citation tracking using Web of Science Cited Reference Search for all included studies;
◦ handsearched proceedings of Association for Research in Vision and Opthalmology ( www.arvo.org) (1969 to 2010); these
abstracts are now covered by MEDLINE, so were not included in the 2018 handsearching activities.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Visual Fields; Quality of Life; Randomized Controlled Trials as Topic; Reading; Stroke [∗complications]; Vision Disorders [etiology;
∗rehabilitation]
MeSH check words
Humans
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